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Abstract  
  Adoptive immunotherapy with autologous T lymphocytes transduced with 
anti-tumour  antigen-specific  T  cell  receptors  (TCRs)  has  emerged  as  a 
promising  anti-cancer  therapy.  In  vitro  studies  have  suggested  that  T  cell 
function  may  be  limited  by  tumour  associated  macrophages  (TAMs)  and 
myeloid-derived suppressor cells (MDSCs). This study aims to determine the 
influence  of  TAMs  and  MDSCs  on  the  antigen-specific  function  of  TCR-
transduced T cells in vitro and in vivo. Two murine tumour models, the EL4 
lymphoma and ID8 ovarian carcinoma were modified to ensure that CD8
+ T 
cells  transduced  with  the  F5-TCR  recognised  tumour  cells  expressing  a 
model  target  antigen,  Influenza  A  Nucleoprotein  (NP)  in  the  presence  of 
tumour-infiltrating TAMs and MDSCs. It was demonstrated that Gr-1
+ MDSCs 
isolated from tumour-bearing mice failed to suppress F5-TCR CD8
+ T cells in 
vitro.  Moreover,  in  vivo  depletion  of  Gr-1
+  MDSCs  following  the 
administration of an anti-Gr-1 antibody did not affect the anti-tumour function 
of adoptively transferred F5-TCR CD8
+ T cells. Interestingly, bone marrow-
derived CD115
+ monocytes potently suppressed T cell proliferation in vitro, 
although these cells failed to impair the anti-tumour function of F5-TCR CD8
+ 
T cells in vivo when adoptively transferred to EL4-NP tumour-bearing mice. 
This  suggested  that  Gr-1
+  MDSCs  and/or  CD115
+  monocytes  may  not 
significantly impair the anti-tumour efficacy of CD8
+ T cells expressing high 
avidity  TCR  in  the  tumour  models  examined.  Further  experiments  are 
warranted to explore their impact on tumour antigen-specific T cells at lower 
frequencies and/or with lower avidity. 
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Chapter 1  Introduction 
1.1  Cancer  
   According  to  the  World  Health  Organisation  (WHO),  8.2  million  people 
worldwide died from Cancer in 2012. A fundamental property of cancer cells 
is  their  ability  to  sustain  chronic  proliferation  in  the  absence  of  growth-
promoting  signalling  and  in  the  presence  of  growth  inhibitory  signalling 
(Hanahan  and  Weinberg,  2011).  At  a  genetic  level,  gain-of-function 
mutations  in  oncogenes  and/or  loss-of-function  mutations  in  tumour-
suppressor genes may underlie the growth and survival advantages acquired 
by cancer cells. Oncogenes and tumour suppressor genes typically code for 
important  regulators  of  the  cell  cycle  or  components  of  growth  factor 
signalling  machinery  (Rosenwald,  2004).  Several  environmental  agents 
known  to  impart  DNA  damage,  including  ultraviolet  radiation,  tobacco, 
asbestos and viral infection significantly increase the risk of development of 
certain  tumours  (Rosenwald,  2004).  Moreover,  defects  in  DNA  repair 
machinery  further  contribute  to  genomic  instability  as  tumours  develop 
(Hanahan and Weinberg, 2011). Cancer progresses in a step-wise manner, 
with  cancer  cells  progressively  acquiring  the  ability  to  break  through  the 
basement  membrane,  invade  underlying  tissues  and  disseminate  to  other 
organs via the bloodstream, a process referred to as metastasis, the major 
cause of cancer deaths and another hallmark of cancer (Wang, 2010).  
1.2  The tumour microenvironment 
   Cancer cells co-exist with multiple non-transformed cell types that compose 
the tumour stroma, including fibroblasts, endothelial cells and immune cells, 
with the ecosystem formed between cancer and stromal cells being termed 
the  tumour  microenvironment  (TME)  (Egeblad  et  al.,  2010).  Tumour  cells 
often produce factors that disturb the homeostatic functions of the different 
stromal cell types in order to facilitate tumour progression (Zitvogel et al., 
2006).  For  instance,  neoplastic  progression  is  associated  with  an 
inflammatory  response  that  suppresses  anti-tumour  immune  responses INTRODUCTION 
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whilst inducing immune cells to release bioactive molecules including growth 
factors  that  sustain  proliferative  signalling,  survival  factors  that  limit  cell 
death,  pro-angiogenic  factors,  extracellular  matrix-modifying  enzymes  and 
chemotactic  factors  that  facilitate  invasion  and  metastasis  (Hanahan  and 
Weinberg, 2011). In fact, cancer-related inflammation has been classified as 
the seventh hallmark of cancer (Zitvogel et al., 2006). 
1.3   The immune system  
   The  immune  system  consists  of  an  interconnected  system  of  humoral 
factors and cells that recognise and eliminate invading pathogens such as 
viruses  and  bacteria.  The  immune  system  is  broadly  divided  into  two 
interconnected branches: the innate and acquired immune systems. 
1.3.1 The innate immune system 
   The  innate  immune  system  represents  the  first  line  of  defence  against 
invading microorganisms. The humoral and cellular components of the innate 
immune  system  quickly  recognise  pathogen-associated  molecular  patterns 
(PAMPs), such as LPS, unmethylated cytosine phosphate guanosine (CpG), 
flagellin  and  many  other  broadly  expressed  bacterial  and  viral  products 
(Kolaczkowska and Kubes, 2013). Activation of the innate immune system 
leads to the directly killing of invading microorganisms and the release of 
soluble  factors  that  further  orchestrate  the  inflammatory  response 
(Kolaczkowska and Kubes, 2013), as described in more detail below.  
1.3.1.1  Humoral arm of the innate immune system  
   The  humoral  arm  of  the  innate  immune  system  is  composed  of  the 
complement system and additional soluble proteins that recognise a range of 
PAMPs,  leading  to  the  activation  of  both  innate  and  adaptive  immune 
systems  (Mogensen,  2009).  The  complement  system  is  composed  of  a 
network  of  circulating  or  membrane-bound  proteins  that  exist  mainly  as 
inactive precursors that are sequentially cleaved and activated (Sarma and 
Ward, 2011). Activation of the complement system typically occurs when the INTRODUCTION 
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C1q  complex  recognises  structures  on  microbial  and  apoptotic  cells  or 
following binding to the Fc portion of IgG or IgM immune complexes present 
on  the  surface  of  microorganisms  (Sarma  and  Ward,  2011).  Complement 
activation  induces  the  formation  of  a  lytic  membrane  attack  complex  on 
bacterial  cells,  leading  to  cell  death  (Ricklin  et  al.,  2010).  Complement 
binding facilitates the subsequent removal of bacteria by phagocytic cells, in 
a process termed opsonisation (Ricklin et al., 2010). Other soluble pattern-
recognition  molecules  include  the  mannose-binding  lectin  and  pentraxin  3 
(PTX3),  which  bind  to  mannose-containing  glycosidic  moieties  and 
conserved  proteins  such  as  enterobacterial  outer  membrane  protein  A, 
respectively (Mantovani et al., 2011a). 
1.3.1.2  Cellular arm of the innate immune system 
   The  cellular  arm  of  the  innate  immune  system  is  composed  of 
macrophages,  dendritic  cells  (DCs),  neutrophils,  natural  killer  (NK)  cells, 
mast  cells,  eosinophils  and  basophils,  which  readily  recognise  broadly 
expressed molecular signatures found in viruses and bacteria through germ-
line  encoded  Pattern-Recognition  Receptors  (PRRs)  that  include  Toll-like 
receptors (TLRs), nucleotide-binding oligomerization domain–like (NOD-like) 
receptors (NLRs), C-type lectin receptors (CLRs), and triggering receptors 
expressed on myeloid cells (TREMs) (Lin and Karin, 2007).  
1.3.1.3  The inflammatory response 
   During  an  infection,  PRR  triggering  causes  the  release  of  cytokines, 
chemokines,  matrix  remodelling  proteases  and  histamine,  leading  to  the 
recruitment of additional immune cells from the circulation (de Visser et al., 
2006). Once in inflamed tissues, innate cells, most notably neutrophils and 
macrophages, eliminate pathogens through phagocytosis or the release of 
cytotoxic  mediators  such  as  reactive  oxygen  species  (ROS)  including 
hydrogen peroxide, superoxide and hydroxyl and hypochlorite-free radicals, 
and reactive nitrogen intermediates, such as nitric oxide (Cain et al., 2009). 
These  intermediates  can  also  cause  tissue  damage  and  give  rise  to 
pathologies such as gastroenteritis, neonatal meningitis, and sepsis, unless INTRODUCTION 
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excessive  inflammation  is  dampened  (Sica  and  Mantovani,  2012). 
Uncontrolled  inflammation  is  also  present  in  several  inflammatory  and 
autoimmune diseases such as Crohn’s disease, rheumatoid arthritis, multiple 
sclerosis and autoimmune hepatitis (Wynn et al., 2013). 
1.3.1.4  Inflammation resolution 
   Once pathogens are cleared, inflammation is resolved and damaged tissue 
repaired through a wound healing response characterised by the production 
of  anti-inflammatory  mediators,  such  as  resolvins,  IL-10  and  TGF-ß, 
clearance of apoptotic and necrotic cells, decrease in vascular permeability, 
formation  of  new  blood  vessels  (angiogenesis),  matrix  remodelling  and 
deposition  (Cain  et  al.,  2009).  Failure  to  eliminate  pathogens  results  in 
chronic inflammation, during which inflammatory and reparative processes 
occur in parallel, leading to tissue scarring and disruption of normal organ 
function  (Nathan  and  Ding,  2010).  Chronic  inflammation  is  a  hallmark  of 
pathologies  such  as  atherosclerosis,  liver  and  lung  fibrosis  and  cancer 
(Nathan and Ding, 2010). 
1.3.1.5  Innate immune cell development 
     Immune and other blood cells originate from the pluripotent and highly 
replicative hematopoietic stem cell (HSC), which in adult mammals is located 
in the bone marrow (Blom and Spits, 2006). Further differentiation of HSCs 
gives rise to the common myeloid and lymphoid progenitors. Innate immune 
cells  derive  from  the  myeloid  progenitors,  with  the  exception  of  NK  cells, 
which  are  derived  from  the  lymphoid  precursor  together  with  T  and  B 
lymphocytes (Blom and Spits, 2006). Dendritic cells (DCs), monocytes and 
macrophages  comprise  the  mononuclear  phagocyte  system,  due  to  their 
common developmental origin and phagocytic properties.   
1.3.1.6  The mononuclear phagocyte system  
   Commitment to the mononuclear phagocyte lineage is determined at the 
level of macrophage and DC progenitor (MDP), at which stage precursors for 
the  erythroid,  megakaryocyte,  lymphoid  and  granulocyte  lineages  have INTRODUCTION 
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already been excluded (Chow et al., 2011). MDPs further differentiate into 
common DC progenitors (CDPs) and monocytes (Chow et al., 2011). CDPs 
give rise to pre-DCs which enter the bloodstream and migrate to lymphoid 
tissues, where they give rise to classical and plasmacytoid DCs (Kushwah 
and Hu, 2011). Fate-mapping studies revealed that a small subset of DCs in 
lymphoid organs develop from common lymphoid progenitors (Satpathy et 
al., 2012). During inflammation, monocytes infiltrate tissues and differentiate 
into macrophages and, to a lesser extent, into DCs (Chow et al., 2011). More 
recently,  a  CD11b
low  Ly6C
hi 
progenitor  has  been  identified  as  the 
intermediate  between  the  MDP  and  the  major  monocyte  subsets  in  mice 
(Hettinger et al., 2013). 
1.3.1.6.1 Monocyte heterogeneity  
   Monocytes are heterogeneous in terms of surface marker expression and 
biological function. In the murine system, two main monocyte subsets have 
been  identified:  the  Ly6C
high  “inflammatory”  monocytes  and  the  Ly6C
low 
CX3CR1
+  “patrolling”  monocyte  subsets.  Ly6C
high monocytes  have  been 
shown to shuttle between the blood and bone marrow and eventually lose 
Ly6C  expression,  suggesting  a  linear  model  of  Ly6C
high converting  into 
Ly6C
low monocytes  (Varol  et  al.,  2007).  Moreover,  depletion  of  Ly6C
high 
monocytes in CCR2
-/- mouse or following the administration of an anti-CCR2 
antibody led to substantial decreases in the number of Ly6C
low monocytes, 
confirming the link between Ly6C
high and Ly6C
low monocytes (Yona et al., 
2013).  “Inflammatory”  monocytes  express  the  chemokine  receptor  CCR2, 
which  facilitate  trafficking  to  sites  of  inflammation  and  their  subsequent 
differentiation into macrophages (Auffray et al., 2007) whereas “patrolling” 
monocytes,  whose  function  is  less  well  understood,  have  been  shown  to 
crawl  along  the  surface  of  endothelium,  scavenge  cellular  debris  in  the 
steady state (Carlin et al., 2013) and invade tissues and differentiate into 
macrophages during tissue damage or infection (Auffray et al., 2007).  In 
humans,  CD4
low  CD16
+  monocytes  (the  correlate  of  Ly6C
low  monocytes) 
have also been shown to patrol the vascular endothelium following adoptive 
transfer  into  immunodeficient  mice  (Cros  et  al.,  2010).  Human  CD14
high INTRODUCTION 
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CD16
− monocytes resemble Ly6C
high monocytes based on gene expression 
profiling and surface marker expression, including high expression of CCR2 
(Ingersoll et al., 2010). 
1.3.1.6.2 Macrophages  
   Macrophages are named “big eaters” from the Greek makros "large" and 
phagein  "eat"  due  to  their  ability  to  take  up  bacteria  by  phagocytosis,  a 
process firstly described by Elie Metchnikoff, winner of the Nobel Prize in 
1918 (Hashimoto et al., 2011b). Macrophages populate virtually every tissue 
in the body and acquire morphologic and functional specialisation depending 
on their location. Examples of tissue resident macrophages are the Kupffer 
cells in the liver, alveolar macrophages in the lung, osteoclasts in bone tissue 
and microglia in the brain (Taylor et al., 2005). Macrophage heterogeneity is 
also seen within individual organs, such as the spleen. In the mouse spleen, 
red pulp macrophages expressing high levels of the F4/80 antigen take up 
and destroy old red blood cells, whereas marginal zone macrophages and 
metallophilic  macrophages,  which  are  F4/80-negative  macrophage 
populations  situated  in  the  splenic  marginal  zone,  phagocytose 
microorganisms entering the spleen and transfer antigen to DCs in the white 
pulp (den Haan and Kraal, 2012). The importance of the spleen in clearing 
blood-borne pathogens is demonstrated by the fact that asplenic individuals 
have  a  50-fold  higher  risk  of  developing  sepsis  and  meningitis  due  to 
infections  with  encapsulated  bacteria  such  as  Neisseria  meningitidis, 
Streptococcus  pneumoniae  and  Haemophilus  influenza  (den  Haan  and 
Kraal, 2012). Macrophage diversity is also seen on a gene expression level: 
a recent study undertaken by the Immunological Genome Project revealed 
that murine tissue-resident macrophage populations isolated from different 
organs display high transcriptional diversity, with minimal overlap (Gautier et 
al., 2012). 
1.3.1.6.3 Origin of Macrophages 
    The origin of tissue macrophages from circulating monocytes had been 
regarded as a consensus in the field until recently. It is, however, becoming INTRODUCTION 
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increasingly  clear  that,  in  the  steady  state,  tissue  resident  macrophage 
populations are established prenatally from yolk sac or fetal liver progenitors 
and  are  maintained  independently  from  bone  marrow-derived  monocytes. 
Firstly,  yolk  sac–derived  macrophages  have  been  shown  to  develop 
independently  of  the  transcription  factor  c-Myb,  which  is  required  for  the 
haematopoietic  stem  cell  (HSC)  development.  Yolk  sac-derived 
macrophages  give  rise  to  F4/80
bright 
macrophages  in  several  tissues, 
including Kupffer cells, Langerhans cells and microglia (Schulz et al., 2012).  
Detailed fate-mapping studies, in which cells of the mononuclear phagocyte 
system  were  conditionally  labelled  with  Yellow  Fluorescent  Protein  (YFP), 
are supportive of this data (Yona et al., 2013).  
   However,  during  tissue  stress  and  inflammation,  monocytes  infiltrate 
tissues and complement the prenatally established macrophage populations, 
indicating a dual origin for macrophages under either steady-state conditions 
or  inflammation  (Hettinger  et  al.,  2013).  In  the  intestinal  lamina  propria, 
macrophages  are  replenished  by  Ly6C
hi  monocytes  in  steady  state 
conditions as a result of the low-grade inflammation induced by the intestinal 
microbiota  (Hettinger  et  al.,  2013).  Macrophages  have  been  shown  to 
proliferate  locally  during  helminth  infection  or  allergy,  which  are  typical 
examples  of  “type-2”  inflammatory  responses  (Jenkins  et  al.,  2011).  For 
instance,  monocyte  depletion  did  not  affect  the  number  of  pleural 
macrophages  in  mice  infected  with  the  filarial  nematode  Litomosoides 
(Jenkins et al., 2011). The developmental origin of the major myeloid cell 
subsets is shown in Figure 1-1.  
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         Figure 1-1: Ontogeny of the major myeloid cell subsets 
 
1.3.1.6.4 Phenotypic states 
   Macrophages are highly plastic, displaying a range of activation states and 
performing various biological roles depending on the stimulus they receive. A 
binary  system  has  been  proposed  to  classify  macrophages  engaging  in 
either Th1-type or Th2-type inflammatory responses, which are termed M1 
and M2 macrophages, respectively (Biswas et al., 2013). For instance, M1 
macrophages  polarised  with  LPS  and  IFN-γ  produce  pro-inflammatory 
mediators such as IL-1, IL-6, IL-12, iNOS, TNF-α, reactive oxygen species 
(ROS) and reactive nitrogen species (RNS) whilst producing low amounts of 
anti-inflammatory cytokines such as IL-10 (Sica and Mantovani, 2012). M2 
macrophages, conversely, respond to IL-4 and IL-13 by up-regulating IL-10 
secretion, Arginase-1, the chitinase-like lectin Ym1, mannose and scavenger 
receptors  and  the  chemokines  CCL17  and  CCL24  (Satoh  et  al.,  2010). 
These activation states are associated with the actions of distinct signalling 
pathways and transcription factors, most notably the Interferon Regulatory INTRODUCTION 
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Factor (IRF) and signalling transducer and activator of transcription (STAT) 
pathways: STAT1 and IRF5 collaborate to induce M1 polarization, whereas 
STAT6  and  IRF4  interact  to  polarise  macrophages  toward  the  M2  fate 
(Hume, 2012). The main properties of M1 and M2-polarized macrophages in 
mice are shown in Figure 1-2. 
Figure 1-2: Polarisation and phenotype of M1 and M2 macrophages 
 
1.3.1.6.5 Diversity in macrophage phenotypes 
   The M1-M2 classification is best regarded as the “ends of a spectrum”, 
which in reality represents a range of activation states that macrophages can 
display  in  vivo,  where  a  wider  range  of  cytokines  and  growth  factors  are 
present  (Sica  and  Bronte,  2007).  For  instance,  although  macrophages 
stimulated  with  IL-10,  glucocorticoid  hormones,  apoptotic  cell  ligands  and 
immune  complexes  express  typical  M2-markers  such  mannose  and 
scavenger  receptors,  they  also  differ  from  typical  M2  macrophages  for 
instance in terms of the chemokine repertoire, being therefore referred to as 
“M2-like”  macrophages  (Sica  and  Mantovani,  2012).  Importantly,  M1-M2 INTRODUCTION 
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macrophages have been distinguished at the gene expression level in the 
murine  system,  with  the  characterisation  of  equivalent  human  subsets 
proving more challenging (Murray and Wynn, 2011). Interspecific differences 
have also been also observed. For instance, human macrophages do not up-
regulate neither ARG-1 or inducible nitric oxide synthase (iNOS) to levels 
comparable  to  murine  macrophages  when  polarised  in  vitro  with  IL-4  or   
IFN-γ, respectively (Murray and Wynn, 2011). Macrophages reversibly shift 
phenotype following changes in the cytokine environment in vitro (Stout et 
al.,  2005)  and  phenotypic  adaptability  has  also  been  shown  in  vivo.  For 
instance,  during  Listeria  monocytogenes  infection  in  mice,  macrophages 
express pro-inflammatory cytokines such as TNF-α and IL-1 at early time 
points,  whereas  at  later  time  points  they  express  M2  markers  such  as 
arginase-1, FIZZ1, macrophage galactose-type C-type lectin-2 (Mgl2), and 
mannose receptors (Auffray et al., 2007). 
1.3.1.6.6 Macrophage receptors  
   The ability of macrophages to recognise and respond to external ligands is 
dependent  on  the  expression  of  a  wide  range  of  surface  receptors,  the 
expression of which varies with their state of activation (Taylor et al., 2005). 
The main macrophage receptors and their functions are listed in Table 1.1. 
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Table 1.1. Important macrophage receptors  
Receptor  Structure  Function  Expression  Reference 
CD11b  Glycoprotein of the 
Integrin  receptor 
family 
Adhesion, migration into 
inflamed tissues, phagocytosis, 
chemotaxis, complement-
opsonized phagocytosis,  
cellular activation, and 
cytotoxicity  
Ubiquitious in 
the 
monocyte-
macrophage 
lineage  in 
mice  and 
humans.  
(Zhou et al., 
2013) 
F4/80  
 
Six  EGF  domains 
linked  to  a  TM7 
region  
Not  fully  understood.  Shown  to 
mediate  peripheral  tolerance  in 
anterior chamber of the eye.  
Most  mature 
tissue 
macrophage 
populations.  
Mouse-
restricted. 
(Lin  et  al., 
2005) 
Toll-like 
receptors  
 
Horseshoe-shaped 
structures built 
from leucine-rich 
repeat motifs. 
Two extracellular 
domains form an 
“m”-shaped 
dimmer upon 
ligand binding  
PAMPs,  including  various 
bacterial  cell  wall  components 
such  as  lipopolysaccharide 
(LPS), peptidoglycan (PGN) and 
lipopeptides, as well as flagellin, 
bacterial DNA and viral double-
stranded RNA. 
Ubiquitious in 
the 
monocyte-
macrophage 
lineage. Ten 
human and 
twelve 
murine TLRs 
have been 
characterised 
 
(Taylor  et 
al., 2005) 
 
Fc 
receptors  
Part  of  the 
immunoglobulin 
family  
 
Binds  the  Fc  region  of 
antibodies,  triggering  antibody-
dependent cellular phagocytosis 
(ADCP) 
Ubiquitious in 
the 
monocyte-
macrophage 
lineage  in 
both  mouse 
and human 
(Hajela, 
1991) 
Scavenger 
Receptor 
Trimeric 
transmembrane 
glycoprotein. 
Ligand  binding  by 
collagen-like 
domain  
 
Binds  polyanionic  ligands  such 
as  modified  low-density 
lipoproteins and acetylated LDL. 
Involved  in  the  uptake  of 
bacteria,  apoptotic  cells, 
adhesion,  phagocytosis  and 
tumour  metastasis.    Important 
for  foam  cell  formation  and 
atherogenesis 
 
Up-regulated 
by  M2-type 
macrophages 
in  mice  and 
humans 
(Taylor  et 
al., 2005) 
 
 INTRODUCTION 
  29 
 
1.3.1.6.7 Function of macrophages in health and disease  
   Macrophages  sense  the  presence  of  and  phagocytose  invading 
microorganisms,  which  are  subsequently  degraded  intracellularly,  with  the 
resulting  peptide  fragments  being  loaded  onto  Major  Histocompatibility 
Complex class II (MHCII) molecules to be presented to T cells (Hashimoto et 
al., 2011b), as discussed in more detail in section 1.3.2.1.2. Once activated 
by microbial ligands, macrophages orchestrate the inflammatory response by 
releasing pro-inflammatory cytokines such as TNF-α, IL-6 and IL-1 (Biswas 
et  al.,  2013),  which  help  recruit  additional  immune  cells  to  the  sites  of 
inflammation  and  are  also  important  in  determining  T  cell  polarisation,  as 
discussed  later  in  section  1.3.2.1.7.  In  addition  to  playing  a  key  role  in 
pathogen  clearance  during  inflammation,  pro-inflammatory  M1-type 
macrophages also contribute to inflammatory and autoimmune diseases and 
insulin resistance in obese individuals (Wynn et al., 2013). In atherosclerosis, 
macrophages  promote  an  inflammatory  response  and  the  formation  of 
atherogenic plaques after taking up oxidised LPS via scavenger receptors 
and  becoming  activated  via  TLRs  and  NOD-like  receptors  (Moore  et  al., 
2013). Advanced plaques can rupture as dying macrophages release lipid 
contents and tissue factors, precipitating a clotting response that can obstruct 
arteries  and  contribute  to  myocardial  infarction  and  stroke  (Moore  et  al., 
2013).  
Mannose 
Receptor 
C-type Lectin  
 
Endogenous  glycoproteins  and 
clearance  of  lysosomal 
hydrolases  during  steady  state 
and inflammatory conditions 
Up-regulated 
by  M2-type 
macrophages 
in  mice  and 
humans 
(Taylor  et 
al., 2005) 
 
CSF1-R 
(CD115) 
Extracellular 
immunoglobulin 
domains  joined  to 
intracellular 
tyrosine  kinase 
catalytic domain  
Binds  M-CSF  and  promotes 
macrophage  growth,  survival 
and  differentiation  from  bone 
marrow precursors 
Ubiquitious in 
the 
monocyte-
macrophage 
lineage 
(Hume  and 
MacDonald, 
2012) INTRODUCTION 
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   During  the  resolution  of  inflammation,  macrophages  adopt  an  M2-like 
phenotype  and  engage  in  immunosuppressive  and  tissue  reparative 
responses. During resolution, macrophages promote repair processes such 
as  angiogenesis,  via  production  of  vascular  endothelial  growth  factor 
(VEGF),  TNF-α,  granulocyte  macrophage  colony-stimulating  factor  (GM-
CSF),  IL-1,  IL-6,  and  nitric  oxide  (Lin  et  al.,  2006)  together  with  matrix 
remodelling, in which macrophages break-down extracellular matrix (ECM) 
through  the  action  of  matrix-metalloproteinases  (MMPs),  serine  proteases 
and cathepsins (Ruffell et al., 2012). In addition, macrophages contribute to 
the clearance of apoptotic cells, such as dying neutrophils (Maskrey et al., 
2011). Such tissue-remodelling properties are also important during organ 
development.  For  instance,  macrophages  remodel  the  extracellular  matrix 
and allow the growth of ductal structures of the mammary gland (Wynn et al., 
2013).  However,  in  diseases  such  as  asthma  and  cancer,  M2-like 
macrophages  contribute  to  the  pathogenesis  through  both  their  immune-
regulatory and tissue remodeling properties. In asthma, macrophages induce 
airway  smooth-muscle  contractility  and  contribute  to  pathological  airway 
remodelling characteristic of the disease (Sica and Mantovani, 2012). The 
role  of  macrophages  in  cancer  will  be  discussed  in  more  detail  later  in 
section 1.5.2.1. 
1.3.1.6.8 Dendritic cells  
   Although  macrophages  engage  in  a  wide  range  of  biological  roles  to 
maintain homeostasis and tissue integrity, dendritic cells (DCs) specialise in 
antigen  processing  and  presentation  (Wynn  et  al.,  2013).  In  mice  and 
humans, DCs are typically defined based on the expression of the integrin 
CD11c (Hashimoto et al., 2011b).  
1.3.1.6.9 Dendritic cell subsets 
   There  are  four  major  subsets  of  DCs:  conventional  DCs  (cDCs)  and 
plasmacytoid  DCs  (pDCs),  Langerhans  cells  and  monocyte-derived  DCs 
(Satpathy et al., 2012). cDCs are highly phagocytic and can be differentiated 
on the basis of CD8 expression, with CD8
+ cDCs being the most efficient at INTRODUCTION 
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cross-presenting  exogenous  antigens  loaded  on  major  histocompatibility 
complex (MHC) class I molecules to CD8
+ T cells (Hashimoto et al., 2011b). 
pDCs  are  not  highly  phagocytic  and  are  characterised  by  their  ability  to 
secrete large amounts of type 1 interferon (Satpathy et al., 2012). Monocyte-
derived  DCs  are  differentiated  in  vitro  or  under  inflammatory  states,  with 
tumour-necrosis  factor-α  –  and  inducible  nitric  oxide  synthase–producing 
inflammatory  DCs  (or  “tip-DCs”)  being  the  main  subset  in  vivo.    Finally, 
Langerhans cells (LCs) consist of a highly phagocytic subset of DCs that 
reside in the epidermal layer of the skin and are capable of taking up antigen 
and migrating to secondary lymph nodes (Satpathy et al., 2012).  
1.3.1.6.10   Dendritic cell maturation and function  
   In the steady state, cDCs are found in an immature state characterised by 
low  lower  surface  expression  of  MHC  class  I  and  II  proteins  and  low 
expression of pro-inflammatory cytokines (Gabrilovich et al., 2012). During 
infection, DCs become activated in response to PAMP recognition, leading to 
the up-regulation of MHC class II, co-stimulatory molecules of the B7 family 
and pro-inflammatory cytokines (Satpathy et al., 2012). Mature DCs capture 
antigens  in  peripheral  tissues  and  up-regulate  chemokine  receptors  that 
allow  them  to  migrate  into  peripheral  lymph  nodes  via  afferent  lymphatic 
vessels  (Satpathy  et  al.,  2012).  Once  in  the  lymph  nodes,  DCs  initiate 
adaptive immune responses by activating naive T cells (Love and Hayes, 
2010).  
1.3.1.7  Neutrophils 
   Neutrophils  are  a  type  of  polymorphonuclear  leukocyte  continuously 
generated in the bone marrow from the granulocyte-monocyte progenitors 
(GMP)  primarily  in  response  to  granulocyte  colony–stimulating  factor  (G-
CSF) (Mayadas et al., 2014). Early studies showed that in the steady state, 
neutrophils have a circulatory half-life of approximately 1.5 and 8 hours in 
mice and humans, respectively, although a recent study proposed a lifespan 
of 12.5 hours and 5.4 days for mouse and human neutrophils, respectively 
(Pillay et al., 2010). In mice, neutrophils are typically identified based on their INTRODUCTION 
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morphology (multi-lobed nuclei and presence of cytoplasmic granules), co-
expression of the pan-myeloid marker CD11b and the granulocyte-specific 
GPI-anchored  receptor  Ly6G  and  the  absence  of  monocyte/macrophage 
markers such as F4/80 (Beyrau et al., 2012). Human neutrophils co-express 
the cell surface markers CD15 and CD16 (Beyrau et al., 2012).    
1.3.1.7.1 Roles in inflammation  
   Neutrophils are typically the first leukocytes to be recruited to inflammatory 
sites  and  are  essential  in  protecting  against  a  wide  range  of  infectious 
pathogens  including  bacteria,  fungi,  and  protozoa,  as  illustrated  by  life-
threatening immuno-deficiencies associated with abnormalities in neutrophil 
differentiation and function (Mantovani et al., 2011a). Neutrophils recognize 
pathogens via PRRs, complement receptors and Fc receptors and eliminate 
them by multiple mechanisms, such as phagocytosis followed by fusion of 
the  endocytic  vacuole  with  cytoplasmic  granules  containing  the  enzymes 
NADPH oxidase and myeloperoxidase (MPO), which generate the powerful 
anti-microbials  ROS  and  hypochlorous  acid,  respectively  (Mayadas  et  al., 
2014).  Moreover,  neutrophil  extracellular  traps  (NETs),  which  consist  of  a 
sticky  meshwork  of  DNA,  histones,  myeloperoxidase,  neutrophil  elastase, 
lactoferrin and pentraxin 3, and allow pathogens to be trapped, facilitating 
their subsequent killing (Mantovani et al., 2011a). 
1.3.1.7.2 Immune-regulatory functions 
   In addition to their anti-microbial functions, neutrophils play an important 
role in immune-regulation and tissue repair. For instance, neutrophils have 
been shown to present antigens and promote the differentiation of antigen- 
specific Th1 and Th17 cells (Beyrau et al., 2012) and activate splenic B cells 
by  releasing  B  cell-activating  factor  (BAFF)  and  CD40  ligand  (CD40L) 
(Kolaczkowska  and  Kubes,  2013).  During  the  resolution  of  inflammation, 
neutrophils produce anti-inflammatory factors such as resolvins and matrix-
degrading  enzymes  such  as  MMP9  (Kolaczkowska  and  Kubes,  2013). 
Furthermore,  neutrophils  can  suppress  T  cell  proliferation  through  up-
regulation  of  Arginase-1,  ROS  and  inducible  nitric  oxide  synthase  (iNOS) INTRODUCTION 
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(Kolaczkowska and Kubes, 2013). The suppressive properties of neutrophils 
have been studied mainly in the context of myeloid-derived suppressor cells, 
a heterogeneous population of myeloid progenitors and immature myeloid 
cells, as discussed in section 1.5.2.2.    
1.3.1.8  Natural Killer cells 
   Natural killer (NK) cells are lymphoid cells that form part of the first line of 
defense against virus-infected and malignant cells (Zaritskaya et al., 2010). 
Unlike T and B cells, NK cells do not express receptors that require somatic 
gene rearrangements to generate receptor diversity (Orr and Lanier, 2010). 
Although  NK  cells  are  widespread  throughout  lymphoid  and  non-lymphoid 
tissues, they usually represent a minor fraction of total lymphocytes (Vivier et 
al.,  2008).  NK  cell  activation  is  controlled  by  inhibitory  and  activating 
receptors. Activating receptors include the natural killer group 2, member D 
(NKG2D)  receptor,  which  recognises  self-ligands  expressed  under  cell 
stress,  including  the  MHC  class  I  chain-related  protein  (MIC)  family  in 
humans and products of the retinoic acid early inducible (Rae) gene family in 
mice,  whereas  inhibitory  receptors  predominantly  recognise  self-MHCI 
molecules  (Orr  and  Lanier,  2010).  MHCI  down-regulation  during  viral 
infection or malignant transformation decreases signalling through inhibitory 
receptors, leading to NK cell activation (Zaritskaya et al., 2010) . NK cells 
also express several TLRs, which can be activated by non-self ligands such 
as  cytomegalovirus-derived  fragments.  In  contrast  to  macrophages, 
neutrophils and DCs, NK cells do not require priming or activation events to 
up-regulate  their  killing  machinery  (Zamai  et  al.,  2007).  The  killing 
mechanisms  deployed  by  NK  cells  and  CD8
+  T  cells  are  similar,  being 
comprised of perforin, granzymes, Fas ligand (FasL), and TRAIL (Zaritskaya 
et al., 2010). Finally, NK cells promote Th1 CD4
+ T cells responses through 
IFN-γ release (Vivier et al., 2008). INTRODUCTION 
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1.3.2 The adaptive immune system 
    The antigen recognition abilities of the innate immune response are by far 
outstripped by the vast number of antigenic peptides found in nature (Sewell, 
2012).  The  advent  of  the  adaptive  immune  system,  formed  by  T  and  B 
lymphocytes bearing somatically re-arranged antigen receptors, allowed the 
repertoire of immune receptors to expand to keep up with pathogen diversity 
(Cooper and Alder, 2006). Adaptive responses are characterised by clonality, 
and lymphocytes specific to a given antigen expand “on demand” during an 
infection,  generating  a  clonal  population  of  cells  that  can  mount  a  robust 
initial  response  against  a  pathogen.  Moreover,  adaptive  responses  are 
stronger  and  faster  at  repeated  infections  as  a  result  of  immunological 
memory  (Cooper  and  Alder,  2006).  The  key  properties  of  the  adaptive 
immune system will be discussed in the subsequent sections.  
1.3.2.1  T lymphocytes 
   T  lymphocytes  are  essential  for  the  development  of  effective  cellular 
immune responses. A significant reduction in their numbers predisposes the 
host to recurrent infections and the development some types of cancers, as 
seen  in  severe  combined  immunodeficiency  (SCID)  and  acquired 
immunodeficiency syndrome (AIDS) resulting from uncontrolled HIV infection 
(Cunningham-Rundles and Ponda, 2005). A defining feature of T cells is the 
presence of the highly diverse heterodimeric T cell receptor (TCR), which 
plays a key role in antigen recognition.  
1.3.2.1.1 Structure of the T cell receptor (TCR)  
   T  cell  receptors  are  heterodimeric  receptors  of  the  immunoglobulin 
superfamily formed by the non-covalent pairing of adjacent alpha and beta 
chains (αβ), which are attached to the plasma membrane via transmembrane 
domains  (Sewell,  2012).  Mature  αβ  TCRs  are  formed  during  T  cell 
development in the thymus and TCR sequence diversity is achieved through 
the random recombination and pairing of the variable (V), diversity (D) and 
joining (J) gene segments comprising the sequence for the alpha and beta 
chains  (Hamrouni  et  al.,  2003).  Further  sequence  diversity  is  obtained INTRODUCTION 
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through the addition of nucleotides at the intersections of these sequences 
together with the random pairing of different α and β chains (Hamrouni et al., 
2003). Each alpha and beta chain contains two extracellular domains: the 
constant region, whose sequence is highly conserved among different T cell 
clones and the variable region, which contain six highly diverse loops (three 
in Vα and three in Vβ) termed complementarity-determining regions (CDRs). 
The CDRs form the antigen-binding site and confer specificity to the TCR 
(Rangarajan and Mariuzza, 2014). However, TCRs display a varying degree 
of cross-reactivity to different peptides. This may be important physiologically 
as the number of MHC binding peptides that can be manufactured from the 
20 amino acids found in nature significantly outnumbers the number of TCRs 
available for recognition (Sewell, 2012). On a structural level, the flexibility of 
the  CDR  loops  contributes  to  antigen  recognition  plasticity  (Sewell  2012). 
The simplified structure of the TCR is shown in Figure 1-3.  
 
 Figure 1-3: Simplified structure of the TCR 
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1.3.2.1.2 The antigen processing pathway  
   In contrast to antibodies, which recognize antigens in their native form, αβ 
T  cell  receptors  (TCRs)  only  recognise  antigens  bound  to  the  highly 
polymorphic  MHC  molecules,  a  feature  known  as  MHC  restriction 
(Rangarajan  and  Mariuzza,  2014).  There  are  two  major  classes  of  MHC 
molecules: MHC class I (MHCI), which has a closed-ended peptide-binding 
groove and binds shorter peptides (typically 8–14 amino acids in length) and 
MHC class II (MHCII), which has an open cleft and can accommodate longer 
peptides of typically between 13 and 17 amino acids in length (Chang et al., 
2006). 
   In  general,  MHC-I  molecules  bind  peptides  derived  from  endogenous 
intracellular sources, such as cellular proteins or peptides derived from viral 
proteins, which are broken down in the proteasome and translocated from 
the cytosol onto vesicles containing MHCI molecules in a process dependent 
on  the  TAP-2  transporter  (Blum  et  al.,  2013).  Subsequently,  vesicles 
containing peptide-MHCI molecules are trafficked to the plasma membrane. 
MHCI  molecules  are  expressed  by  virtually  every  nucleated  cell  although 
exceptions occur in immune-privileged organs such as the testis and the eye 
(Lu and Finn, 2008). MHCII molecules, conversely, present peptides derived 
from extracellular sources, such as bacterial cells, which become internalised 
and degraded by lysosomal enzymes following the fusion of lysosomes with 
the late endosomes containing the internalised cargo (Blum et al., 2013). The 
resulting antigenic peptides are then loaded onto MHCII molecules prior to 
the migration and fusion of the vesicles with the plasma membrane, which 
results in the insertion of the peptide-MHC-II complexes onto the cell surface 
(Blum  et  al.,  2013).  The  expression  of  MHCII  molecules  is  restricted  to 
antigen-presenting cells (APCs) such as dendritic cells, macrophages and B 
cells. APCs, especially DCs, can also load peptides derived from exogenous 
sources onto MHCI molecules for subsequent presentation to CD8
+ T cells in 
a process termed cross-presentation (Melief, 2008).  INTRODUCTION 
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1.3.2.1.3 TCR signalling 
   Although  the  TCR  lacks  intrinsic  signalling  transducing  activity,  it 
associates non-covalently with the CD3 complex, which is composed of four 
distinct subunits (γ, δ, ε and ζ) containing the signalling-transducing Immune 
receptor Tyrosine-based Activation Motifs (ITAMs) (Love and Hayes, 2010). 
TCR  signalling  is  initiated  following  TCR  binding  to  peptide-MHC,  which 
triggers  the  phosphorylation  of tyrosine  residues  in  the  ITAMs by  the  Lck 
kinase (Brownlie and Zamoyska, 2013). Subsequently, the kinase ZAP70 is 
recruited and phosphorylated, allowing it to phosphorylate the key adaptor 
molecule  Linker  for  Activation  of  T  cells  (LAT)  (Brownlie  and  Zamoyska, 
2013). LAT phosphorylation is followed by a signalling amplification cascade 
that  ultimately  results  in  a  range  of  cellular  changes,  such  as  calcium 
mobilisation, cytoskeletal re-arrangements, activation of integrins needed for 
T  cell  adhesion  and  movement  into  effector  sites  and  the  activation  of 
transcription  factors  such  as  NFAT,  leading  to  the  up-regulation  of  genes 
necessary  for  T  cell  growth,  differentiation,  cytokine  production  and  other 
effector  functions  (Brownlie  and  Zamoyska,  2013).  TCR  signalling  is 
attenuated  by  tyrosine  phosphatases  such  as  SHP-1  and  PTPN22,  which 
dephosphorylate  effector  kinases  such  as  ZAP-70  and  Lck  (Wiede  et  al., 
2011).  The  association  between  the  TCR  and  the  CD3  complex  is  also 
essential for TCR expression on the cell surface (Stauss et al., 2007). 
1.3.2.1.4 T cell development 
   Although  T  cells  originate  from  haematopoietic  stem  cells  in  the  bone 
marrow, their maturation into functional antigen-specific cells occurs entirely 
in the thymus. T cell development begins at the level of double-negative (DN) 
thymocytes lacking expression of CD4 and CD8 co-receptors and absence of 
a mature TCR (Klein et al., 2014). Subsequently, further maturation steps 
occur, including the re-arrangement of the TCR α and β chains to form a 
complete  αβ  TCR  and  the  formation  of  double  positive  DP  thymocytes 
expressing both CD4 and CD8 co-receptors (Germain 2002). MHC restriction 
and positive selection takes place as DP thymocytes interact with cortical 
epithelial cells expressing self-peptides presented by MHC class I and class INTRODUCTION 
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II molecules (Germain, 2002). If the interaction between the TCR and self-
peptide-MHC is too weak, cells die by apoptosis whereas thymocytes binding 
self-antigens  with  intermediate  affinity  presented  by  MHCI  are  positively 
selected  and  become  CD8
+  T  cells  while  thymocytes  binding  self-antigen 
presented by MHCII become CD4
+ T cells (Chang et al., 2006). The CD8 and 
CD4 co-receptors help stabilise the interaction between the TCR and MHC 
Class I and II, respectively (Chang et al., 2006). Single-positive thymocytes 
(CD4
+ or CD8
+) then migrate to the thymic medulla, where they interact with 
medullary  thymic  epithelial  cells  which  promiscuously  express  tissue-
restricted antigens under the control of the transcription factor auto-immune 
regulator  (AIRE)  (Eldershaw  et  al.,  2011).  SP  thymocytes  bearing  high 
affinity TCR to self-antigens are deleted at this stage (negative selection). In 
conclusion, during thymic maturation T cells are selected on the basis of self-
MHC  recognition,  although  T  cells  that  bind  strongly  to  self-antigens  are 
eliminated,  preventing  high  affinity  T  cells  specific  to  self-antigens  from 
entering  the  circulation  and  causing  auto-immune  disease  (Klein  et  al., 
2014). 
1.3.2.1.5 T cell trafficking  
   Following thymic maturation, T cells enter the blood in a naïve or antigen-
inexperienced  state.  Naïve  T  cells  circulate  in  blood  and  eventually  enter 
lymph nodes after crossing high endothelial venules (HEV), in a mechanism 
dependent  on  L-selectin,  integrins  and  the  chemokine  receptor  CCR7 
(Marelli-Berg  et  al.,  2008).  Once  in  the  lymph  nodes,  naïve  T  cells  may 
become  activated  upon  encountering  their  specific  antigen  presented  by 
professional APCs in the T cell zone of the lymph node, leading to T cell 
expansion and the formation of effector and memory T cells (Shulman et al., 
2012).  Activated  or  naïve  T  cells  eventually  exit  the  lymph  nodes  in  a 
mechanism dependent on the expression of Sphingosine-1-Phosphate Type-
1 receptors (S1P1R) (Matloubian et al., 2004). Moreover, activated T cells 
acquire the ability to move into sites of inflammation due to the up-regulation 
of  guanine  nucleotide–binding  (G)  protein–coupled  receptors  (GPCRs) 
specific for inflammatory chemokines, in addition to E and P-selectin ligands INTRODUCTION 
  39 
(Shulman et al., 2012). In the absence of antigen encounter, naïve T cells 
continue circulating and can survive for prolonged periods of time due to the 
pro-survival  signalling  received  following  binding  to  MHC–self-peptide  and 
exposure to homeostatic cytokines such as IL-7 (Germain, 2002). 
1.3.2.1.6 Memory and effector T cells 
   Naive  T  cells  can  expand  remarkably  following  activation,  producing  as 
much as a 10
5
-fold increase in the number of antigen-specific cells (Mueller 
et  al.,  2013).  T  cell  activation  also  leads  to  up-regulation  of  the  growth-
promoting  cytokine  Interleukin-2  (IL-2),  the  IL-2  receptor  (CD25)  and  the 
formation of effector and memory T cells (Ferrero et al., 2007). Once the 
invading  pathogen  is  cleared,  the  vast  majority  of  effector  cells  die  by 
apoptosis (the contraction phase), leaving a small subset of memory cells, 
which quickly expand following secondary exposure. Up to >50-fold lower 
peptide concentrations can trigger antigen-experienced T cells compared to 
naive  T  cells  (Veiga-Fernandes  et  al.,  2000).  The  memory  T  cell 
compartment is composed of two main subsets: central memory (TCM) and 
effector  memory  (TEM)  (Sallusto  et  al.,  2004).  TCM  home  to  peripheral 
lymphoid organs due to the expression of CCR7 and CD62L and have a 
higher capacity to proliferate and differentiate into effector cells in response 
to antigen stimulation, whereas TEM are less proliferative, migrate to inflamed 
peripheral  tissues  and  display  effector  functions,  including  the  release  of 
effector cytokines such as IFN-γ (Sallusto et al., 2004). 
1.3.2.1.7 T cell subsets 
  The mature T cell lineage is divided into CD4
+ and CD8
+ αβ T cells and 
innate-like T cells. CD4
+ T cells differentiate into different subsets, namely 
Type-1  helper  (TH1),  Type-2  helper  (TH2),  Type-17  helper  (TH17)  and 
regulatory T (Treg) cells (Kim and Cantor, 2014). Innate-like T cells share 
innate and adaptive characteristics and comprise a small percentage of the 
total T cell compartment (Brennan et al., 2013). The main subsets of innate-
like T cells identified so far are gamma-delta (γδ) and invariant natural killer 
(iNK) T cells.  INTRODUCTION 
  40 
1.3.2.1.8 CD8
+ T cells  
   CD8
+ T cells contribute to host defence against tumours and during acute 
and  chronic  infection  with  viruses,  intracellular  bacteria  and  parasites 
(Germain,  2002).  CD8
+  T  cells  are  also  termed  cytotoxic  T  lymphocytes 
(CTLs) due to their cytotoxic function. Upon activation, CD8
+ T cells release 
granules  containing  the  pore-forming  molecule  perforin  and  granzymes, 
which induce target cell lysis and apoptosis, respectively (Zaritskaya et al., 
2010). CD8
+ T cells also up-regulate the expression of the membrane-bound 
TNF-family members Fas Ligand (FasL) and TNF-related apoptosis-inducing 
ligand (TRAIL), which trigger the apoptosis of target cells after binding to Fas 
and TRAIL receptors, respectively (Zaritskaya et al., 2010). 
1.3.2.1.9 CD4
+ T cells 
   CD4
+ T cells are termed T helper cells due to their key role in orchestrating 
humoral  and  cellular  immune  responses.  CD4
+  T  cells  are  polarized  into 
different subtypes with distinct biological functions depending primarily on the 
antigen, the strength of the TCR signalling, and the cytokines present in the 
surrounding  extracellular  environment  during  activation  (Kim  and  Cantor, 
2014). Th1 cells are polarised by IL-12 released by macrophages and DCs 
during  type  1  inflammatory  responses  (Ferrero  et  al.,  2007).  Th1  T  cells 
express the transcription factor T-bet, up-regulate IFN-γ expression and are 
important during immune responses against intracellular pathogens by either 
enhancing CD8
+ T cell response or by directly activating macrophages and 
promoting  their  bactericidal  activity  (Kim  and  Cantor,  2014).  Th2  cells 
express the transcription factor GATA-3 and produce the cytokines IL-4, IL-
13, and IL-10 and important in promoting humoral responses and immunity 
against parasitic worms and are the predominant Th subtype during allergy, 
where  they  stimulate  IgE  production  and  eosinophil  and  granulocyte 
recruitment  (Johansson  et  al.,  2008).  Th17  T  cells  are  induced  by  the 
combined actions of TGF-β and IL-6 and express the STAT3 and RORgt 
transcription  factors  and  the  cytokine  IL-17  and  neutrophil-recruiting 
chemokines such as CXCL1 and CXCL2 (Johansson et al., 2008). Although 
Th17  are  important  in  protection  against  invading  microorganisms,  they INTRODUCTION 
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contribute to the severe inflammation in chronic inflammatory diseases such 
as rheumatoid arthritis (Kim and Cantor 2014).  
1.3.2.1.10  Regulatory T cells 
   Th cells also contain a subset termed regulatory T cells (Treg) responsible 
for  dampening  excessive  immune  responses,  playing  a  vital  role  in  self-
tolerance  and  inhibition  of  autoimmunity  (Kim  and  Cantor  2014).  Treg 
function  depends,  at  least  partially,  on  the  expression  of  the  transcription 
factor FoxP3. In humans, mutations in the FOXP3 gene are associated with 
the  fatal  systemic  autoimmune  condition  called  immune-dysregulation 
polyendocrinopathy enteropathy X-linked syndrome (IPEX) (Sakaguchi et al., 
2012).  Deletion  of  the  FoxP3  gene  in  mice  also  causes  a  similar  auto-
immune condition (Sakaguchi, Powrie et al. 2012). In addition, ectopic FoxP3 
expression  confers  suppressive  function  to  conventional  T  cells  (Tconv) 
(Morikawa  and  Sakaguchi,  2014).  The  adoptive  transfer  of  conventional 
CD4+  T  cells  transduced  with  the  FoxP3  gene  ameliorated  disease  in  a 
murine model of arthritis (Wright et al., 2009). 
   Two main subsets of Treg cells have been identified: natural and induced 
Treg  cells.  Natural  Tregs  (nTregs)  form  in  the  thymus  when  developing 
thymocytes  recognise  self-antigens  with  high-affinity,  albeit  below  the 
threshold needed to	 ﾠinduced T cell apoptosis (Ohkura et al., 2013). Induced 
Tregs  (iTregs)  differentiate  in  peripheral  tissues  in  response  to  IL-10  or   
TGF-β  (Johansson  et  al.,  2008).  Natural  Treg  cells  typically  suppress 
immune responses through the cell surface molecule cytotoxic T lymphocyte 
antigen  4  (CTLA4),  TGF-β,  and  adenosine  whereas  induced  Treg  cells 
suppress mainly through the release of soluble factors, such as IL-10 and 
TGF-β (Johansson et al., 2008). FoxP3 expression has been shown to be 
more stable in nTregs compared to iTreg cells due to differences in DNA 
methylation patterns in the FoxP3 locus (Ohkura et al., 2013). 
1.3.2.1.11  Innate-like T cells  
   In contrast to αβ T cells, innate-like T cells respond rapidly to infection or 
tissue  dysregulation  through  cytokine  production  and  express  TCRs  of INTRODUCTION 
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limited  sequence  diversity.  Innate-like  T  cells  respond  and  play  important 
immunoregulatory  functions  during  tissue  stress  in  conditions  such  as 
cancer, allergy and inflammation (Brennan et al., 2013). Regarding their main 
subsets, γδ T cells are usually found in tissues, especially the epidermis and 
dermis, where they recognise non-peptide antigens up-regulated by stressed 
cells (Vantourout and Hayday, 2013). γδ T cells can release granzyme, IFN-γ 
and  IL-4,  which  highlights  the  pleotropic  functions  of  this  cell  type 
(Vantourout and Hayday 2013). iNKT cells recognise self and foreign lipid 
antigens presented by the non-polymorphic MHC class I-like molecule CD1d 
and  have  been  shown  to  have  either  protective  or  harmful  roles  in  many 
pathological  states,  including  microbial  infection,  auto-immune  disease, 
allergy and cancer. Like their γδ counterparts, iNKT cells produce both Th1 
and Th2 cytokines, depending on the cytokine environment and nature of the 
lipid antigen (Brennan et al., 2013). 
1.3.2.1.12  Anergy, exhaustion, senescence and tolerance  
   In  addition  to  the  TCR-peptide  MHC  interaction,  a  second  signalling 
referred to as co-stimulation is needed for full T cell activation to occur (Chen 
and Flies, 2013). Co-stimulation occurs as the B7-family receptors CD80 and 
CD86 expressed on the surface of APCs bind to CD28 expressed on the T 
cell surface (Chen and Flies 2013). Sub-optimal T cell activation leads to 
overlapping  states  of  T  cell  dysfunction  termed  anergy,  exhaustion, 
senescence  and  tolerance.  Anergy  is  caused  by  T  cell  stimulation  in  the 
absence of co-stimulation (Crespo et al., 2013). Anergic T cells are unable to 
produce  IL-2  or  proliferate  in  response  to  a  second  round  of  antigen 
stimulation (Schietinger and Greenberg, 2011). In contrast to anergy, which 
is induced rapidly after stimulation, exhaustion takes place when T cells are 
repeatedly stimulated by antigen over a period of weeks or months, such as 
during chronic viral infections and cancer (Schietinger and Greenberg, 2014). 
Importantly, T cell exhaustion may be enhanced by suppressive cytokines 
such  as  IL-10  and  transforming  growth  factor  (TGF)-β,  as  discussed  in 
section 1.5.2.1.8. T cell exhaustion is associated with the up-regulation of co-
inhibitory receptors such as programmed cell death 1 (PD-1), lymphocyte-INTRODUCTION 
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activation  gene  3  (LAG-3),  T  cell  immunoglobulin  and  mucin  domain-
containing  molecule  3  (TIM-3)  and  cytotoxic  T  lymphocyte-associated 
antigen-4 (CTLA-4) (Crespo et al., 2013). T cell senescence is marked by 
telomere shortening, cell cycle arrest and phenotypic defects such as loss of 
CD28 expression and defective killing ability (Crespo et al., 2013). Although 
senescence  occurs  with  normal  cellular  ageing,  chronic  activation  during 
autoimmune  disease  or  chronic  viral  infection  can  also  lead  to  cell 
senescence (Crespo et al., 2013). Finally, tolerance is characterised by a 
state of hypo-responsiveness to self-antigen imparted in the thymus as self-
reactive  T  cells  are  deleted  during  negative  selection  (central  tolerance). 
Self-reactive T cells escaping thymic deletion may be rendered inactive in the 
periphery (peripheral tolerance) due to the absence of antigen (ignorance), 
due to sub-optimal T cell stimulation by APCs expressing low levels of co-
stimulatory molecules or as a result of active suppression by regulatory cell 
types such as Tregs (Schietinger and Greenberg 2014). Peripheral tolerance 
can  be  broken  when  self-antigen  is  detected  in  the  presence  of  pro-
inflammatory signals (Ohashi and DeFranco, 2002). 
1.3.2.2  B lymphocytes 
   B  cells  are  adaptive  immune  cells  that  develop  in  adult  mammals  from 
hematopoietic  precursor  cells  in  the  bone  marrow  (Pieper  et  al.,  2013). 
Analogous  to  T  cells,  B  cells  contain  a  highly  diverse  and  somatically 
rearranged  antigen  receptor,  which  is  called  the  B  cell  receptor  (BCR), 
formed by a plasma membrane bound immunoglobulin molecule linked to the 
signalling transducing Igα/Igβ heterodimer (Khan and Turner, 2006). B cells 
play a key role in protection against a wide range of pathogens due to their 
ability to produce antibodies and regulate immune responses through antigen 
presentation and cytokine production. Abnormal B cell function is associated 
with immune-deficiencies and the pathogenesis of autoimmune diseases and 
allergy (Mauri and Bosma, 2012).  INTRODUCTION 
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1.3.2.2.1 Antibody structure and function  
   Immunoglobulins, or antibodies, are composed of two light and two heavy 
chains linked by disulphide bonds, forming a Y-shaped molecule containing 
two identical Fab arms formed by both light chains paired with the variable 
and a constant region of the heavy chains (Wingren et al., 2005). Fab arms 
are joined to a stem termed the Fc portion, which is formed by the remaining 
two  constant  regions  of  both  heavy  chains  (Wingren  et  al.,  2005).  The 
antigen binding sites of an antibody are located at the tips of Fab arms, in 
regions  of  high  sequence  diversity  called  complementarity  determining 
regions  (CDRs)  (Pieper  et  al.,  2013).  The  Fc  fragment  is  responsible  for 
mediating  effector  functions  such  as  complement  activation  and  antibody-
dependent  cell-mediated  cytotoxicity  (ADCC),  which  consists  of  the 
phagocytosis and degradation of antigen-antibody complexes following the 
recognition of the Fc region by Fc receptors expressed by innate immune 
cells such as macrophages and dendritic cells (Pieper et al., 2013). 
1.3.2.2.2 Antibody classes  
   Immunoglobulins  are  divided  into  different  classes  depending  on  the 
structure of the heavy chain constant regions. In mammalians, there are five 
classes: IgA, IgD, IgE, IgG and IgM. IgM has a pentameric structure and is 
the first antibody produced during primary immune responses, whereas IgA 
is found predominantly in mucosal linings and in regions constantly exposed 
to pathogens, such as the gastrointestinal tract (Khan and Turner 2006). The 
IgG class is the major circulating immunoglobulin class, being also the most 
effective  at  activating  complement  and  inducing  ADCC.  IgE,  on  the  other 
hand,  is  the  least  abundant  immunoglobulin  and  interacts  with  cells 
basophils,  mast  cells  eosinophils  during  allergy  and  parasitic  infections 
(Wingren et al., 2005). 
1.3.2.2.3 B cell activation  
    B cells are activated following the binding of extracellular antigen to the 
BCR, leading to the phosphorylation of tyrosine residues in the ITAMs of the INTRODUCTION 
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Igα/Igβ  heterodimer,  which  triggers  downstream  tyrosine  phosphorylation 
and additional signalling events in a similar manner to the TCR (Dal Porto et 
al., 2004). B cell activation results in B cell differentiation into memory B cells 
and the antibody secreting plasma cells (Pieper et al., 2013). During plasma 
cell differentiation, B cells frequently come into contact with T cells in the 
germinal centres of the lymph nodes, where T cell derived signalling help B 
cells produce affinity matured and class switched antibodies (Pieper et al, 
2013). 
1.3.2.2.4 The germinal centre reaction  
   Most humoral immune response require the interaction of B cells with T 
helper  cells  located  in  specialised  structures  within  the  B  cell  follicles  of 
secondary lymphoid organs called germinal centres (Gatto and Brink, 2010). 
A  subset  of  CD4
+  T  cells  expressing  CXCR5  and  the  inducible  T-cell 
costimulator  (ICOS)  termed  T  follicular  helper  cells  (TFH)  specialise  in 
interacting with B cells in the germinal centres (Ferrero et al., 2007). TFH cells 
deliver  activation  signalling  to  B  cells  via  the  CD40-CD40L  axis,  which 
support antibody production and class switching (Thielen and Heinen, 2010). 
Class  switching  occurs  as  B  cells  re-arrange  their  heavy  chain  genes, 
leading to the production of immunoglobulins of different subtypes (Thielen 
and  Heinen  2010).  Importantly,  different  T  helper  subsets  influence  the 
outcome of class switching. For instance, Th2 cells favour switching to the 
IgE  isotype  whereas  Th1  cells  favour  switching  to  complement-activating 
immunoglobulins  such  as  IgG  (Thielen  and  Heinen  2010).  Additional 
outcomes of T cell-dependent B cell activation are somatic hypermutation 
and  affinity  maturation,  in  which  high  frequency  point  mutations  in  the 
hypervariable regions in the variable chains are followed by the selection of 
antibody  variants  with  the  highest  antigen  affinity  (Pieper  et  al.,  2013). 
Following activation, BCR-antigen complexes are internalised, degraded and 
peptides  presented  in  association  with  MHCII  molecules  the  activation  of 
CD4
+  T  helper  cells  (Mauri  and  Bosma,  2012).  Finally,  B  cells  with 
suppressive  capacity  (Bregs)  have  been  described  in  a  range  of 
inflammatory  disease  models  such  as  experimental  autoimmune INTRODUCTION 
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encephalomyelitis (EAE), collagen-induced arthritis (CIA), and colitis (Mauri 
and Bosma, 2012). 
1.4  Tumour immune-surveillance 
   Clinical and pre-clinical evidence have demonstrated the vital role played 
by  the  immune  system  on  impeding  tumour  development.  For  instance, 
immuno-deficient  individuals,  such  as  organ  transplant,  long-term 
immunosuppressed or AIDS patients are pre-disposed to the development of 
certain cancers (Swann and Smyth, 2007). Cancer predisposition has also 
been  observed  in  patients  with  inherited  immune-deficiencies,  such  as 
individuals  carrying  loss-of-function  mutations  in  the  perforin,  FasL  and 
NKG2D  genes  and  Chediak–Higashi  syndrome  patients,  a  disease 
characterized  by  abnormal  NK  cell  function  (Zitvogel  et  al.,  2006). 
Conversely, T cell infiltration is associated with better prognosis in a range of 
human cancers, including breast cancer, renal cell carcinoma, melanoma, 
ovarian cancer and gastrointestinal stromal tumors (Gajewski et al., 2013). 
Genetically engineered mice lacking essential components of the innate or 
adaptive immune system are also more susceptible to the development of 
spontaneous and chemically induced tumours.  For instance, RAG deficient 
mice, which lack both B and T cells, develop spontaneous adenocarcinomas 
in  the  intestine  and  lung  (Swann  and  Smyth  2007).  Spontaneous  tumour 
development is also observed in mice lacking Granzyme B, Perforin, IFN-γ 
receptor  1  and/or  signalling  transducer  and  activator  of  transcription  1 
(STAT1), a key transcription factor for IFNγ-induced signalling (Zitvogel et al., 
2006).  However,  protection  conferred  by  the  immune  system  is  often 
incomplete, with less immunogenic tumour cell variants frequently emerging 
as  a  result  of  the  selective  pressure  imparted  by  the  immune  system,  as 
described by the immune-editing hypothesis.	 ﾠ 
1.4.1 Immune-editing  
   The immune-editing hypothesis suggests that the immune system “sculpts” 
the  immunogenicity  of  growing  tumours  by  selecting  less  immunogenic INTRODUCTION 
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variants (Schreiber et al., 2011). For instance, Methylcholanthrene (MCA)-
induced sarcomas grown in immunocompetent mice develop more robustly 
when transferred to immunocompetent secondary recipient mice compared 
to tumours grown in immune deficient mice (Schreiber et al., 2011). Immune-
editing occurs in three phases: elimination, equilibrium and escape.  
1.4.1.1  Elimination  
   The  elimination  phase  of  immune-editing  is  analogous  to  immune-
surveillance,  whereby  the  immune  system  prevents  tumour  growth  into  a 
clinically detectable size. A central tenet of cancer immunoediting is that T 
cell  recognition  of  tumour  antigens  drives  the  destruction  of  developing 
tumours (Matsushita et al., 2012). New advances in sequencing technology 
have allowed researchers to characterise the endogenous immune response 
to cancer antigens in humans.  
1.4.1.1.1 Classes of human tumour antigens  
   In  human  cancers,  tumour  infiltrating  lymphocytes  reactive  to  tumour 
antigens  have  been  characterised  primarily  in  melanoma,  assisted  by  the 
natural  immunogenicity  and  the  ease  in  obtaining  biopsy  material  in  this 
tumour type (Coulie et al., 2014). Tumour antigens are broadly divided into 
two classes: tumour-specific antigens (TSAs), or “neo-antigens”, and tumour-
associated antigens (TAAs). TSAs arise as a result of somatic mutations and 
are  generally  produced  in  increasing  numbers  in  more  advanced  tumours 
with higher genomic instability (Kvistborg et al., 2012). TAAs, on the other 
hand,  are  over-expressed  non-mutated  host  proteins,  being  also  called 
“shared self- antigens” (Kvistborg et al., 2012). TAAs are further subdivided 
into  four  classes:  tissue  differentiation  antigens,  which  are  restricted  to 
tumours and the specific tissue lineage tumours originate from, such as the 
melanoma antigen MART-1; ubiquitous cellular proteins over-expressed in 
tumours, such as the Her-2/Neu and PRAME antigens and antigens whose 
expression  is  restricted  to  tumours  and  male  germline  cells,  such  as  the 
MAGE antigens (Heemskerk et al., 2013). INTRODUCTION 
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1.4.1.1.2 Identifying human cancer antigen-specific T cells  
   Recent  advances  in  genomic  sequencing  have  helped  identify  tumour 
antigens targeted during anti-tumour T cell responses and the corresponding 
sequences  of  the  TCRs  involved.  The  process,  termed  “reverse 
immunology”, consists of sequencing the tumour genome, identifying mutant 
antigens  by  comparing  with  normal  tissue  antigens  and  using  established 
databases to predict which peptides bind MHC molecules (Gajewski et al., 
2013). Subsequently, synthetic peptides are designed and large collections 
of peptide–MHC complexes produced using UV-induced peptide exchange 
(Heemskerk et al., 2013). Finally, T cell reactivity can be tested in vitro and 
TCR genes sequenced (Linnemann et al., 2014). A recent study showed that 
tumour infiltrating T cells from melanoma patients display no reactivity to a 
panel  of  over  150  shared  antigens,  suggesting  that  recognition  of  neo-
antigens may be a prominent feature in melanoma (Kvistborg P, et al 2012). 
It is plausible that tumours with a high mutation load, such as melanoma, are 
dominated  by  patient-specific  neo-antigens  (Kvistborg  et  al.,  2013).  More 
studies are needed to elucidate the reactivity of naturally occurring T cells in 
other tumour types. 
1.4.1.1.3 Role of the innate immune system in the elimination phase 
   It  is  now  established  that  the  coordinated  action  of  both  innate  and 
adaptive immunity is needed to protect the host against developing tumours 
(O'Sullivan et al., 2012). For instance, innate cells mediate tumour regression 
through a series of mechanisms, such as: type I interferons (IFNs), activation 
of  receptors  recognising  damage-associated  molecular  patterns  (DAMPs) 
released by dying tumour cells such as RAE-1 and H60 (mouse) or MICA/B 
(human) up-regulated on the surface of tumour cells (Schreiber et al., 2011) 
or  direct  tumour  killing  by  M1-polarised  macrophages  (O'Sullivan  et  al,. 
2012). INTRODUCTION 
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1.4.1.2  Equilibrium  
   A subpopulation of tumour cell variants may survive the elimination phase 
and enter a dormant state during which further tumour growth is prevented 
by the immune system, which is termed the equilibrium phase (Koebel et al., 
2007). In the murine system, T lymphocytes have been shown to play a key 
role  in  the  equilibrium  phase  as  treatment  with  CD4  and  CD8  depleting 
antibodies  caused  MCA-induced  tumours  to  re-emerge  from  a  state  of 
dormancy  (Koebe  et  al.,  2007).  In  contrast  to  elimination,  the  equilibrium 
phase  does  not  seem  to  require  the  presence  of  innate  immune  system 
(Schreiber et al., 2011). 
1.4.1.3  Escape  
   The escape phase is characterised by the growth of the less immunogenic 
tumour cell variants that survived during the equilibrium phase into clinically 
detectable tumours (Koebel et al., 2007). Immune editing is better seen as a 
bi-directional process whereby cancer cells evolve in response to immune 
pressure and shape the immune system to a dysfunctional state that favours 
tumour progression. The mechanisms underlying tumour immune escape will 
be discussed in the next section.  
 
1.4.2 Mechanisms of evasion from immune-surveillance 
   Evasion  from  immune-surveillance  occurs  due  to  tumour  cell-intrinsic 
changes  and/or  through  impairment  of  immune  function.  Tumour-intrinsic 
changes, which are powered by genomic instability and immune selection 
pressure, include: antigen loss, MHCI down-regulation and expression of co-
inhibitory and anti-apoptotic molecules. Immune impairment during cancer is 
associated with the establishment of a chronic inflammatory-like state that 
ultimately promotes tumour development. The mechanisms of evasion from 
immune-surveillance will be described below.  INTRODUCTION 
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1.4.2.1  Antigen loss  
   Immune escape due to antigen loss has been well characterised in murine 
models of cancer. For instance, exome sequencing has demonstrated that 
escape  variants  of  highly  immunogenic  MCA-induced  sarcoma  lose 
expression  of  antigens  such  as  Spectrin-β2  following  transplantation  into 
immune-competent recipients (Matsushita et al., 2012). Immune escape due 
to antigen loss is less well characterised in human cancer patients. In the 
setting  of  immunotherapy  with  antigen-specific  T  cells,  loss  of  the 
melanocytic  antigen  MART-1  was  observed  in  nodules  at  relapse  in 
melanoma  patients  treated  with  melanoma  antigen-specific  CD8
+  T  cells 
(Yee et al., 2002). Antigen loss occurred despite normal levels of HLA-A2 
expression (Yee et al., 2002). 
1.4.2.2  MHC Class I down-regulation  
   Tumour cells often become invisible to T cell recognition through down-
regulation of MHCI expression or due to defects in the antigen processing 
machinery. Common defects in antigen processing and presentation include 
the loss of the TAP1 transporter, MHC class I, β2 microglobulin (β2m) and 
the proteosome subunits LMP2 and LMP7 (Vesely et al., 2011). For instance, 
loss  of  HLA-class  I  antigen  presentation  in  tumour  cells  isolated  from  a 
melanoma  patient  was  associated  with  2  mutational  events  affecting  both 
copies of the β2m gene (Paschen et al., 2003). Moreover, tumour cells from 
this  patient  became  insensitive  to  IFN-γ-induced  MHCI  up-regulation 
(Paschen et al., 2003). 
1.4.2.3  Low affinity T cell receptors  
    Due to the fact that the majority of TAAs are over-expressed self-proteins, 
the vast majority of T cells expressing high-affinity TCRs specific to TAAs are 
usually deleted in the thymus (central tolerance) or rendered inactive in the 
periphery (peripheral tolerance) (Aggen et al., 2012). Although high-affinity T 
cells  that  escape  tolerance  mechanisms  have  been  isolated  from  tumour 
biopsies, it is thought that the vast majority of TCRs from TAA-specific T cells 
found  in  the  periphery  are  low  affinity,  which  likely  significantly  limits  the INTRODUCTION 
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efficacy of anti-tumour T cell responses (Morris et al., 2006). In contrast, T 
cells  bearing  TCRs  recognising  TSAs  are  more  likely  to  bypass  central 
tolerance,  permitting  the  generation  of  more  robust  T  cell  responses 
(Heemskerk et al., 2013).  
1.4.2.4  T cell exhaustion  
   Tumour infiltrating T cells typically show impaired cytokine production and 
lytic activity ex vivo compared to T cells isolated from blood or normal tissue 
of the same patient (Ahmadzadeh et al., 2009). T cell exhaustion in cancer is 
associated with the up-regulation of the co-inhibitory receptors PD-1, LAG-3, 
TIM-3, and CTLA-4 in addition to attenuated TCR signalling due to the up-
regulation of the tyrosine phosphatases SHP-1 and/or SHP-2	 ﾠ(Crespo et al., 
2013). Interestingly, genome-wide transcriptome analysis of Mart-1-specific 
CD8
+  T  cells  isolated  from  melanoma  patients  revealed  a  very  similar 
exhaustion  profile  to  T  cells  isolated  during  chronic  LCMV  infection 
(Schietinger and Greenberg, 2014). Importantly, a plethora of cell types and 
humoral factors present in the tumour microenvironment contribute to T cell 
dysfunction, as discussed later in section 1.5.2. 
1.5  The hostile tumour microenvironment 
   Solid tumors are better understood as “organs” composed of multiple cell 
types, including immune cells, fibroblasts, adipocytes and endothelial cells 
embedded in an extracellular matrix. This milieu contains a range of growth 
factors,  chemokines,  cytokines,  antibodies  and  metabolites,  which 
collectively  with  the  cell  types  mentioned  above  form  the  tumour  stroma 
(Egeblad et al., 2010).  During tumour progression, stromal cells are actively 
recruited  from  the  general  circulation,  neighbouring  tissues,  bone  marrow 
and  spleen  (Fang  and  Declerck,  2013).  Moreover,  changes  in  the  overall 
histological  organisation  of  the  stroma  as  tumours  become  more  invasive 
help determine the stage of cancer development and the likely outcome in 
cancer  patients  (Egeblad,  et  al.,  2010).  Most  tumours  are  marked  by  a INTRODUCTION 
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chronic  inflammatory  state  in  which  tumour  stromal  cell  types  become 
educated to promote tumour development, as discussed below. 
1.5.1 Cancer-related inflammation  
   The link between cancer and inflammation was proposed by Virchow in the 
19
th century following the observation that tumours were often infiltrated by 
immune cells (Quail and Joyce, 2013). Current estimates suggest that about 
25% of cancers are associated with chronic inflammation (Coussens et al., 
2013).  Examples  include  inflammatory  bowel  disease,  prostatitis,  obesity, 
cigarette  smoking  or  infections  with  microoganisms  such  as  Helicobacter 
pylory,  Hepatitis  B,  Human  papilloma  virus  (HPV),  Schistosoma  and 
Bacteroides, which predispose to gastric, liver, cervical, bladder and colon 
cancer,  respectively  (Coussens  et  al.,  2013).  Even  cancers  that  are  not 
epidemiologically linked to inflammation are characterised by the presence of 
inflammatory  cells  and  mediators  (Balkwill  et  al.,  2012).  Epidemiological 
evidence  that  long-term  use  of  nonsteroidal  anti-inflammatory  drugs 
(NSAIDs) reduce the overall risk of colon and breast cancer supports the 
idea that inflammation contributes to tumour development (Grivennikov et al., 
2010).  Conversely,  it  is  possible  that  inflammation  promotes  tumour 
regression by stimulating anti-tumour immunity, as demonstrated by Coley, 
who  successfully  treated  sarcomas  with  bacterial  mixtures  in  the  1890s 
(Coussens  et  al.,  2013).  Much  of  the  paradoxical  role  of  inflammation  in 
tumour  progression  can  be  explained  by  the  enormous  plasticity  of  the 
immune cells found in the tumour microenvironment, as explained in section 
1.5.2.  
1.5.1.1  Extrinsic and intrinsic pathways 
   Cancer-induced  inflammation  is  divided  into  the  extrinsic  and  intrinsic 
pathways depending on the source of the agent triggering the inflammatory 
process.  The  extrinsic  pathway  is  driven  by  infections  or  inflammatory 
disorders such as inflammatory bowel disease and prostatitis (Mantovani et 
al., 2008). These external stimuli typically activate innate immune cells via INTRODUCTION 
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PRRs such as TLRs, leading to NF-κB pathway activation and the production 
of chemokines, pro-angiogenic factors, pro-inflammatory cytokines such as 
IL-1, IL-6 and TNF-α in addition to the bioactive mediators Prostaglandin E2 
(PGE2) and Nitric Oxide (NO) via up-regulation of the enzymes COX-2 and 
iNOS, respectively (Schroder and Tschopp, 2010).  
   The intrinsic pathway is utilised when mutations in cancer cells trigger the 
production of pro-inflammatory cytokines and chemokines such as IL-6, IL-8, 
IL-1, M-CSF, M-CSF, GM-CSF, CCL2 and CCL20 (Grivennikov et al., 2010). 
For  instance,  MYC  over-expression  drives  IL-1  up-regulation  in  several 
human  cancers  (Shchors  et  al.,  2006)  whereas  activating  Kras  mutations 
drive GM-CSF up-regulation in pancreatic cancer (Bayne et al., 2012). DNA 
damage can also induce a local inflammatory response through up-regulation 
of NKG2D ligands on the surface of cancer cells, which are recognised by 
NK  and  γδ  T  cells  (Grivennikov  et  al.,  2010).  Regardless  of  the  origin, 
inflammation influences every stage of tumour development, as described 
below.  
1.5.1.2  Role in tumour initiation  
   Pro-inflammatory  cytokines  and  growth  factors  produced  by  chronically 
activated  leukocytes  stimulate  tumour  cell  survival  and  proliferation.  For 
instance,  STAT3  phosphorylation  induced  by  myeloid-cell  derived  IL-6 
induces  the  up-regulation  of  cyclins,  the  proto-oncogene  MYC  and  anti-
apoptotic  proteins  such  as  Bcl-2  in  tumour  cells  (Elinav  et  al.,  2013). 
Additional  pro-growth  factors  produced  during  inflammation  include: 
Epithelial Growth Factor (EGF), TGF-β, TNF-α and fibroblast growth factors 
(FGF) (Coussens et al., 2013). In addition, DNA damage induced by reactive 
oxygen species (ROS) and reactive nitrogen intermediates (RNI) released by 
neutrophils and macrophages contribute to genetic instability in cancer cells 
(Grivennikov, et al., 2010).  INTRODUCTION 
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1.5.1.3  Role in tumour progression  
    Tumour  development  is  associated  with  the  active  recruitment  of 
leukocytes promoted by tumour cell-derived factors such as GM-CSF and 
CSF-1  (Coussens  et  al.,  2013).  In  established  tumours,  various  cytokines 
and  signalling  present  in  the  tumour  microenvironment,  including  IL-10, 
PGE2,  TGF-β  and  CSF-1,  skew  tumour-induced  inflammation  towards  a 
“wound-healing”  response  marked  by  immune-suppression  in  addition  to 
trophic and regenerative responses associated with angiogenesis and tissue 
remodelling, which contribute to tumour growth and spread to distant sites 
(metastasis) (Elinav, et al., 2013). 
1.5.1.3.1 Role in angiogenesis  
	 ﾠ	 ﾠ	 ﾠAs tumours grow, the increased requirement for oxygen and nutrients is met 
through the formation of new blood vessels, a process termed angiogenesis. 
Angiogenesis  requires  the  co-operation  of  multiple  cell  types,  including 
vascular  endothelial  cells,  pericytes  and  tumour-associated  macrophages 
(TAMs) (Quail and Joyce, 2013). The numbers of TAMs have been shown to 
correlate with vessel density in a range of human tumours (Allavena et al., 
2008). During tumour development, TAMs acquire a pro-angiogenic program 
in  response  to  hypoxia  through  the  activation  of  the  transcription  factor 
hypoxia-inducible  factor-1  (HIF-1),  leading  to  the  production  of  pro-
angiogenic factors such as TGF-β, TNF-α, Vascular endothelial growth factor 
(VEGF),  Platelet-derived  growth  factor  (PDGF),  Fibroblast  growth  factor 
(FGF)  and  angiogenic  chemokines  (Allavena,  et  al.,  2008).    In  fact,  TAM 
depletion  inhibited  tumour  growth  and  drastically  reduced  tumour  blood 
vessel  density,  with  the  strongest  effects  seen  when  TAM  depletion  was 
combined  with  a  VEGF-neutralising  antibody  in  the  murine  F9 
teratocarcinoma  and  human  A673  rhabdomyosarcoma  mouse  tumour 
models (Zeisberger et al., 2006). Moreover, a subpopulation of myeloid cells 
characterised by the expression of monocyte/macrophage markers and the 
endothelial cell marker angiopoietin receptor (TIE2) has recently been shown 
to be crucial for angiogenesis in orthotopic and transgenic tumour models 
(Ruffell et al., 2012). INTRODUCTION 
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1.5.1.3.2 Role in epithelial to mesenchymal transition 
    Inflammation also contributes to the epithelial to mesenchymal transition 
(EMT), in which tumour cells lose epithelial markers, acquire stem cell-like 
markers and gain mesenchymal and invasive properties (Quail and Joyce 
2013).  Myeloid  cell-derived  cytokines  such  as  TGF-β,  IL-6  and  IL-1  have 
been shown to promote EMT (Bates and Mercurio, 2003). For instance, in a 
murine melanoma model, TNF-α triggered the dedifferentiation of melanoma 
cells,  which  was  associated  with  a  loss  of  melanocytic  antigens  and 
resistance  to  adoptive  immunotherapy  with  antigen-specific  T  cells 
(Landsberg et al., 2012). 
1.5.1.4  Role in metastasis 
   Around 90% of cancer mortality is associated with metastasis, defined as 
the spread of tumours from the primary site to other parts of the body via the 
bloodstream or the lymphatic system (Mantovani et al., 2008). Metastasis is 
a  multistage  process  that  involves  local  invasion  of  primary  cancer  cells, 
intravasation  into  nearby  blood  or  lymphatic  vessels,  survival  in  the 
circulation  and  ultimately  dissemination  and  colonization  of  distant  sites 
(Elinav et al., 2013). TAMs often assemble at the invasive edge of growing 
tumours and help “guide” tumour cells towards blood vessels by promoting 
tumour cell chemotaxis and remodelling the underlying stroma through the 
up-regulation  of  Epithelial  Growth  Factor  (EGF)  and  matrix 
metalloproteinases  (MMPs),  respectively  (Goswami  et  al.,  2005).  The 
pleiotropic role of TAMs during tumour development is illustrated in Figure 
1-4. INTRODUCTION 
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Figure 1-4: Role of TAMs during tumour progression 
 
1.5.2 Properties of the immune cell types found in the tumour 
microenvironment 
   Tumour development is associated with dynamic changes in immune cell 
composition  and  phenotype.  For  instance,  early  stage  and  regressing 
tumours  often  show  an  abundance  of  cytotoxic  CD8
+  memory  T  cells, 
whereas an increase in the levels of Tregs, myeloid derived suppressor cells 
(MDSCs),  M2-like  macrophages,  neutrophils,  Tie2
+  monocytes,  dendritic INTRODUCTION 
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cells (DCs), and Th2 CD4
+ effector T cells is frequently observed in more 
advanced tumours (Shiao et al., 2011). The immune cell types in established 
tumours  often  display  immunosuppressive  properties  that  may  help 
developing tumour cells escape T cell killing. The properties of the different 
immune cell types present in the tumour microenvironment will be discussed 
below, with emphasis on their role in regulating anti-tumour immunity.  
1.5.2.1  Tumour-associated macrophages (TAMs) 
   TAMs  represent  the  major  hematopoietic  cell  type  infiltrating  human 
cancers, with high TAM density being associated with poor prognosis in a 
wide  spectrum  of  human  cancers,  including  breast,  cervix,  bladder  and 
gastric (Galdiero et al., 2013). Mechanistic studies in mice showed that TAMs 
generally play a tumour-promoting role in vivo. Moreover, TAMs may be “re-
educated” to acquire anti-tumour properties in vivo.  
1.5.2.1.1 Effect of TAM depletion on tumour development 
    Macrophage  depletion  using  genetically  engineered  mice  or 
pharmacological  agents  provided  further  evidence  that  TAMs  ultimately 
contribute  towards  tumour  development.  For  instance,  crossing  the 
transgenic  PyMT  breast  cancer  model  with  mice  whose  monocyte-
macrophage lineage is depleted due to a recessive null mutation in the CSF-
1  gene  (Csf1
op  mice)  resulted  in  delayed  development  of  invasive 
carcinomas and a significant decrease in pulmonary metastasis (Lin et al., 
2001). Similar findings have been observed when monocyte infiltration into 
tumours was blocked using an anti-CCR2 neutralising antibody (Qian et al., 
2011), a CCR2-silencing short interfering RNA (Leuschner et al., 2011) or in 
CCR2 knockout mice (Franklin et al., 2014). 
1.5.2.1.2 Origin of TAMs 
  Although  tissue-resident  macrophage  populations  are  predominantly 
derived from yolk-sac and fetal liver progenitors in steady-state conditions 
(Yona et al., 2013), as described in section 1.3.1.6.3, TAM populations rely 
on the infiltration of circulating monocytes in response to CCL2, M-CSF or INTRODUCTION 
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GM-CSF  (Gabrilovich  et  al.,  2012).  A  major  reservoir  of  monocytes, 
macrophages and immature myeloid cells becomes established in the spleen 
during  tumourigenesis  (Cortez-Retamozo  et  al.,  2012).  Importantly, 
splenectomy  in  tumour  bearing  mice  significantly  reduced  TAM  levels, 
suggesting that monocytes mobilised from the spleen differentiate into TAMs 
(Cortez-Retamozo et al., 2012).  
1.5.2.1.3 TAM phenotype  
	 ﾠ
	 ﾠ	 ﾠ	 ﾠ	 ﾠTAMs  isolated  from  mouse  tumours  generally  show  an  M2-like  gene 
expression and cytokine release pattern characterised by the expression of 
the  typical  M2  markers  arginase-1,  YM1,  FIZZ1,  MGL2,  Scavenger  and 
Mannose Receptors; defective expression of the inflammatory cytokines IL-
12, TNF-α, CCL3, and IL-1 and high expression of the immunosuppressive 
cytokines IL-10 and TGF-β (Biswas et al., 2008). In tumours, the trophic and 
wound-healing  properties  of  M2-macrophages  are  “hijacked”  to  promote 
tumour development (Wynn et al., 2013).  
1.5.2.1.4 Main drivers of M2-polarisation in tumours  
   Tumour and adaptive immune cell-derived factors in addition to hypoxia 
have  been  shown  to  be  the  main  drivers  of  M2  polarisation  in  cancer 
(Mantovani  et  al.,  2008).  For  instance,  co-culture  of  human  macrophages 
with  ovarian  carcinoma  cell  lines  lead  to  the  up-regulation  of  typical  M2-
markers, with tumour cell-derived TNF-α being partially responsible for M2 
polarisation (Hagemann et al., 2006). Tumour cell-derived M-CSF has also 
emerged as an important M2-polarising factor in vitro and in vivo (Lacey et 
al., 2012). In the MMTV-PyMT model of mammary carcinogenesis, Th2 CD4
+ 
T cells promote M2 polarisation via IL-4 production (DeNardo et al., 2009). 
Moreover, human monocytes cultured with CD4
+ 
CD25
+ 
CD127
low FOXP3
+ 
regulatory  T  cells  acquire  a  M2-like  phenotype  characterised  by  high 
expression of mannose and scavenger receptors, low HLA-DR and impaired 
capacity to produce the pro-inflammatory mediators IL-1, IL-6, IL-8, MIP-1 
and TNF-α following LPS stimulation (Tiemessen et al., 2007). In the K14-INTRODUCTION 
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HPV16 mouse model of squamous carcinogenesis, autoantibodies produced 
by  B  cells  have  been  shown  to  polarize  macrophages  towards  a  tumour-
promoting phenotype via activation of Fcγ receptors (Andreu et al., 2010). 
Finally, hypoxia induces the expression of the M2 mediators IL-10, arginase-
1  and  PGE2  in  a  mechanism  dependent  on  the  up-regulation  of  the 
transcription  factors  hypoxia-inducible  factors  1  and  2  (HIF-1  and  HIF-2) 
(Biswas et al., 2008). In addition, loss of HIF-2a reduced TAM recruitment in 
models of inflammatory hepatocellular and colon carcinoma (Imtiyaz et al., 
2010).  
1.5.2.1.5 Phenotypic diversity of TAMs  
   Recent  studies  have  suggested  that  TAMs  display  phenotypic 
heterogeneity  and  their  strict  classification  into  M2  macrophages  is  over-
simplistic.  For  instance,  TAMs  infiltrating  subcutaneous  mammary 
adenocarcinoma  TS/A  tumours  were  comprised  of  two  distinct  subsets 
depending on their localisation in the tumour mass: M2-like MHC II
low TAMs 
were enriched in hypoxic areas whereas M1-like MHC II
high TAMs were more 
prevalent in normoxic areas of the tumour (Movahedi et al., 2010). TAMs with 
a mixed M1-M2 phenotype have been isolated from colon adenocarcinoma 
38 and GL261 murine glioma subcutaneous tumours (Umemura et al., 2008). 
Importantly, the phenotypic classification of TAMs may rely on a different set 
of markers and functional assays in different studies. For instance, TAMs 
isolated  from  the  MMTV-PyMT  tumour  model  were  classified  as  M2 
macrophages based on the expression of Ym1, Fizz1, and Mrc1 in one study 
(Franklin et al., 2014) and based on the expression of Arg-1, TGF-ß and 
VEGF-A in another study (DeNardo et al., 2009). 
1.5.2.1.6 Effect of TAM re-education on tumour growth  
    Adoptive transfer of macrophages defective in NF-κB signalling promoted 
tumour  regression  in  mice  bearing  advanced  ID8  ovarian  tumours 
(Hagemann et al., 2008). Moreover, TAMs switched towards an IL-12
high IL-
10
low M1-like phenotype marked by decreased expression of arginase-1 and 
elevated  iNOS  expression  following  NF-κB  inhibition  (Hagemann  et  al., INTRODUCTION 
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2008). More recently, a transgenic mouse model of Glioblastoma multiforme 
(GBM)  treated  with  a  CSF-1R  inhibitor  showed  tumour  regression  and 
improved survival (Pyonteck et al., 2013). Interestingly, the CSF-1R acted by 
decreasing  the  expression  of  M2-markers  such  as  Arg-1  and  mannose 
receptor rather than by depleting TAMs in the tumour tissue (Pyonteck et al., 
2013). 
1.5.2.1.7 TAM modulation in combination with standard anti-cancer therapies 
   Synergistic  effects  have  been  observed  when  pharmacological  agents 
targeting TAMs and MDSCs are administered in combination with standard 
anti-cancer  treatments  such  as  chemotherapy  drugs,  radiotherapy  or 
angiogenesis inhibitors in pre-clinical models and early phase clinical trials 
with cancer patients. In a genetically engineered mouse model of pancreatic 
ductal  adenocarcinoma,  an  agonistic  antibody  against  the  co-stimulatory 
molecule  CD40  given  in  combination  with  the  gemcitabine  up-regulated 
MHCII and CD86 expression (typically expressed in M1 TAMs) and promoted 
TAM-mediated  tumour  regression  in  vitro  and  in  vivo,  independently  of  T 
cells  (Beatty  et  al.,  2011).  In  the  same  study,  tumour  regression  by  anti-
tumour macrophages was also seen in a small cohort of pancreatic ductal 
adenocarcinoma patients treated by the combination regimen (Beatty et al., 
2011).  Moreover,  antibody-mediated  depletion  of  CD11b
+ 
myeloid  cells  in 
human  head  and  neck  tumours  grown  in  immunodeficient  mice  also 
demonstrated a synergistic effect when given with radiation therapy (Ahn et 
al., 2010). Although orally available small molecule tyrosine kinase inhibitors 
targeting  the  CSF1R  usually  show  minimal  anti-tumour  effects  when 
administered as single agents, they can potentiate the anti-tumour effect of 
standard  cancer  treatments.  For  instance,  the  CSF1R  inhibitor  GW2580 
inhibited TAM and MDSC recruitment into subcutaneous 3LL lung carcinoma 
tumours  and  enhanced  the  anti-tumour  and  anti-angiogenic  effect  of  a 
blocking antibody against VEGFR-2 (Priceman et al., 2010).  INTRODUCTION 
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1.5.2.1.8 Immune-regulatory properties of TAMs 
   It has been suggested that TAMs may have negative effects on T cells in 
the  ‘hostile’  tumour  microenvironment.  A  series  of  studies  exploring  the 
immunosuppressive effects of TAMs have been performed, predominantly ex 
vivo  with  macrophages  or  myeloid  derived  suppressor  cells  (MDSCs) 
isolated from tumours and spleens of tumour-bearing mice co-cultured with 
polyclonally  activated  or  antigen-specific  T  cells  stimulated  with  relevant 
peptide. Blocking antibodies, enzyme inhibitors and gene knockout models 
have been used to characterise the suppressive mechanisms deployed by 
TAMs, which include the production of reactive nitrogen species via iNOS up-
regulation,  release  of  the  immunosuppressive  cytokines  IL-10  and  TGF-ß 
and  the  up-regulation  of  the  enzymes  arginase-1  and  Indoleamine-pyrrole 
2,3-dioxygenase (IDO), which break down the essential aminoacids for T cell 
survival l-arginine and l-tryptophan, respectively (Ruffell et al., 2012). TAMs 
have also shown to cause T cell apoptosis through binding of PD-L1 to PD-1 
expressed  on  the  surface  of  activated  T  cells  (Gabrilovich  et  al.,  2012). 
Finally, TAMs promote Treg infiltration into tumours through the production of 
the chemokine CCL22 (Allavena et al., 2008). 
1.5.2.2  Myeloid-derived suppressor cells (MDSCs) 
   Cancer progression is associated with an abnormal myelopoietic process in 
which immature myeloid precursors expand without terminally differentiating 
into  mature  macrophages,  dendritic  cells,  or  granulocytes  (Ostrand-
Rosenberg,  2010).  This  heterogenous  group  of  immature  precursors  is 
termed  myeloid-derived  suppressor  cells  (MDSCs)  due  to  their  ability  to 
suppress T cell function (Nagaraj et al., 2010). MDSCs also expand during 
bacterial,  viral  and  parasitic  infections,  traumatic  stress  and  autoimmunity 
(Ostrand-Rosenberg 2010). Tumour-derived GM-CSF has been shown to be 
required for MDSC expansion and recruitment in a transgenic mouse model 
of pancreatic ductal adenocarcinoma (Bayne et al., 2012). However, the full 
range of factors responsible for MDSC expansion and activation in cancer 
remain to be determined.  INTRODUCTION 
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1.5.2.2.1 MDSC identification in mice and humans 
   MDSCs  characterisation  is  based  on  a  combination  of  surface  marker 
expression, morphology and suppressive phenotype. In mice, MDSCs are 
divided  into  CD11b
+  Ly6C
+  monocytic  MDSCs  (Mo-MDSC)  and  CD11b
+ 
Ly6G
+  polymorphonuclear  MDSCs  (PMN-MDSC)  (Galdiero  et  al.,  2013). 
Human  MDSCs  have  been  isolated  mainly  from  the  peripheral  blood  of 
cancer  patients  and  are  defined  as  CD14
-  CD11b
+  CD33
+  CD15
+  cells 
lacking the expression of mature myeloid markers such as HLA-DR (Khaled 
et  al.,  2013).  In  melanoma  patients,  MDSCs  have  been  further  classified 
CD14
+ monocytes/macrophages, CD14
- CD15
high immature myeloid cells and 
CD14
-  CD15
int  neutrophils/eosinophils  (Gros  et  al.,  2012).  It  must  be 
emphasised  that  MDSCs  are  defined  predominantly  by  their  ability  to 
suppress T cell function rather than by the expression of a restricted set of 
surface markers or commitment to a specific myeloid lineage. Furthermore, 
MDSCs have been shown to differentiate into TAMs in vitro in response to 
all-trans retinoic acid and GM-CSF (Gabrilovich et al., 2001). 
1.5.2.2.2 Suppressive properties of MDSCs 
   Current  evidence  suggests  that  MDSCs  employ  both  pro  and  anti-
inflammatory mediators to suppress T cell function (Nagaraj et al., 2010). In 
addition, MO-MDSCs and PMN-MDSCs have been shown to use different 
mechanisms  to  suppress  T  cell  function.  MO-MDSCs  produce  the  highly 
reactive intermediates Peroxynitrites (PNT) through the cooperative activities 
of NADPH oxidase, ARG-1 and iNOS (Gabrilovich et al., 2012). Peroxynitrite 
radicals  block  TCR  signalling  by  nitrosylating  key  tyrosine  residues  in  the 
TCR complex and driving the down-regulation of the CD3ζ chain (Gallina et 
al.,  2006,  Nagaraj  et  al.,  2010).  Moreover,  MO-MDSCs  can  exert  their 
suppressive  activity  in  an  antigen-independent  manner  through  the 
production  of  the  immunosuppressive  cytokines  IL-10  and  TGF-ß 
(Gabrilovich et al., 2012). Polymorphonuclear MDSCs, on the other hand, 
have been shown to suppress T cells in an antigen-dependent manner via 
ROS  production,  which  requires  cell-to-cell  contact  during  antigen 
presentation  (Nagaraj  et  al.,  2013).  It  has  been  suggested  that  tumour-INTRODUCTION 
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derived factors allow MDSCs to suppress in an antigen-independent manner 
(Lesokhin et al., 2012). Finally, MDSCs can potentiate immune-suppression 
by inducing the expansion of Foxp3
+ CD25
+ Tregs in vivo and in vitro (Huang 
et al., 2006). The suppressive mediators deployed by TAMs and MDSCs are 
illustrated in Figure 1-5.  
Figure 1-5: Suppressive mediators deployed by TAMs and MDSCs 
 
1.5.2.3  Effect  of  TAM  and  MDSC  modulation  on  endogenous  T  cell 
immunity in vivo 
   Although the T cell suppressive properties of TAMs and MDSCs are well-
established in vitro, the effect of targeting these myeloid cell populations on T 
cell function in vivo is still a matter of debate. The final outcome (immune-
suppression versus stimulation) is likely to be influenced by the activation 
states  of  TAMs  and  MDSCs,  which  may  vary  in  different  tumour  models 
and/or  stage  of  tumour  development  due  to  differences  in  the  cellular 
composition  and  the  levels  of  cytokines  and  other  factors  in  the  tumour 
microenvironment. The effect of TAM and MDSC targeting on endogenous T INTRODUCTION 
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cell immunity has been studied primarily in pre-clinical models and mainly in 
combination with standard anti-cancer treatments, such as chemotherapy or 
with immune checkpoint blockade inhibitors. The effect of TAM and MDSC 
targeting on adoptive T cell therapy will be discussed later in section 1.6.1.5 
1.5.2.3.1  TAM/MDSC modulation combined with chemotherapy 
   A recent trial with cancer patients treated with a humanised anti-CSF1R 
antibody led to TAM depletion and a marked increase in CD4
+ and, more 
predominantly, CD8
+ T cells in tumour tissues (Ries et al., 2014). However, 
the vast majority of studies reporting an enhancement in endogenous T cell 
immunity following TAM/MDSC modulation in vivo have used combination 
regimens  with  chemotherapy  drugs,  checkpoint  blockade  and  tumour 
vaccines. For instance, administration of a CSF1R inhibitor in combination 
with Gemcitabine increased the intra-tumour levels of CD4
+ and CD8
+ T cells 
and  reduced  Treg  levels  in  mice  bearing  Kras-INK  pancreatic  tumours 
(Mitchem et al., 2013). The anti-tumour efficacy of the combination regimen 
was  significantly  impaired  following  antibody  depletion  of  CD8
+  T  cells 
(Mitchem  et  al.,  2013).  Similar  findings  were  observed  in  MMTV-PyMT 
transgenic mice treated with a CSF1R-signalling antagonist in combination 
with paclitaxel (DeNardo et al., 2011).  
   It  should  be  emphasized  that  chemotherapy  drugs  can  stimulate  T  cell 
immunity  as  single  agents,  for  instance  through  “immunogenic  cell  death” 
following  the  release  of  tumour  antigens,  pro-inflammatory  cytokines, 
damage associated molecular patters (DAMPs) such as ATP, high mobility 
group  protein  B1  (HMGB1)  and  ligands  to  NKG2D-expressing  cells 
(Kolaczkowska  and  Kubes,  2013).  These  factors  activate  NK  cells  and 
promote DC maturation and antigen presentation, resulting in improved T cell 
priming and function (Zitvogel et al., 2006). Moreover, some chemotherapy 
drugs have been shown to induce the apoptosis of murine Tregs in vitro and 
in vivo without affecting the viability of conventional CD4
+ T cells (Alizadeh 
and Larmonier, 2014).  INTRODUCTION 
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1.5.2.3.2  TAM  and  MDSC  modulation  combined  with  immune  checkpoint 
blockade  
   TAM or MDSC depletion has also been shown to boost endogenous T cell 
immunity  and  enhance  the  anti-tumour  function  of  immune  checkpoint 
inhibitors and tumour vaccines. In a mouse model of rhabdomyosarcoma, 
knockout  of  the  chemokine  receptor  CXCR2  combined  with  anti-PD1 
antibody treatment led to improved anti-tumour responses and significantly 
lower  MDSC  levels  and  higher  endogenous  CD8
+  T  cells  in  tumours 
compared to wild-type hosts treated with the anti-PD1 antibody alone (Highfill 
et al., 2014). A synergistic anti-tumour effect was also observed when an 
anti-CCL2 blocking antibody was administered in combination with a tumour 
antigen vaccine, which was associated with increased intra-tumoural levels 
of endogenous tumour antigen-specific CD8
+ cells and lower levels of Tregs 
were observed in mice bearing non-small cell lung tumours expressing the 
viral HPV-E7 antigen treated with the combination regimen (Fridlender et al., 
2010).  
1.5.2.3.3  TAM/MDSC modulation by inducers of type-1 inflammation  
   Pro-inflammatory  stimuli  such  as  TLR  agonists  have  been  shown  to 
stimulate anti-tumour immunity as single agents by reverting the immune-
suppressive properties of the tumour microenvironment. For instance, intra-
tumoral  injection  of  CpG  oligodeoxynucleotides  (ODN)  promoted  tumour 
regression and increased the number of tumour-infiltrating T and NK cells 
while  decreasing  the  frequency  and  inhibitory  activity  of  MDSCs  in  mice 
bearing CT26 colon tumours (Shirota et al., 2012). The anti-tumour function 
of CpG required the presence of CD8
+ T cells and NK cells. MDSCs isolated 
from  tumours  displayed  an  increased  production  of  pro-inflammatory 
cytokines and impaired production of arginase-1 and NO when analised ex 
vivo (Shirota et al., 2012).  INTRODUCTION 
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1.5.2.4  Tumour associated neutrophils (TANs) 
   The  role  of  neutrophils  in  tumour  development  has  been  less  widely 
studied compared to TAMs and MDSCs due to the fact that neutrophils have 
a shorter life-span and are found at lower levels in tumours compared to 
TAMs  and  MDSCs  (Mantovani  et  al.,  2011a).  Recent  phenotypic  studies 
revealed  that  neutrophils  can  display  a  pro-inflammatory  and  anti-tumour 
“N1”  phenotype,  as  opposed  to  an  anti-inflammatory  and  pro-tumour  “N2” 
phenotype, in a manner analogous to macrophages (Mantovani et al., 2011). 
1.5.2.4.1 Role of TANs in tumour development  
   Early  studies  showed  that  neutrophil  depletion  led  to  reduced  tumour 
growth in an UV-induced sarcoma (Pekarek et al., 1995). In a rat mammary 
adenocarcinoma  model,  co-injection  of  cancer  cells  with  neutrophils  from 
tumour-bearing rats markedly increased metastasis (Welch et al., 1989). A 
further  seminal  study  showed  that  TGF-ß  inhibition  switched  neutrophil 
phenotype  towards  an  “N1”  type  characterised  by  higher  cytotoxic  activity 
towards cancer cells, lower ARG-1 and higher TNF-α expression (Fridlender 
et al., 2010). Moreover, the anti-tumour effects of TGF-ß inhibition were lost 
following  neutrophil  depletion  (Fridlender  et  al.,  2010).  Moreover,  UV 
irradiation  in  mice  bearing  DMBA-initiated  primary  melanomas  triggered  a 
neutrophilic  inflammatory  response  that  stimulated  angiogenesis  and  lung 
metastasis (Bald et al., 2014). Blocking the inflammatory response in TLR4-
deficient  mice  led  to  a  dramatic  inhibition  in  lung  metastasis  (Bald  et  al., 
2014).  
1.5.2.4.2 Immunoregulatory roles of TANs 
   Although neutrophils were previously regarded as being solely committed 
to  microbial  killing,  their  immunoregulatory  role  is  being  increasingly 
understood. For instance, neutrophils produce complement components, Fc 
receptors, chemokines, cytokines and anti-inflammatory factors that promote 
the  resolution  of  inflammation  (Mantovani  et  al.,  2011a).  As  far  as  T  cell 
suppression is concerned, neutrophils isolated from the peripheral blood of INTRODUCTION 
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healthy  volunteers  challenged  with  LPS  to  induce  acute  inflammation 
suppressed  T  cell  proliferation  in  vitro  through  the  release  of  hydrogen 
peroxide (H202) in a Mac-1 (CD11b/CD18)-dependent manner (Pillay et al., 
2010). More studies are needed to determine whether neutrophils isolated 
from  tumour  bearing  mice  in  the  absence  of  exogenous  inducers  of 
inflammation, such as UV light and LPS, suppress T cell function. Moreover, 
since  PMN-MDSCs  encompass  neutrophilic  precursors,  the  suppressive 
mechanisms  of  neutrophils  and  PMN-MDSCs  may  overlap.  In  fact,  the 
classification  of  PMN-MDSC  as  simply  a  functional  characteristic  of 
neutrophils  (T  cell  suppression)  has  been  proposed  (Pillay  et  al.,  2010). 
Moreover, the relationship between TAN infiltration and prognosis of human 
cancers needs to be systematically investigated.  
1.5.2.5  Dendritic cell phenotype in cancer 
	 ﾠ	 ﾠ	 ﾠDendritic cells isolated from tumour bearing mice or human cancer patients 
often show an immature phenotype marked by low co-stimulatory molecule 
expression and decreased capacity to present antigens and activate T cells 
ex vivo (Balkwill et al., 2012). In addition, these DCs have been shown to be 
defective  in  type  I  interferon  production  and  up-regulate  the  suppressive 
markers  IDO  and  PD-L1  (Gajewski  et  al.,  2013).  In  fact,  DCs  infiltrating 
murine  tumours  have  been  shown  to  suppress  CD8
+  T  cells  through 
arginase-1  production  (Norian  et  al.,  2009).  Moreover,  human  DCs 
differentiated in vitro from monocyte precursors in the presence of tumour-
conditioned medium induced T cell apoptosis through CD3ε down-regulation 
and ROS production (Kuang et al., 2008). Impaired DC differentiation and 
function are associated with tumour microenvironment-derived factors such 
as VEGF, M-CSF, IL-6, hypoxia and adenosine (Gabrilovich et al., 2012). In 
murine  models  of  ovarian  cancer,  DCs  have  been  shown  to  acquire 
endothelial cell properties and contribute to tumour vascularisation in vivo 
(Benencia et al., 2012). INTRODUCTION 
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1.5.2.6  Role of NK cells in cancer 
   NK cells recognise and kill tumour cells lacking MHCI expression or up-
regulating the NKG2D ligands Rae1 or H60 (Jaiswal et al., 2010). In fact, 
mice  depleted  of  NK  cells  are  more  susceptible  to  methylcholanthrene-
induced sarcomas (Jaiswal et al., 2010). Moreover, higher incidence of MCA-
induced tumours was observed in RAG2
-/-x γc
-/- mice, which lack adaptive 
immune  cells  and  NK  cells,  compared  to  RAG2
-/-  mice,  which  lack  only 
adaptive  cells  (O'Sullivan  et  al.,  2012).  Tumours  evade  NK  cell  attack  by 
down-regulating  or  shedding  NK  cell  receptor  ligands,  up-regulating  MHC 
molecules or releasing of inhibitory cytokines (Sabry and Lowdell, 2013).  
1.5.2.7  T cell subsets in the tumour microenvironment 
   Although  T  cells  isolated  from  tumour  biopsies  of  cancer  patients  often 
show  an  exhausted  phenotype,  accumulating  evidence  suggests  that  the 
levels of the other T helper cell subsets is highly dependent on the tumour 
type  and  stage  of  development,  as  different  microenvironmental  factors 
polarise T cells towards distinct subsets (Ansell and Vonderheide, 2013). For 
instance, the MMTV-PyMT transgenic model of mammary adenocarcinoma 
is characterised by the infiltration of Th2 T cells (DeNardo et al., 2009), and 
this is also observed in pancreatic carcinoma patients (Tassi et al., 2008). 
Moreover,  dynamic  changes  in  the  T  cell  composition  can  occur  during 
tumour  development.  In  gastric  cancer  patients,  tumour  progression  was 
associated with a gradual decrease in the Th17 / Treg ratio (Maruyama et al., 
2010). In cancer patients, high levels of CD8
+, Th1 and CD45RO
+ memory T 
cells  are  generally  positively  related  to  disease-free  survival  whereas  low 
CD8
+, high Treg and high TAM levels are associated with poor prognosis 
(DeNardo et al., 2011). 
1.5.2.8  Role of B cells in cancer 
   Gene knockout models and adoptive transfer experiments demonstrated 
that B cells influence tumour development in a context-specific manner. In 
the  K14-HPV16  transgenic  model  of  multistage  epithelial  carcinogenesis, INTRODUCTION 
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immuno-deficient K14-HPV16 Rag
-/- mice show reduced tumour growth and 
limited tumour-induced inflammation compared to immuno-competent K14-
HPV16 animals (de Visser et al., 2005). Importantly, adoptive transfer of B 
cells isolated from tumours of K14-HPV16 mice into K14-HPV16 Rag
-/- mice 
promoted  tumour  development  and  triggered  a  chronic  inflammatory 
response  marked  by  innate  cell  infiltration,  angiogenesis  and  hyper-
proliferative epidermis (de Visser et al., 2005). In the same model system, 
knockout  of  activating  Fcγ  receptors  in  HPV16/FcRγ
-/-  mice  significantly 
impaired  tumour  growth,  angiogenesis  and  leukocyte  infiltration,  indicating 
that  immune-complex  deposition  plays  a  significant  role  in  B  cell-induced 
inflammation (Andreu et al., 2010). Moreover, the growth of B16 melanomas, 
EL4 thymomas and MC38 colon carcinomas was significantly reduced in B 
cell-deficient mice (Fremd et al., 2013). However, evidence suggests that B 
cells can also limit tumour development. For instance, higher tumour growth 
was  observed  when  mature  B  cells  were  depleted  with  an  anti-CD20 
antibody in mice bearing B16 melanomas (Fremd et al., 2013). Moreover, the 
adoptive  transfer  of  B  cells  activated  by  the  TLR9  agonist  CpG-
oligodeoxynucleotides,  blocked  the  growth  and  metastases  of  B16-F10 
melanoma cells implanted in B cell-deficient mice (Fremd et al., 2013).  
	 ﾠ	 ﾠ	 ﾠAlthough B cells usually promote T cell function, current evidence suggests 
that B cells can also impair T cell function. For instance, T cells isolated from 
B-cell deficient mice show enhanced IFN-γ production and greater cytolytic 
activity  against  tumour  targets  ex-vivo  (Zhang  et  al.,  2013).  Moreover, 
tumour-induced IL-10 production by Bregs attenuated IFN-γ production by T 
cells in vitro (Inoue et al., 2006). In contrast, CD40-activated B cells pulsed 
with melanoma cell lysates potently stimulated melanoma antigen-specific T 
cells, suggesting that the state of B cell activation has a major impact on their 
immuno-regulatory functions (Zhang et al., 2013). Importantly, it remains to 
be  determined  whether  the  tumour  microenvironment  enhances  the 
suppressive potential of B cells and the cellular and soluble factors governing 
the interaction between B and T cells in cancer (Balkwill et al., 2013). Finally, INTRODUCTION 
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systematic analysis of B cells levels and prognostic in human cancers remain 
to be undertaken.  
1.5.2.9  Tumour associated fibroblasts  
   Tumour associated Fibroblasts (TAFs) are an important component of the 
inflammatory and tissue reparative processes present in cancer (Gajewski et 
al., 2013). In skin, breast and pancreatic murine tumours, TAFs acquire a 
pro-inflammatory gene signature in response to tumour-derived IL-1 (Erez et 
al., 2010). Activated, pro-inflammatory fibroblasts release tumour-promoting 
factors such as IL-6, IL-8 and matrix-metalloproteinases (Madar et al., 2013). 
Regarding  the  immuno-regulatory  properties  of  TAFs,  in  vivo  depletion  of 
fibroblasts expressing the Fibroblast Activation Protein (FAP) led to tumour 
regression in a mechanism dependent on IFN-γ and TNF-α-mediated CD8
+ T 
cell  cytotoxicity  (Kraman  et  al.,  2010),  suggesting  that  TAFs  may  play  a 
suppressive role in vivo. Moreover, collagen deposition by TAFs can block T 
cell  entry  into  tumours  (Gajewski  et  al.,  2013).  The  immune-regulatory 
properties of TAFs need to be fully characterised in a wider range of tumour 
models  and  the  suppressive  mechanisms  characterised  through  in  vitro 
suppression  assays  in  combination  with  blocking  antibodies,  enzyme 
inhibitors and gene-knockout systems. 
 
1.6  Enhancing anti-tumour immunity 
   A greater understanding of the mutations and signalling pathway defects 
that drive malignant transformation has allowed the development of targeted 
therapies such as tyrosine kinase inhibitors targeting the EGFR, BRAF, KIT 
and BCR-ABL (Vanneman and Dranoff, 2012). Although these drugs have 
often achieved impressive anti-tumour responses in some patients, tumour 
recurrence  may  develop  due  to  the  emergence  of  drug-resistant  variants 
(Vanneman  and  Dranoff  2012).  In  the  past  two  decades,  tumour 
immunotherapy  has  emerged  as  a  promising  tool  to  treat  human  cancer 
patients,  with  the  most  impressive  clinical  results  to  date  having  been INTRODUCTION 
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obtained  with  adoptive  T  cell  therapy  and  checkpoint  blockade  inhibition. 
Researchers and clinicians worldwide are working to make immunotherapy 
more affordable and effective to a wider subset of patients. 
1.6.1 Adoptive T cell therapy  
   Adoptive T cell therapy (ACT) typically involves the ex vivo expansion of 
autologous  tumour  antigen-specific  T  cells,  which  are  then  adoptively 
transferred  back  into  cancer  patients  (Shi  et  al.,  2013).    Tumour  antigen-
specific T cells can be derived from endogenous T cell populations infiltrating 
tumour  biopsies,  which  are  called  tumour-infiltrating  lymphocytes  (TILs) 
(Restifo  et  al.,  2012).  Alternatively,  the  specificity  of  peripheral  blood 
lymphocytes  can  be  re-directed  through  the  transfer  of  tumour  antigen-
specific TCRs or chimeric antigen receptors (CARs) using retro or lenti-viral 
vectors (Restifo et al., 2012).	 ﾠ 	 ﾠ
1.6.1.1  Tumour infiltrating lymphocytes (TILs) 
	 ﾠ	 ﾠ	 ﾠThe efficacy of adoptive T cell therapy with tumour infiltrating lymphocytes 
(TILs) has been investigated mainly in melanoma patients, as TIL isolation in 
melanoma is facilitated by the tumour’s immunogenic properties and ease in 
extracting tumour biopsy material (Wu et al., 2012). Following isolation, TILs 
are usually expanded in vitro with anti-CD3 antibodies or APCs loaded with 
tumour-specific  antigens  and  selected  on  the  basis  of  specific  lysis  of 
antigen-positive  tumour  targets  prior  to  re-infusion  (Galluzzi  et  al.,  2012). 
Clinical outcomes are significantly improved when hosts are lymphodepleted 
with chemotherapy and/or total body irradiation prior to T cell transfer and 
treated  with  IL-2  systemically  following  T  cell  transfer  as  this  regimen 
contributes  to  the  expansion  of  the  adoptively  transferred  T  cells  and 
acquision of effector functions (Wu et al., 2012). For instance, in a series of 
three  trials  with  metastatic  melanoma  patients  receiving  TIL  therapy, 
objective  response  rates  of  49%,  52%,  and  72%  were  obtained  when 
patients  were  conditioned  with  chemotherapy  alone  or  chemotherapy  in 
combination with 2 or 12 Gy of irradiation, respectively (Rosenberg et al., INTRODUCTION 
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2011).  Moreover,  22%  of  the  patients  achieved  a  complete  tumour 
regression  (Rosenberg  et  al.,  2011).   However,  the  isolation  of  antigen-
specific T cells is more challenging in less immunogenic cancers and/or in 
cases  when  the  surgical  resection  of  the  tumour  is  not  feasible,  which 
currently limit the widespread application of TIL therapy (Shi et al., 2013).  
1.6.1.2  CAR gene modified T cells 
   Chimeric  antigen  receptors  (CARs)  are  composed  of  an  extracellular 
single-chain  antibody  variable  fragment  domain  (scFv)  linked  to  an 
intracellular signalling domain containing the CD3ζ chain, which is linked to 
the co-stimulatory domains of 4-1BB and CD28 in newer generation CARs in 
order  to  potentiate  T  cell  activation  (Restifo  et  al.,  2012).  As  CARs  are 
derived from antibodies, antigen binding occurs at a higher affinity compared 
to TCRs (Kershaw et al., 2013). Moreover, antigen recognition by CARs is 
non-MHC restricted, allowing CAR transduced T cells to be used in patients 
of  any  HLA  subtype  or  against  tumours  that  have  lost  MHC  expression 
(Kershaw et al., 2013). However, antigen recognition by CARs is restricted to 
membrane-bound  proteins,  whereas  TCRs  potentially  recognise  a  wider 
range  of  intracellular  proteins  presented  by  MHC  molecules  (Rosenberg, 
2011). Figure 1-6 shows the overall structure of a typical CAR.   
Figure 1-6: Overall structure of a chimeric antigen receptor (CAR) 
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1.6.1.2.1 Clinical responses in human cancer patients 
   Although CARs targeting a range of human tumour antigens have been 
tested in the clinic, such as CARs targeting the Folate receptor and ERBB2 
in ovarian and colon cancer, respectively, the most successful clinical results 
to  date  have  been  obtained  by  CARs  targeting  the  B  cell  antigen  CD19, 
which is over-expressed in over 80% of non-Hodgkin lymphomas, chronic 
lymphocytic  leukemia  (CLL)  and  acute  lymphoid  leukemia  (ALL)  patients 
(Rosenberg 2011). For instance, treatment with anti-CD19 CAR-transduced 
T cells led to complete remissions in a CLL patient (out of one treated) and 
one ALL patient (out of two treated) (Porter et al., 2011). In the ALL trial, 
tumour relapse was associated with loss of CD19 expression in the blast 
cells  (Grupp  et  al.,  2013).  As  a  result,  the  therapeutic  efficacy  of  CAR-
transduced T cells in a wider number of patients and tumour types remains to 
be determined.  
1.6.1.3  TCR gene-modified T cells.  
   Gene  transfer  of  high-affinity  TCRs  using  retro  or  lenti-viral  vectors 
represents a powerful strategy to redirect the specificity of T lymphocytes 
towards tumour antigens. Genes for the α and β chain encoding the TCR can 
be  cloned  from  TILs  expanded  in  vitro  and  selected  for  tumour  antigen 
reactivity (Morris et al., 2006). High affinity TCRs specific to human cancer 
antigens can also be isolated from the non-tolerant repertoire from allogeneic 
T  cell  cultures  or  human-MHC  transgenic  mice  immunised  with  human 
peptides (Morris et al., 2006). Alternatively, a vast array of TCR sequences 
can be inserted into bacteriophages, screened and selected based on the 
binding  affinity  to  tumour  antigens,  in  what  has  been  termed  the  Phage 
Display  technique  (Kershaw  et  al.,  2013).  Figure  1-7  shows  the  overall 
strategy of TCR-gene transfer, which consists in re-directing the specificity of 
autologous T cells towards tumour antigens.  INTRODUCTION 
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Figure 1-7: Adoptive cell therapy with autologous T cells transduced 
with TCRs specific to cancer antigens  
 
1.6.1.3.1 Clinical responses in cancer patients following therapy with TCR-
transduced T cells 
   T cell persistence and anti-tumour activity has been observed in pre-clinical 
and clinical studies following adoptive immunotherapy with TCR-transduced 
T cells. For instance, human peripheral blood lymphocytes transduced with a 
TCR specific for a Wilms Tumour Antigen 1 (WT1)-derived epitope cloned 
from allo-restricted CD8
+ T cells mediate the regression of human leukemia 
cells in NOD/SCID mice (Xue et al., 2005). In a pioneer Phase 1 clinical trial, 
tumour regression was observed in 2 of 17 metastatic melanoma patients 
treated  with  autologous  polyclonal  T  cells  transduced  with  the  MART-1-
specific  TCR  (Morgan  et  al.,  2006).  In  a  subsequent  trial,  6  out  of  20 
metastatic  melanoma  patients  treated  with  autologous  T  cells  transduced 
with TCRs specific for the MART-1 melanoma antigen and 3 of 16 patients 
treated  with  T  cells  against  the  gp100  melanoma  antigen  experienced INTRODUCTION 
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objective anti-tumour responses (Johnson et al., 2009). Promising phase I 
results  have  also  been  observed  in  metastatic  melanoma  and  metastatic 
synovial cell sarcoma patients receiving autologous T cells transduced with a 
TCR  recognizing  the  cancer-testis  antigen  NY-ESO,  where  approximately 
50% of patients showed objective clinical responses (Robbins et al., 2011).  
1.6.1.4  Improving the efficacy of adoptive therapy with TCR transduced 
T cells  
    Improving the therapeutic efficacy of adoptively transferred TCR-modified 
T cells ultimately depends on enhancing their functional avidity, defined as 
the  ability  of  T  cells  to  proliferate  and  mount  effector  responses  when 
stimulated by a given concentration of antigen (Uttenthal et al., 2012). On a 
TCR level, functional avidity can be improved by enhancing the affinity of the 
TCR for its cognate peptide-MHC or by increasing the TCR expression levels 
on  the  T  cell  surface  (Nicholson  et  al.,  2012).  Moreover,  adoptively 
transferred TCR-modified T cells must recognise the desired tumour antigen 
without  cross-reacting  with  normal  self-antigens  in  order  to  ensure  that 
therapeutic efficacy and safety are met. Finally, improving T cell responses 
also depends on reversing the hypo-responsive state that T cells frequently 
acquire  in  the  tumour  microenvironment,  as  described  in  more  detail  in 
section 1.6.1.4.3.  
	 ﾠ
1.6.1.4.1 Increasing TCR affinity  
   High-affinity TCRs can be developed through in vitro affinity maturation, a 
technique based on in vitro mutagenesis followed by selection of high-affinity 
TCRs by yeast or phage display (Thomas et al., 2011). Although high-affinity 
TCRs  are  generally  associated  with  better  responses in  vitro  and  in  vivo, 
TCR affinities above the physiological range can impair T cell responses to 
low-density  peptide,  indicating  that  TCRs  require  a  serial  triggering 
interaction with pMHC in order for full T cell activation to occur (Thomas et 
al., 2011). Moreover, high-affinity TCRs can cause in vivo toxicity through the 
recognition of TAAs expressed in normal tissues (on target/off tumour effect) INTRODUCTION 
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or  through  the  recognition  of  unrelated  antigens  (off-target  effect).  For 
instance,  melanoma  patients  treated  with  T  cells  transduced  with  a  high-
affinity TCR against the melanoma antigen MART-1 developed colitis, skin 
rashes,  uveitis  and  hearing  loss  as  a  result  of  the  destruction  of  normal 
melanocytes  (Johnson  et  al.,  2009).  In  a  recent  trial,  patients  receiving  T 
cells  transduced  with  an  affinity-enhanced TCR against  the  melanoma 
MAGE-A3  antigen  died  as  a  result  of  cardiogenic  shock  caused  by  TCR 
cross-reactivity  towards  the  cardiac  striated  muscle-specific  protein  titin 
(Linette et al., 2013). 
1.6.1.4.2 Increasing TCR surface expression 
    T cell activation is critically dependent on the number of TCRs on the cell 
surface  and  the  affinity  at  which  each  TCR  binds  its  cognate  antigen 
(Uttenthal,  et  al.,  2012).  As  TCR  surface  expression  is  dependent  on  the 
association with the CD3 complex, introduced and endogenous TCRs chains 
compete for limiting levels of endogenous CD3 molecules (Nicholson et al., 
2012). In a pre-clinical tumour model, co-transduction of TCR and CD3 led to 
enhanced  TCR  surface  levels,  in  vitro  responses  and  in  vivo  tumour 
protection (Ahmadi et al., 2011).  
1.6.1.4.3 Using less differentiated T cells 
   Mounting evidence suggests that T cells at earlier stages of differentiation 
provide  better  anti-tumour  responses  in  vivo.  For  instance,  pmel-1  TCR 
transgenic  T  cells  stimulated  multiple  times  in  the  presence  of  specific 
antigen and IL-2 were less effective in providing tumour protection following 
adoptive transfer compared to naïve T cells (Gattinoni et al., 2005). Recently, 
a  memory  T  cell  subset  displaying  naïve  and  memory  T  cell  properties, 
including robust self-renewal abilities, expression of the lymph node homing 
receptor  CD62L  and  the  capacity  to  produce  effector  T  cells  following 
secondary antigen exposure has been described and termed stem central 
memory T cells (TSCM) (Gattinoni et al., 2011). Human TSCM cells transduced 
with  a  mesothelin-specific  CAR  provided  enhanced  tumour-protection 
compared  to  central  memory  (TCM)  and  effector  memory  (TEM)  T  cells  in 
immunodeficient mice bearing human mesothelioma (Gattinoni et al., 2011). INTRODUCTION 
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Overall, these data suggest that naïve and early effector T cells might be 
most effective for adoptive cell transfer in cancer patients. However, most 
TCR  gene  transfer  protocols  to  date  are  based  on  retroviral  transduction, 
which require prior T cell activation in vitro, which leads to the acquisition of a 
more terminally effector T cell phenotype. Alternative strategies to infect non-
proliferating T cells using lentiviral vectors are currently being developed and 
have  been  used  successfully  to  re-direct  the  antigen  specificity  of  resting 
primary human T cells towards the WT1 antigen in vitro (Perro et al., 2010). 
1.6.1.4.4 Checkpoint blockade  
	 ﾠ	 ﾠ	 ﾠCo-inhibitory receptor blockade has been shown to enhance anti-tumour T 
cells  responses  in  pre-clinical  models  and  cancer  patients.  For  instance, 
adoptively  transferred  TCR  transgenic  CD4
+  T  cells  specific  for  the 
melanoma  antigen  tyrosinase-related  protein  1  (Trp1)  acquired  direct 
cytotoxic  properties  in  lymphopenic  hosts  treated  with  an  anti-CTLA-4 
blocking antibody (Quezada et al., 2010). Tumour regression mediated by 
cytotoxic  CD4
+  T  cells  was  dependent  on  the  production  of  IFN-γ  by  the 
tumour  antigen-specific  T  cells  and  the  recognition  of  MHC  class  II 
expressed by tumour cells (Quezada et al., 2010). In a phase III trial, the 
anti-CTLA-4 blocking antibody Ipilimumab improved the survival of metastatic 
melanoma patients by 10 months compared with 6.4 months in the single-
agent vaccine cohort, which led to the approval of Ipilimumab for patients 
with  advanced  melanoma  (Acharya  and  Jeter,  2013).  Nivolumab,  a 
monoclonal  antibody  that  blocks  the  co-inhibitory  receptor  PD-1  achieved 
encouraging  responses  in  28%,  27%  and  18%  of  melanoma,  renal  cell 
carcinoma and non-small-cell lung cancer patients, respectively, whereas no 
objective  responses  were  seen  in  prostate  and  colon  cancer  patients  
(Topalian  et  al  2012  JEM).  The  efficacy  of  combination  therapy  with 
ipilimumab and nivolumab is currently being investigated in a Phase II trial 
after a favourable safety profile was obtained in a phase I trial with advanced 
melanoma patients (Wolchok et al 2013 JEM). A possible synergistic effect 
between  checkpoint  blockade  inhibitors  and  adoptive  therapy  with  TCR-INTRODUCTION 
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transduced T cells remains to be demonstrated in pre-clinical models and 
cancer patients. 
1.6.1.4.5 Activation of co-stimulatory receptors 
   Anti-tumour immunity can be also stimulated through the activation of co-
stimulatory  receptors,  of  which  the  vast  majority  belong  to  the  TNFR 
superfamily members, including CD40, OX40, 4-1BB and the glucocorticoid-
induced  TNF  receptor  (GITR)  (Aranda  et  al.,  2013).  Pre-clinical  evidence 
suggests that agonistic antibodies against a number of TNFR superfamily 
members  promote  antitumor  immune  responses  through  boosting  T  cell 
proliferation  and  effector  function  or  through  the  activation  of  innate  cells 
such as NK cells and macrophages (Moran et al., 2013). Antibodies against 
CD40, OX-40, 4-IBB and GITR are currently in early clinical development. It 
also remains to be determined whether co-inhibitory receptor blockade or co-
stimulatory receptor activation improve the anti-tumour function of adoptively 
transferred TCR-transduced T cells in pre-clinical models and human cancer 
patients.  
1.6.1.5  Effect of TAM/MDSC depletion on adoptive T cell therapy  
   The  effects  of  targeting  TAMs  and  MDSCs  to  modulate  the  anti-tumour 
function  of  adoptively  transferred  T  cells  have  been  explored  in  a  limited 
number of studies using predominantly polyclonal T cells or TCR-transgenic 
T cells specific to tumour-associated antigens or model antigens. The effect 
of  myeloid  cell  depletion  on  the  function  of  adoptively  transferred  T  cells 
observed in different tumour models is discussed below. 
1.6.1.5.1  Improvement in the function of adoptively transferred T cells  
   Improved  anti-tumour  function  and  significantly  greater  intra-tumour 
accumulation of adoptively transferred pmel-1 TCR transgenic CD8
+ T cells 
were  seen  in  B16  melanoma  tumour  bearing  mice  reconstituted  with  the 
bone marrow from CCR2-DTR mice, in which CCR2
+ cells were depleted 
following the administration of Diphtheria toxin (Lesokhin et al., 2012). In a 
separate study, the small molecule CSF-1R inhibitor PLX3397 improved the INTRODUCTION 
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anti-tumour activity of TCR-transgenic pmel-1 CD8
+ T cells in mice bearing 
SM1 melanoma tumours (Mok et al., 2014). Similar results were observed 
when PLX3397 and OT-1 CD8
+ T cells where administered to mice bearing 
OVA-expressing SM1 tumours (Mok et al., 2014). PLX3397 also increased T 
cell levels in tumours and IFN-γ production following in vitro re-stimulation 
(Mok  et  al.,  2014).  Some  chemotherapy  drugs  such  as  Doxorubicin  have 
been shown to reduce MDSC frequency and absolute numbers in a range of 
tumour models (Alizadeh and Larmonier, 2014). Doxorubicin administration 
in combination with adoptively transferred polyclonal CD4
+ T cells polarised 
in vitro with Th1 or Th17-inducing cytokines significantly reduced the number 
of  metastatic  nodules  in  the  lungs  and  impaired  tumour  growth  when 
compared  to  either  mono-therapy  in  mice  bearing  4T1  breast  tumours 
(Alizadeh and Larmonier 2014). 
1.6.1.5.2  Impairment in the function of adoptively transferred T cells   
   In vivo studies using MHC-negative tumour cells have shown that CD4
+ 
and CD8
+ T cells can mediate tumour killing in the absence of direct tumour 
antigen recognition by enhancing the tumoricidal activity of tumour infiltrating 
macrophages  via  IFN-γ  secretion  (Corthay  et  al.,  2005).  Similarly,  high 
affinity TCR-transduced T cells may release pro-inflammatory factors to re-
program  tumour  infiltrating  myeloid  towards  a  tumour-killing  phenotype.  In 
this setting, TAM depletion may impair the function of adoptively transferred 
T  cells.  In  a  recent  study,  depletion  of  peritoneal  macrophages  with 
clodronate  liposomes  impaired  the  ability  of  CD4
+  and  CD8
+  T  cells 
transduced with a CAR consisting of the NK cell receptor NKG2D fused with 
CD3ζ (NKG2D CAR T cells) to induce tumour regression in mice bearing ID8 
ovarian tumours (Spear et al., 2012). Importantly, effector cytokines secreted 
by  adoptively  transferred  NKG2D  CAR  T  cells  harnessed  the  anti-tumour 
effect of tumour infiltrating macrophages. For instance, TAMs isolated from 
CAR T cell-treated mice showed enhanced ability to lyse ID8 tumour cells in 
vitro  and  decreased  expression  of  reactive  oxygen  species  and  the  M2-
markers  YM-1,  HIF-1a,  and  VEGF  (Spear  et  al.,  2012).  A  deeper 
understanding  into  the  factors  that  allow  the  tumour  microenvironment  to INTRODUCTION 
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acquire  immunostimulatory  and  anti-tumour  properties  may  allow 
researchers to engineer T cells with additional genes that modulate myeloid 
cells towards promoting anti-tumour immunity and tumour destruction.  
1.6.2 Modulating the tumour microenvironment through T cell 
engineering 
   Modulating the tumour microenvironment through T cell engineering efforts 
can  be  considered  as  an  attractive  approach  to  enhance  anti-tumour 
immunity. In fact, CD8
+ T cells have been co-transduced with the melanoma-
specific pmel-1 TCR and a vector expressing IL-12 under the control of the 
NFAT  promoter,  in  which  IL-12  release  occurs  following  T  cell  activation 
(Zhang  et  al.,  2011).  Double-transduced  T  cells  demonstrated  superior 
regression  of  established  B16  melanoma  compared  to  T  cells  transduced 
with  the  pmel-1  TCR  only  (Zhang  et  al.,  2011).  Subsequent  mechanistic 
studies revealed that IL-12 increased the infiltration of adoptively transferred 
T  cells  into  tumours  and  promoted  in  vivo  cross-presentation  of  tumour 
antigens by IL-12 receptor-expressing CD11b
+ myeloid–derived stromal cells 
(Kerkar  et  al.,  2011).  Moreover,  MDSCs  and  macrophages  isolated  from 
tumours of mice treated with IL-12 releasing pmel-1 TCR T cells stimulated 
the  proliferation  of  pmel-1  CD8
+  T  cells  in  vitro  whereas  MDSCs  and 
macrophages isolated from mice treated with T cells transduced with only the 
pmel-1 TCR were suppressive in vitro (Kerkar et al., 2011).  
1.6.3 Increasing T cell resistance to immuno-suppressive 
factors through T cell engineering 
    Alternatively,  T  cells  may  be  engineered  to  bypass  immunosuppressive 
barriers  present  in  the  tumour  microenvironment.  In  the  genetically 
engineered TRAMP model of prostate cancer, adoptive transfer of CD8
+ T 
cells co-transduced with a TCR specific to the tumour-associated SV40 and 
a  dominant-negative  TGF-ß  receptor  II  induced  complete  and  sustained 
regression of advanced tumours and improved overall survival compared to 
mice treated with CD8
+ T cells transduced with the SV40-TCR only (Bendle INTRODUCTION 
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et al., 2013). Future T cell therapies may involve re-directing T cell specificity 
towards cancer antigens through CAR or TCR engineering in combination 
with  strategies  to  modulate  the  microenvironment  and/or  allow  T  cells  to 
overcome immunosuppressive barriers.  
1.7  Research aims 
   As mentioned above, there is currently little in vivo evidence to support the 
in vitro findings that TAMs and MDSCs suppress anti-tumour T cell activation 
and  function,  especially  in  the  context  of  adoptive  therapy  with  TCR-
transduced  T  cells.  As  the  use  of  adoptive  immunotherapy  with  antigen-
specific  T  cells  in  early  phase  clinical  trials  increases,  it  is  important  to 
determine  the  extent  to  which  TAMs  and  MDSCs  and  the  tumour 
microenvironment  influence  the  anti-tumour  effects  of  TCR-transduced  T 
cells.  A  better  understanding  of  whether  TAMs  and  MDSCs  impair  or 
contribute to the anti-tumour function TCR-transduced T cells in vivo is vital 
prior to designing novel engineering approaches to generate T cells resistant 
to the immune-suppressive effects of the tumour microenvironment. 
   This project aims to characterise the effect of TAMs and MDSCs on the 
antigen-specific function of TCR-transduced T cells in vitro and in vivo in two 
murine  tumour  models:  the  ID8  ovarian  cancer  model,  where  TAMs  have 
been shown to promote tumour development (Hagemann et al., 2008) and 
the EL4-NP lymphoma model, where TCR gene-modified antigen-specific T 
cells have been shown to confer tumour protection (Ahmadi et al., 2011).  MATERIALS AND METHODS 
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Chapter 2  Materials and Methods 
2.1  Molecular cloning 
2.1.1 RNA extraction 
    RNA was extracted from 3 x 10
6 EL4-NP cells using the Qiagen RNeasy 
Mini Kit (Qiagen 74104). RNA was eluted in 40 µl of nuclease free water and 
frozen  at  -80°C.  RNA  concentration  was  determined  using  a 
spectrophotometer (Amersham Biosciences). For the reverse transcriptase 
(RT) reaction, 5µg of RNA was heated for 10 minutes at 65°C on a heat 
block in a volume of 15 µl in a 1.5 ml Eppendorf tube and pulsed down on ice 
for  a  few  seconds  before  adding  20  µl  of  RT  reaction  mix  containing  the 
following reagents (volume per reaction): 3 µl of nuclease-free H2O, 6 µl of 5 
mM  dNTPs  (Promega-U1330),  7  µl  of  5x  buffer  (Invitrogen  Y00146),  1  µl 
0.1M DTT (Invitrogen Y00147), 1 µl of random hexamers (500 ng/µl), 1 µl of 
RNAse inhibitor (Promega 14422705), 1 µl of M-MLV Reverse Transcriptase 
200 U/µl (Invitrogen 29025-013). Tubes were left in a plate incubator at 37°C 
for 2 hours to allow the reaction to occur. The cDNA was then pulsed down 
on ice, heated on a heat block at 65
oC for 10min and stored at -20°C.  
2.1.2 Primer design and Polymerase Chain Reaction (PCR) 
   EL4-NP  cells  express  a  truncated  form  of  the  Influenza  A  virus 
Nucleoprotein  (NP)  containing  amino  acids  327–498  (Cordaro,  T.  A.  et  al 
2000), which includes the immunodominant epitope 366–374 presented by 
H2D
b and recognised by the F5-TCR. The nucleotide sequence of the 327–
498 region was obtained from public databases and primers were designed 
to include Not1 and Sal1 restriction sites to allow subsequent ligation into the 
pMP71-invCRE-IRES-GFP vector. The expected product size is 543bp long. 
The following primers were synthesized by Invitrogen: 
 MATERIALS AND METHODS 
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Forward primer:  
5’ACTTACAGGCGGCCGCGCCACCATGGCATGCAATTCTGCTGCATTTG-3’ 
   Reverse primer:   
  5’-ATCTCGAGGTCGACTTAATTGTCGTACTCCTCTGCATTG-3’ 
   The PCR reaction was performed using 1.0 µl of cDNA added to 8.8 µl of a 
mastermix containing the following reagents from Qiagen Taq polymerase kit 
(Cat. No. 201203), volumes per reaction: 0.1 µl of Taq polymerase, 1.0 µl of 
10x buffer, 1.0 µl dNTPs, 0.25 µl of Fw primer (25µM stock), 0.25 µl of Rev 
primer (25µM stock) and 6.2 µl nuclease free H2O. PCR settings (36 cycles): 
3 minutes initial denaturation at 95°C, 40 second denaturation at 95°C per 
cycle, 50 second annealing at 60°C, 50 second elongation at 72°C and 7 
minute final elongation at 72°C. PCR product was run on a gel (2% Agarose, 
0.5x  TBE  +  0.5x  H2O,  Ethidium  Bromide  1:1000)  after  addition  of  Gel 
Loading Solution (Sigma G2526) in a 1:5 dilution alongside 5 µl of Hyper 
Ladder 1 (Bioline 33025) to determine the fragment size. Gel was analyzed 
using Ultrospec 1100 pro (Amersham Biosciences) and the specific band cut 
and purified with QIA Quick Gel extraction kit (Qiagen 28704).  
2.1.3 Digestion and ligation into the pMP71-GFP vector 
backbone 
   DNA was eluted in 50 µl of nuclease free water and the whole volume 
digested with 5 µl of NotI (NEB R0189L) and 5 µl of SalI (NEB R0138L) 
restriction  enzymes,  10  µl  of  10x  buffer  3  (NEB  B7003S)  and  30  µl  of 
nuclease  free  water.  Total  volume/reaction:  100  µl.  The  known  in-house 
vector pMP71-invCRE-IRES-GFP was also digested with the NotI and SalI 
enzymes using the same volumes to allow the insertion of the NP fragment. 
Digestion  reactions  took  place  at  37°C  for  1  hour  and  digestion  products 
were analysed by gel electrophoresis as described above. The larger 7864bp 
fragment of the pMP71-invCRE-IRES-GFP was extracted with QIAquick Gel MATERIALS AND METHODS 
  84 
Extraction Kit and eluted in 50 µl of nuclease free water. The ligation reaction 
was  carried  out  in  an  Eppendorf  tube  at  room  temperature  for  5  minutes 
containing  the  following  reagents:  10  µl  2x  Quick  Ligase  Buffer  (NEB 
B2200S), 1.5 µl of the digested vector backbone, 1.5 µl digested NP insert, 
1.5 µl Quick T4 DNA Ligase (NEB M2200L) and 5.5 µl nuclease free H2O. 
Figure 2-1 shows a diagram of the vectors used in the study. 
 
2.1.4 Transformation 
   2 µl of the ligation product was added to 25 µl of Max Efficiency DH5α 
bacteria (NEB C2987H) in a 1.5 ml eppendorf, pipette tip moved gently in 
circles and tubes left on ice for 30 minutes. Tubes were heat-shocked in the 
water bath at 42
oC for 35 seconds followed by a 2-minute incubation on ice. 
Subsequently, 250 µl of SOC medium (Invitrogen 15544-034) was added and 
tubes  left  in  the  rotating  incubator  at  37
oC  for  1h.    200µl  of  transformed 
bacteria were streaked uniformly onto pre-warmed agar plates containing the 
selective antibiotic Ampicillin and left in the incubator overnight. DNA was 
extracted  using  QIAPrep  Spin  Miniprep  kit  (Qiagen  27106)  and  sent  to 
Eurofins MWG Operon for sequencing. 
2.2  Cell culture 
   Phoenix Eco cells were grown in tissue culture flasks 75 cm
2 (TPP 90076) 
with  Iscove’s  modified  Dulbecco  medium  (IMDM)  (Lonza  BE12722F), 
Figure 2-1: Schematic representation of the retroviral vectors used in 
the study MATERIALS AND METHODS 
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supplemented with 10% Fetal Calf Serum (FCS) (Biosera), 1% L-Glutamine 
200  mM  (GIBCO  25030)  (2  mM)  and  1%  Penicillin/Streptomycin  (GIBCO 
15070) (100 U/ml). Cells were split when 90% confluent by adding 3 ml of 
0.05%  Trypsin-EDTA  (GIBCO  25300)  for  1  minute  before  adding  fresh 
medium.  
   ID8 cells, also known as Mouse Ovarian Surface Epithelial cells (MOSEC), 
were obtained by the spontaneous transformation of surface epithelial cells 
from the ovaries of C57BL/6 mice after multiple passages in-vitro (Roby, K.F. 
et  al  2000).  ID8  cells  transfected  with  firefly  luciferase  (ID8luc)  were 
maintained in DMEM Medium (Lonza 12-604Q) supplemented with 4% Fetal 
Calf  Serum  (FCS)  (Biosera),  1%  Penicillin/Streptomycin  (100  U/ml)  and 
Insulin-transferrin-sodium selenite (ITS) media supplement (Sigma I1884). 
   EL4-NP is a murine lymphoma cell line stably expressing a truncated form 
of the influenza A virus nucleoprotein (NP), as described above, a kind gift 
from  Dr  B.  Stockinger  (National  Institute  for  Medical  Research,  London). 
EL4-NP cells were maintained in RPMI 1640 medium (Lonza BE12-167F), 
supplemented with 10% Fetal Calf Serum (FCS) (Biosera), 1% L-Glutamine 
(2mM) and 1% Penicillin/Streptomycin (100 U/ml) and split every 2 days. 
  For T cell culture, RPMI 1640 medium was supplemented with 10% Fetal 
Calf  Serum  (FCS)  (Biosera),  1%  L-Glutamine  (2  mM),  1% 
Penicillin/Streptomycin  (100  U/ml)  and  2-Beta-Mercaptoethanol  (final 
concentration 50 µM). All cells were grown at 37°C and 5% CO2 and tissue 
culture work carried out in Biohit Biological Safety Cabinet Class 2 hoods. A 
Labcare CR422 centrifuge was used for spinning cells down. 
2.3  Flow cytometry 
   Between 1 x 10
5 and 5 x 10
5 cells were used for FACs analysis. Cells were 
washed  once  with  PBS  and  resuspended  in  50  µl  of  FACs  buffer  (1% 
FCS/PBS) containing the monoclonal antibodies of interest in the appropriate 
dilutions. Cells were incubated in the dark on ice for 20 minutes, washed MATERIALS AND METHODS 
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twice and resuspended in 200 µl/well of FACs buffer, followed by analysis on 
either BD LSR II or Fortessa. The scale of the flow cytometry plots present in 
the study is shown in Figure 2-2. The antibodies used in the study are listed 
in Table 2.1. 
Figure 2-2: Scale of flow cytometry plots present in the study 
 
Table 2.1: List of flow cytometry antibodies used in the study 
Specificity  Fluorochrome  Manufacturer/Catalogue 
number  Dilution 
CD3  FITC  BD 555274  1:100 
CD4  APC-H7  BD 580181  1:200 
CD8  v450  BD 560469  1:400 
CD8  PE  eBioscience 12-0081-83  1:400 
CD19  APC  eBioscience 17-0191-82  1:200 
CD11b  eFluor450  eBioscience 48-0112  1:400 
CD11c  FITC  BD 553801  1:200 
CD25  FITC  BD 553072  1:100 
CD45.1  APC-
eFluor780 
eBioscience 47-0453  1:100 
CD45.2  Biotin  eBioscience13-04-54  1:400 
CD115  PE  eBioscience 12-1152-83  1:200 
CD115  Biotin  eBioscience 13-1152-82  1:100 MATERIALS AND METHODS 
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F4/80  AlexaFluor647  AbD serotec  MCA497A647  1:100 
F4/80  FITC  eBioscience 11-4801-81  1:200 
Ly6C  PE-Cy7  BD 560593  1:400 
Ly6G  PE-Cy7  BD 560601  1:100 
FoxP3  APC  eBioscience 17-5773-82  1:30 
vβ11  PE  BD 553196  1:200 
Thy1.1  PE-Cy7  eBioscience 25-0900-82  1:10000 
 
Thy1.2  PE-Cy7  eBioscience 25-0902-81  1:12500 
 
Streptavidin  PE  eBioscience 12-4317-87 
 
1:200 
Gr-1  FITC  BD 553126  1:100 
MHC Class I 
(H2Db) 
PE  eBiosciences 12-5999-82  1: 200 
 
2.4  Retroviral transduction of ID8luc ovarian cancer cells 
with the pMP71-NP-GFP vector 
   A standard in-house retrovirus spin transduction protocol was followed. 1.5 
x 10
6 Phoenix Eco (PhEco) packaging cells were plated out on a 60.1 cm
2 
tissue culture Petri dish (TPP 93100) in 8 ml of IMDM medium and cultured 
overnight.  On  the  following  day,  medium  was  replaced  4  hours  before 
transfection  (final  volume:  5  ml).  10  µL  Fugene  HD  Transfection  Reagent 
(Roche 04709713001) was added to 75 µL OPTI-MEM (GIBCO 31985) in a 
1.5 ml Eppendorf tube. The DNA mix was prepared in a separate eppendorf 
tube by adding 2.6 µg pMP71-NP-IRES-GFP (NP fragment inserted into the 
pMP71-invCRE-IRES-GFP  vector  backbone)  or  the  pMP71-invCRE-IRES-
GFP (un-ligated, control vector) DNA and 1.5 µg pCL-Eco DNA followed by 
distilled water to make a total volume of 50 µL. The DNA was carefully added 
to the Fugene mix and incubated at RT for 15 minutes before being added 
gently  in  a  drop-wise  manner  to  the  PhEco  cells.  On  the  following  day, 
PhEco  medium  was  replaced  (final  volume:  5  ml)  and  cells  incubated 
overnight. On the following day, viral supernatant was collected from Phoenix MATERIALS AND METHODS 
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Eco cells and spun down to remove cell debris. 1 x 10
5 ID8luc cells were 
resuspended in 1 ml of viral supernatant/well and transferred onto a non-
tissue-culture  treated  24-well  plate  coated  with  750  µL/well  Retronectin 
(Takara T100B) on the previous day and left at 4°C.  Retronectin coated 
plates  were  blocked  with  filter-sterilised  2%  BSA/PBS  for  30  minutes  and 
washed twice with PBS to facilitate the infection of tumour cells with retroviral 
particles.  Plates  containing  tumour  cells  and  viral  supernatant  were 
centrifuged  at  2000  rpm  for  90  minutes  at  32°C  and  incubated  under 
standard conditions. On the following day, DMEM medium was added to a 
final volume of 2 ml/well. When confluent, cells were split and analysed for 
transduction efficiency (GFP expression) by flow cytometry. Subsequently, 
GFP
+ cells were enriched by flow cytometric sorting (Aria). The main steps of 
this experimental protocol are shown in Figure 2-3. MATERIALS AND METHODS 
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Figure 2-3: Transduction of ID8luc ovarian tumour cells with the pMP71-
NP-IRES-GFP or the pMP71-invCRE-IRES-GFP retroviral vectors     
 
2.5  In vitro luciferase expression by the newly transduced 
ID8luc-NP and ID8luc-control vector cells 
    In vitro luciferase expression was measured by plating adding 20 µl of D-
Luciferin  (Caliper  Life  Sciences,  cat  n.:  122796,  stock  concentration:  60 
mg/ml)  to  1  x  10
6  cells/well  in  6-well  plates.  Plates  incubated  at  room 
temperature  for  2  minutes  and  imaged  with  the  Xenogen  IVIS-100 
bioluminescence  imaging  at  an  exposure  time  of  1  minute.  Data  were 
analysed  using  Living  Image  software  (Xenogen)  and  presented  as 
photons/sec and/or colour images. 
2.6  CD8
+ T cell purification 
   C57BL/6  mice  were  culled  according  to  Schedule  I  home  office 
requirements, spleens were dissected, mashed through a cell strainer (BD MATERIALS AND METHODS 
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Falcon 352340) into a 50 ml Falcon tube and washed with autoclaved PBS in 
order to produce single cell suspensions. Splenocytes were resuspended in 
40  µL  MACS  buffer  (PBS  containing  0.5%  BSA  and  2mM  EDTA,  filter 
sterilized) and 10 µL of Miltenyi CD8a (Ly-2) MicroBeads (Cat. No. 130-049-
401) or CD4 MicroBeads (L3T4) (Cat. No. 130-049-201) per 10
7 cells and 
incubated at 4°C for 20 minutes. In the meantime, LS magnetic separation 
columns (Miltenyi 130-042-401) were placed on a separator and primed with 
6 ml MACS buffer. After incubation, cells were washed with 10 ml MACS 
buffer and resuspended in 1 ml (up to 10
8 cells) or 3 ml (>10
8 cells) of MACS 
buffer. Cells were added to the separation column, which was subsequently 
washed 3 times. Columns were placed in Falcon tubes and 5 ml of MACS 
buffer added to each column. Cells of interest (positive fraction) were flushed 
with the plunger supplied and resuspended in T cell medium. Purity of the 
sorted cells was checked by flow cytometry. 
2.7  Retroviral transduction of murine CD8
+ T cells with the 
F5-TCR 
   Murine CD8
+ T-cells were sorted from C57BL/6 spleens as described in 
section  2.6.  and  activated  with  Concanavalin  A  (ConA)  (2  µg/ml  final 
concentration)  and  IL-7  (1  ng/ml  final  concentration)  one  day  prior  to 
transduction. 2 x 10
6 CD8
+ T cells/well were spin- transduced in retronectin 
coated  24-well  plates  with  viral  supernatant  derived  from  PhEco  cells 
transfected with the F5-TCR retroviral vector (pMP71-TCRα-2A-TCRβ, a kind 
gift  from  Prof  T.  Schumacher)  and  pCL-Eco  DNA  using  the  conditions 
described in section 2.4, except that PhEco cell medium was replaced with T 
cell  medium  one  day  before  transduction  and  2  ml/well  of  T  cell  medium 
containing  IL-2  (Chiron)  at  100  units/ml  added  on  1  and  3  days  after 
transduction.  Transduction  efficiency  was  determined  four  days  after 
transduction by flow cytometry using the anti-murine Vβ11 antibody. MATERIALS AND METHODS 
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2.8  Dye dilution assays for T cell proliferation  
  T cells were washed twice in PBS to remove serum and labelled with either 
CellTrace
TM  CFSE  Cell  Proliferation  Kit  (Invitrogen  C34554)  or  Cell 
Proliferation Dye eFluor 670 (eBioscience 65-0840-85). A CFSE stock of 5 
mM was made up by adding 18 µl of DMSO to the CFSE in powder form. Up 
to  1  x  10
7  cells  were  labelled  with  1  ml  PBS  containing  CFSE  in  a  final 
concentration of 1 µM (= 1:5000 dilution of stock) and incubated at 37°C for 3 
minutes  with  gentle  agitation  every  60  seconds.  Cells  were  then  washed 
once  with  4  ml  of  ice-cold  8%  FCS/PBS  and  twice  with  ice-cold  2% 
FCS/PBS. Cells were spun down at 1500 rpm for 5 minutes at 4°C. The rate 
of cell proliferation was determined by FACs analysis of the diluted CFSE on 
the FITC channel. For eFluor 670 labelling, cells were washed twice in PBS 
to remove serum and resuspended in 1ml of PBS per 1 x 10
6 cells containing 
the eFluor 670 dye diluted 1:1000 (corresponding to an end concentration of 
5 µM). Cells were vortexed and incubated in the tissue culture incubator for 
10min. Labelling was stopped by adding 4-5 volumes of cold medium and 
leaving  on  ice  for  5min.  Cells  were  washed  in  medium  three  times  and 
resuspended  at  the  appropriate  density.  The  dilution  of  eFluor  670  was 
studied by FACs analysis on the APC channel. 
2.8.1 Proliferation index estimation 
   The proliferation index was calculated using the Proliferation Platform of 
the FlowJo software after gates were drawn over the histogram plots of cell 
frequency versus CFSE intensity for each condition. The proliferation index 
estimates the average number of divisions per cell and was calculated by 
FlowJo  taking  into  account  the  total  number  of  peaks  that  separate  each 
generation of divided cells (i.e. total number of divisions in the population) 
divided by the number of cells that went into division.  MATERIALS AND METHODS 
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2.9  Stimulation of F5-TCR CD8
+ T cells with ID8luc-NP cells 
   Tumour cells (ID8-NP, ID8luc-NP or ID8-control vector) were irradiated for 
14min (50Gy) in Falcon tubes, spun and resuspended in RPMI. Cells were 
added  to  tissue  culture-treated  96-well  plates  to  give  final  target:  effector 
ratios  of  2:1,  1:1,  1:10  or  1:20.  F5-TCR  transduced  CD8
+  T  cells  were 
labelled with eFluor 670 as described in Section 2.8 and added to the tumour 
cells at a fixed density of 1 x 10
5 F5-TCR expressing cells/well. Plates were 
incubated in standard conditions (5% CO2 and at 37
oC) and supernatants 
collected for ELISA after 18h. Medium was changed one and three days after 
co-culture  by  removing  100  µl/well  and  adding  150  µl/well  of  fresh  RPMI 
without exogenous cytokines. T cell proliferation was determined by FACs 
after a 3-day culture period. CD8
+ T cells were discriminated from tumour 
cells by morphology and the use of anti-CD8 and anti-Thy1.2 antibodies. The 
main steps involved in transduction and stimulation of F5-TCR transduced 
CD8
+ T cells are shown in Figure 2-4 and cell densities are listed in Table 
2.2. 
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Figure 2-4: In vitro stimulation of F5-TCR transduced CD8
+ T cells with 
ID8luc-NP or ID8luc-control vector cells   
 
 
Table 2.2: In vitro stimulation of F5-TCR transduced CD8
+ T cells with 
ID8luc-NP or ID8luc-control vector cells: cell densities.  
Target:  
effector ratio 
Number of target     
cells/well 
Number of effector 
cells/well 
Total cell  
density/well 
2:1  2 x 10
5  1 x 10
5  3 x 10
5 
1:1  1 x 10
5  1 x 10
5  2 x 10
5 
1:10  1 x 10
4  1 x 10
5  1.1 x 10
5 
1:20  0.5 x 10
4  1 x 10
5  1.05 x 10
5 
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2.10  IL-2 and IFN-γ ELISA 
   Supernatants  were  collected  from  the  co-cultures  between  F5-TCR 
transduced  CD8
+  T  cells  and  ID8luc,  ID8luc-NP  or  ID8luc-control  vector 
tumour cells after a 24h culture period. IL-2 and IFN-γ ELISA were performed 
using BD OptEIA kit 555418 and 555138, respectively, as per manufacturer’s 
instructions.  Supernatants  were  diluted  1:10  for  IL-2  and  1:100  for  IFN-γ 
ELISA.  Capture  and  detection  antibodies  were  diluted  1:250  for  both 
cytokines. 
2.11  In vitro phenotypical characterisation of bone marrow 
derived macrophages (BMDMs) 
2.11.1  Isolation of BMDMs 
   Bilateral tibias and femurs dissected from C57BL/6 mice were flushed with 
5  ml  of  DMEM  medium  supplemented  with  +10%  FBS  and  1% 
Penicillin/Streptomycin into a 50 ml tube (TPP), washed in medium once and 
filtered through a cell strainer (BD 352340) into 100 mm × 20 mm tissue 
culture-treated dishes (SIGMA CLS430167). 20 ml of medium was added, 
followed  by  5  µl  of  recombinant  mouse  M-CSF  (R&D  416-ML)  at  a  final 
concentration of 20 ng/ml. Cells were then left in the incubator for 6-7 days. 
Differentiation  into  mature  macrophages  was  determined  by  morphology, 
adherence and expression of surface markers by flow cytometry.  
2.11.2  Polarisation of BMDMs 
   Medium  was  removed  from  dishes  containing  BMDMs  and  wells  were 
washed once with sterile PBS. Subsequently, 15 ml of enzyme-free, PBS 
based Cell Dissociation Buffer (Gibco 13151-014) was added and dishes left 
in  the  incubator  for  20min.  Adherant  BMDMs  were  detached  by  scraping 
unidirectionally  with  a  cell  scraper  (Fisher  08-100-242),  added  to  50  ml MATERIALS AND METHODS 
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Falcon  tubes,  spun  and  re-suspended  in  medium  containing  the  following 
mouse recombinant cytokines at concentrations reproduced from Stout et al., 
2005:  20  ng/ml  M-CSF,  100  ng/ml  Lipopolysaccharide  (LPS,  Millipore 
LPS25)  +  20  ng/ml  IFN-γ  (eBiosciences  14-8311),  or  20  ng/ml  IL-4 
(eBiosciences  14-8041)  +  20  ng/ml  IL-13  (eBiosciences  14-8131).  The 
following morning, BMDMs were washed once with PBS and stimulated with 
DMEM containing 100 ng/ml of LPS for 6 hours. 
2.11.3  Quantification of gene expression by real-time 
Reverse Transcription Polymerase Chain Reaction 
(Real-time RT-PCR) 
2.11.3.1  RNA sample preparation 
   BMDMs were derived as described in section 2.11.1, plated at a density of 
0.5 x 10
6 cells/well in tissue culture treated 6-well plates (TPP Z707759), left 
to  adhere  for  2  hours  in  the  tissue  culture  incubator,  polarized  to  an 
inflammatory (M1) phenotype by LPS and IFN-γ, to alternatively activated 
(M2)  macrophages  by  IL-4  and  IL-13  or  treated  with  M-CSF  only  (M0), 
followed  by  stimulation  with  LPS  for  6h,  as  described  in  section  2.11.2. 
Subsequently, medium was removed, cells washed once with PBS and lysed 
by adding 350 µl/well of RLT lysis buffer (RNeasy Microkit, Qiagen 74004) 
and mixed by pipetting up and down. Lysates were collected into Eppendorf 
tubes, vortexed for 1 minute and stored at -80
oC. RNA was extracted using 
the RNeasy Microkit (Qiagen 74004) as per manufacturer’s instructions. RNA 
concentration was determined by the Nanodrop spectrophotometer (Thermo 
Scientific) following manufacturer’s instructions. Please see Figure 2-5 for an 
overview of the procedure. 
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Figure  2-5.  Polarisation  of  BMDMs  followed  by  LPS  stimulation  and 
RNA extraction 
 
2.11.3.2  cDNA synthesis 
   For cDNA synthesis, 2 µg of RNA was added to non-stick RNAase free 1.5 
ml  tubes  (Invitrogen  AM12400)  in  addition  to  8.75  µL  of  a  master  mix 
containing the reagents listed in Table 2.3. RNAase free H2O was added to 
adjust the volumes to 20 µl, tubes sealed with strip and spun briefly. The 
following PCR program was run: 10 minutes at 25°C, 60 minutes at 42°C 
(reverse  transcription)  and  5  minutes  at  90°C  (reverse  transcriptase 
inactivation).  
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Table  2.3:  Reagents  in  mastermix  for  cDNA  synthesis  (volumes  per 
reaction)   
Reagent  Supplier  Reference 
Stock  
conc.  End conc. 
Volume for 
1 reaction 
(µl) 
First strand 
buffer  Invitrogen  18064-014  5x  1x  4 
DTT  Invitrogen  18064-014  100 mM  10 mM  2 
dNTP  Promega  U1240  10 mM  0,5 mM  1 
Random 
hexamers  Promega  C1181  500 ng/µL  12,5 ng/µL  0.5 
Oligo dT 15 
mers  Promega  C1101  500 ng/µL  6,25 ng/µL  0.25 
RNasin  Promega  N2111  40 U/µL  1 U/µL  0.5 
SuperScript II  Invitrogen  18064-014  200 U/µL  5 U/µL  0.5 
 
2.11.3.3  Quantitative PCR with TaqMan probes 
   Quantitative PCR (qPCR) with TaqMan probes was performed in a 384 
well  PCR  plate  format.  TaqMan  probes  for  housekeeping  gene  18S  and 
target genes were purchased from Applied Biosystems. Please see the list of 
probes in Table 2.4.The qPCR mix contained (volume/reaction/well): 1 µl of 
the TaqMan Gene Expression Assay mix (Applied Biosystems) for the 18S 
housekeeping gene, which consists of a pair of unlabeled primers specific to 
18S and a TaqMan probe with a VIC dye label; 1 µl of the TaqMan Gene 
Expression Assay mix for the target gene, which consist of unlabeled primers 
specific to the target gene (iNOS, TNF-α, ARG-1, IL-1, IL-6, IL-12p40 or IL-
10),  a  FAM  dye  label  (for  the  target  gene  primer)  and  a  nonfluorescent 
quencher;  10  µl  of  2x  qPCR  Mastermix  (Applied  Biosystems  4352042). 
Subsequently, a volume of cDNA corresponding to 5 ng of the original RNA 
was  added,  followed  by  RNAase-free  H20  to  a  final  volume  of  20  µl/well. 
Plates were sealed and spun briefly in a plate centrifuge before being run on 
the  Step  One  Machine  (Applied  Biosystems)  using  the  following  cycling 
conditions: 1 cycle of 95
oC for 5 minutes (initial denaturation); 30 cycles of MATERIALS AND METHODS 
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95
oC for 15 seconds (denaturation), followed by 55
oC for 20 seconds (primer 
annealing) and 72
oC for 2 minutes (extension); and finally one cycle of 72
oC 
for 10 minutes (final extension). Cycle threshold (CT) values were obtained 
with  Step  One  software  (Applied  BioSystems)  in  the  linear  region  of  the 
amplification curve in order to predict the target gene copy. CT values were 
analysed in Microsoft Excel and calculated relative to the housekeeping gene 
18S  using  the  2
−∆∆CT  formula,  with  ∆Ct  corresponding  to  the  difference 
between the Ct values obtained for the target and the housekeeping genes.	 ﾠ
Table 2.4: List of Applied Biosystems primers used to study changes in 
gene expression in polarised BMDMs 
Target	 ﾠgene	 ﾠ Region	 ﾠof	 ﾠthe	 ﾠgene	 ﾠamplified	 ﾠ Taq-ﾭ‐man	 ﾠprobe	 ﾠlabel	 ﾠ
IL-1β 
Exons 1-2 
(NCBI Reference Sequence: 
NM_008361.3) 
Fam 
IL-6 
Exons 2-3 
(NCBI Reference Sequence: 
NM_031168.1) 
Fam 
IL-10 
Exons 1-2 
(NCBI Reference Sequence: 
NM_010548.2) 
Fam 
IL-12p40 
Exons 5-6 
(NCBI Reference Sequence: 
NM_008352.2) 
Fam 
TNFα 
Exons 1-2 
(NCBI Reference Sequence: 
NM_001278601.1) 
Fam 
iNOS 
     Exons 20-21 
(NCBI Reference Sequence: 
NM_010927.3) 
Fam 
ARG-1 
Exons 4-5 
(NCBI Reference Sequence: 
NM_007482.3) 
Fam 
	 ﾠ
2.11.4  ELISA to determine in vitro secretion of IL-10 and 
IL-12p40 by BMDMs 
   BMDMs  were  polarized  as  described  above,  plated  on  tissue  culture-
treated 96-well plates (Sigma Z707899) at a density of 1x10
5 cells/well and 
incubated overnight. The following day, BMDMs were stimulated with LPS for 
6h  and  50  µl  of  supernatant/well  was  collected  and  frozen  at  -20°C  for MATERIALS AND METHODS 
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ELISA. IL-10 (BD 555252) and IL-12p40 (BD 555256) ELISA kits were used. 
Capture antibodies were diluted 1:250 in coating buffer for both cytokines. 
Working detector solution contained detection antibody diluted at 1:250 (IL-
10)  or  1:1000  (IL-12p70)  and  Avidin-HRP  reagent  diluted  at  1:250.  The 
procedure  was  performed  following  manufacturer’s  instructions.  The 
absorbance  rate  at  450  nm  was  determined  on  an  ELISA  plate  reader. 
Standard  curves  were  plotted  in  Microsoft  Excel  and  concentrations  of 
samples calculated relative to the standard curves.  
2.12  Mice 
   Female C57BL/6 WT B6 mice at 8 weeks of age were obtained from the in-
house animal facility at the Royal Free Campus, UCL and all experiments 
were  carried  out  under  a  home  office  license  (project  license  number 
70/7300). 
2.13  In vivo tumour challenge experiments 
2.13.1  ID8luc ovarian cancer model 
   The growth of ID8luc, ID8luc-NP and ID8luc-control vector tumours were 
assessed  in  immunocompetent  or  conditioned  C57BL/6  mice  or 
unconditioned Rag-1 knockout mice (Charles River). Cells were washed and 
resuspended in sterile PBS at a density of 5 x 10
7/ml and injected i.p. at a 
density  of  1  x  10
7/mouse  (total  volume  per  injection=  200µl).  Conditioned 
mice  were  sub-lethally  irradiated  (5.5Gy)  4  hours  prior  to  the  injection  of 
tumour cells and housed in IVC cages. Animals were sacrificed after a 20% 
weight gain (Home Office regulations) due to ascitic fluid accumulation. 
2.13.1.1  Bioluminescence imaging  
   The in vivo growth of ID8luc, ID8luc-NP and ID8luc-control vector tumours 
were monitored by bioluminescence. Mice were injected i.p. with 200 µl of 
Luciferin  (Caliper  Life  Sciences,  cat  number  122796,  stock  concentration: 
60mg/ml) prior to being anesthetised with isofluorane. Mice were imaged with MATERIALS AND METHODS 
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Xenogen IVIS-100 (Caliper Life sciences) 5 minutes after luciferin injection, 
at  the  5-minute  exposure  time.  Data  were  analysed  using  Living  Image 
software (Xenogen) and presented as photons/sec and/or colour images. 
2.13.2  EL4-NP model 
   1 x 10
6 EL4-NP cells were injected subcutaneously (sc) into sub-lethally 
irradiated (5.5Gy) C57BL/6 mice, as previously described (Ahmadi, M. et al 
2011)  or  into  unconditioned  Rag-1  knockout  mice.  Tumour  growth  was 
measured  every  two  days  using  callipers  by  multiplying  the  horizontal 
diameter by the vertical diameter of the tumour. Mice were sacrificed when 
tumour  size  was  greater  than  15mm  on  either  the  horizontal  or  vertical 
diameters.  
2.14  Analysis of myeloid and lymphoid populations in 
different organs 
   Tumour  bearing  mice  were  sacrificed  and  organs  were  removed  and 
processed for flow cytometric assessment of constituent cells. The following 
tissues were analysed: ascitic fluid; draining lymph nodes (mesenteric and 
inguinal);  tumour  tissue;  lung;  liver;  spleen;  bone  marrow;  and  peripheral 
blood.  Ascitic fluid was obtained by injecting mice ip with 5 ml of 1mM EDTA 
using a 23 gauge needle and then aspirating fluid using the same needle, 
after  pressing  the  area  gently  to  mix  the  contents.  Draining  lymph  nodes 
(mesenteric and inguinal) were extracted and passed through a cell strainer 
to  generate  a  single  cell  suspension.  Cells  were  retained  on  ice  prior  to 
staining.  
   Lungs were flushed with 5mls 1x HBSS via a 27 gauge needle inserted in 
the trachea. One lung was removed, followed by the spleen and liver. Livers, 
lungs and tumour tissue were cut into small pieces using scissors and spleen 
cells were removed by scraping its surface with a 23 gauge needle in sterile 
petri dishes containing 4ml of 1x HBSS. Subsequently, livers, lungs, spleen 
and  tumour  tissue  samples  were  digested  by  adding  0.5  ml/dish  of MATERIALS AND METHODS 
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Collagenase Type 4 (Worthington CLS-4) (4000 U/ml for spleen and tumours 
and  2000  U/ml  for  liver  and  lung)  and  pipetting  up/down.  Dishes  were 
incubated at 37°C for 30-45 min then quenched with 0.5 ml of 100 nM EDTA 
(Invitrogen  15575-020)  per  dish,  mixed  by  pipetting  up  and  down  prior  to 
being incubated at room temperature for 5 min. 3 ml of FACs buffer was 
added and samples were passed through a cell strainer into 50 ml tubes. 
Subsequently, red blood cells were lysed by resuspending cells in 3 ml of 
ACK lysis buffer (Gibco A10492-01), incubating at RT for 2 min and adding 
40 ml of PBS/tube to stop the lysis. Peripheral blood was taken from lateral 
tail veins and red blood cells lysed using a standard osmotic red blood cell 
lysis  protocol.  After  washing,  all  cell  suspensions  were  spun  and  re-
suspended in 200 µl FACs buffer prior to staining. 
2.15  Isolation of myeloid populations from tumour bearing 
mice 
   CD115
+  monocytes  or  Gr-1
+  myeloid-derived  suppressor  cells  (MDSCs) 
were  isolated  from  immunocompetent  EL4  tumour-bearing  or  tumour-free 
mice for subsequent in vitro suppression assays or in vivo adoptive transfer 
experiments.  
2.15.1  Isolation of CD115
+ monocytes  
   Monocytes were isolated from the bone marrow based on CD115 (CSF-
1R) expression according to the protocol developed by Yona et al., 2010. 
Briefly, cell suspensions were obtained by flushing femurs and tibias with a 
5-ml syringe containing PBS connected to a 26 gauge needle. Subsequently, 
the mononuclear leukocyte fraction was separated by Ficoll density gradient 
centrifugation  (GE  Healthcare  71-7167-00  AG)  and  labelled  with  a 
biotinylated anti-CD115 antibody (eBioscience 13-1152-82), followed by anti-
biotin microbeads (Miltenyi 130-090-485). CD115
+ cells were then isolated by 
positive magnetic cell sorting using LS MACS columns. The purity of isolated 
monocytes was analysed by FACs following treatment of the positive fraction 
with PE-conjugated Streptavidin, which binds to the biotin molecules present MATERIALS AND METHODS 
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in the biotinylated anti-CD115 antibody used for sorting, as shown in Figure 
2-6. 
Figure 2-6:  Isolation of CD115
+ monocytes by positive selection 
 
 
2.15.2  Isolation of Gr-1+ MDSCs  
   Gr-1
+ MDSCs were isolated from spleens or tumour tissue according to the 
protocol  developed  by  Bayne  and  Vonderheide  2013.  Briefly,  single  cell 
suspensions were obtained by mashing spleens through a cell strainer and 
cutting tumours in small pieces, followed by collagenase-digestion of tumour 
tissue  samples.  Subsequently,  red  blood  cells  were  lysed  with  ACK  lysis 
buffer, washed and incubated with a biotinylated anti-murine Gr-1 antibody 
(Miltenyi 130-101-894), followed by anti-Biotin microbeads (Miltenyi 130-090-
485). Gr-1
+ cells were then isolated by positive magnetic cell sorting using 
MS MACS columns (Miltenyi 130-042-201). The purity of isolated Gr-1
+ cells 
was analysed by FACs following treatment of the positive fraction with PE-
conjugated  Streptavidin,  as  performed  for  the  isolation  of  CD115
+  cells 
(Figure 2-6). 
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2.16  Non-antigen specific suppression assays  
   Gr-1
+ MDSCs, CD115
+ monocytes or polarised BMDMs (also collectively 
referred to here as myeloid populations) were co-cultured with CFSE-labelled 
CD8
+ T cells stimulated with CD3/28 beads. Firstly, Gr-1
+ MDSCs or CD115
+ 
monocytes  were  isolated  from  EL4  tumour  bearing  or  wild-type  C57BL/6 
mice (section 2.15) and plated into round bottom tissue culture-treated 96-
well  plates  at  different  densities.  In  the  case  of  BMDMs,  medium  was 
removed  from  96-well  plates  containing  BMDMs  polarised  with  different 
cytokines the previous day (section 2.11.2) and wells washed once with PBS 
to  remove  excess  cytokine.  Subsequently,  CD8
+  T  cells  sorted  from  the 
spleens  of  immunocompetent  C57BL/6  mice  (section  2.6)  were  CFSE-
labelled (section 2.8), plated at a constant density of 1 x 10
5 cells/well and 
stimulated with CD3/28 Dynabeads Mouse T-Activator (Invitrogen 114.53D) 
as follows: beads were washed with 1 ml PBS and collected with a magnet 
following manufacturer’s instructions. 2.5 µl of beads were added per well, 
giving  a  final  bead-to-cell  ratio  of  1:1,  as  recommended  by  the  supplier.	 ﾠ
Plates were incubated in standard conditions and supernatants collected for 
ELISA after 18h. Medium was changed one and three days after co-culture 
by  removing  100  µl/well  and  adding  100  µl/well  of  fresh  RPMI  without 
exogenous  cytokines.  T  cell  proliferation  was  determined  after  a  3-day 
culture  period  by  flow  cytometric  analysis  of  CFSE  dilution.  Different 
myeloid/T cell ratios were tested: 3:1, 1:1, 1:2 and 1:8 in triplicate wells. An 
overview  of  the  protocol  is  shown  in  Figure  2-7.  Final  cell  densities  are 
shown in Table 2.5. 
2.17  Antigen specific suppression assays 
   Gr-1
+ MDSCs, CD115
+ monocytes or polarised BMDMs were co-cultured 
with CFSE-labelled F5-TCR transduced CD8
+ T cells stimulated with EL4-NP 
cells. Firstly, EL4-NP cells were irradiated for 14min (10Gy) and added to 
round-bottom  96-well  tissue  culture  plates  at  a  constant  density  of  1  x 
10
5/well,  followed  by  the  different  myeloid  populations,  as  described  in 
Section 2.16. Secondly, F5-TCR TCR CD8
+ T cells were added at a constant MATERIALS AND METHODS 
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density  of  1  x  10
5 F5-TCR  expressing  cells/well.  Cells  were  incubated  in 
standard conditions, supernatants removed for ELISA and T cell proliferation 
was measured by CFSE dilution as described in Section 2.16. As a result, 
F5-TCR  transduced  CD8
+  T  cells  and  EL4-NP  cells  were  cultured  at  a 
constant ratio of 1:1, whereas the numbers of myeloid cells were varied in 
order  to  test  the  impact  of  myeloid-mediated  suppression  on  the  in  vitro 
function of F5-TCR transduced CD8
+ T cells. An overview of the protocol is 
shown in Figure 2-7. Cell densities are shown in Table 2.6. 
 
Figure 2-7: Overview of the non-antigen specific and antigen-specific 
suppression assays 
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Table 2.5: Cell densities in non-antigen specific suppression assay 
Myeloid: 
T cell 
ratio 
 
3:1  1:1  1:2  1:4  1:8 
T cells + 
CD3/28 
beads only 
Myeloid       
cells 
only 
CD8+ T 
cells 
(constant) 
100,000  100,000  100,000  100,000  100,000  100,000  0 
Myeloid 
cells 
300,000  100,000  50,000  25,000  12,500  0  300,000 
Total cell 
density 
400,000  200,000  150,000  125,000  112,500  100,000  300,000 
 
Table 2.6: Cell densities in antigen-specific suppression assay 
 
Myeloid: 
T cell 
ratio 
 
3:1  1:1  1:2  1:4  1:8 
T cells + 
EL4-NP 
cells 
only 
Myeloid 
cells       
only 
F5-TCR 
CD8+T cells 
(constant) 
100,000  100,000  100,000  100,000  100,000  100,000  0 
Myeloid 
cells 
300,000  100,000  50,000  25,000  12,500  0  300,000 
EL4-NP 
cells 
(constant) 
100,000  100,000  100,000  100,000  100,000  100,000  0 
Total cell 
density 
500,000  300,000  250,000  225,000  212,500  200,000  300,000 MATERIALS AND METHODS 
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2.18  Reconstitution of the myeloid compartment of 
conditioned C57BL/6 mice bearing EL4-NP tumours 
  1 x 10
6 CD115
+ monocytes isolated from the bone marrow of tumour-free 
congenically  marked  (CD45.1
+)  C57BL/6  mice  (section  2.15.1)  were 
adoptively  transferred  by  intravenous  tail  vein  injection  into  sub-lethally 
irradiated C57BL/6 (CD45.2
+) mice bearing subcutaneous EL4-NP tumours 3 
or 8 days after tumour challenge (section 2.13.2). Infiltration of adoptively 
transferred cells into tumour tissue and spleens of EL4-NP tumour bearing 
mice  was  studied  by  FACs  analysis  on  Day  15  post  tumour  challenge. 
Tumours and spleens were processed as described in section 2.14.  
2.19  Effect of adoptively transferred CD115
+ cells on the anti-
tumour function of F5-TCR CD8
+ T cells in vivo 
   1  x  10
6  CD115
+  monocytes  were  injected  i.v.  into  sub-lethally irradiated 
C57BL/6 mice bearing subcutaneous EL4-NP tumours 3 days after tumour 
challenge. Subsequently, 2 x 10
5 CD8
+ T cells transduced with the F5-TCR 
vector  (section  2.7)  were  injected  i.v.  on  day  5  post  tumour  challenge. 
Tumour  growth  and  survival  of  tumour-bearing  mice  were  analysed  as 
described in section 2.13.2. The main steps involved in this experiment are 
shown in Figure 2-8. 
Figure 2-8: Effect of CD115
+ monocytes on the anti-tumour function of 
F5-TCR transduced CD8
+ T cells in conditioned C57BL/6 mice bearing 
EL4-NP tumours 
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2.20  Depletion of myeloid cell populations in vivo 
2.20.1  Clodronate liposomes 
   Clodronate  (stock  concentration:  5mg/ml)  and  control  (PBS)  liposomes 
were  supplied  by  Dr.  Nico  van  Rooijen  (VU  University  Medical  Center 
Amsterdam,  clodronateliposomes.org)  and  stored  at  4
oC.  Liposomes  were 
administered  to  immunocompetent  and  tumour-free  C57BL/6  mice  via  the 
intraperitoneal (i.p) or intravenous (i.v) routes following a regimen previously 
published (Zeisberger et al., 2006), which consisted of three injections given 
on consecutive days in week 1 and one injection per week in weeks 2 and 3, 
as shown in Figure 2-9. For both regimens, 200 µl of liposomes were given 
per injection (1mg of Clodronate/injection). In order to test the depletion of 
myeloid  cells,  FACs  analysis  was  performed  on  peripheral  blood,  BM, 
spleen,  LNs  and  other  organs.  Organs  were  processed  as  described  in 
section 2.14. The main steps involved in this experiment are shown in Figure 
2-9. 
Figure 2-9: Administration of Clodronate liposomes to tumour-free mice 
i.p. or i.v. 
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2.20.2  Anti-Gr-1 antibody 
   The anti-Gr-1 antibody (Clone RB6-8C5) was purchased from BioX Cell 
(Cat. number BE0075) and stored at 4
oC. The anti-Gr-1 antibody was diluted 
in  sterile  PBS  under  a  tissue  culture  hood  to  a  final  concentration  of 
0.2mg/injection, as previously tested (Srivastava et al 2012, Ma et al 2012) 
and  administered  intraperitoneally  to  immunocompetent  C57BL/6  mice 
bearing  subcutaneous  EL4  tumours  on  days  10,  12  and  14  post-tumour 
challenge,  as  shown  in  Figure  2-10.  Animals  were  euthanised  on  day  15 
post-tumour  challenge  and  the  depletion  of  Gr-1
+  cells  studied  by  FACs 
analysis  of  tumour  tissue,  peripheral  blood,  ascites,  spleen  and  draining 
lymph nodes.  
Figure  2-10:  Administration  of  the  anti-Gr-1  antibody  to  EL4  tumour-
bearing mice i.p. 
 
2.21  Effect of myeloid depletion with the anti-Gr-1 antibody 
on the anti-tumour function of F5-TCR transduced CD8
+ 
T cells 
  The effect of the anti-Gr-1 antibody on the anti-tumour function of F5-TCR 
transduced CD8
+ T cells was tested in unconditioned Rag-1 knockout mice 
bearing either EL4-NP or ID8luc-NP tumours. In the EL4-NP model, the anti-
Gr-1 antibody was administered on days 5, 7 and 9 whereas F5-TCR CD8
+ T 
cells were administered on day 10 post-tumour challenge. In the ID8luc-NP MATERIALS AND METHODS 
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model, the anti-Gr-1 antibody was administered on days 3, 5 and 7 whereas 
F5-TCR CD8+ T cells were administered on day 8 post-tumour challenge. 
The anti-Gr-1 antibody was administered intraperitoneally at 0.2mg/mouse in 
all experiments whereas F5-TCR transduced CD8
+ T cells were administered 
at 2 x 10
5 and
 5 x 10
5 /mouse in the EL4-NP and ID8-NP tumour models, 
respectively. Tumour growth was monitored as described in sections 2.13.2 
and 2.13.1.1. The injection regimen used in these experiments is shown in 
Figure 2-11. 
 
Figure 2-11: Effect of anti-Gr-1 antibody on the anti-tumour function of 
F5-TCR  CD8
+  T  cells  in  Rag
-/- mice  bearing  ID8luc-NP  or  EL4-NP 
tumours  
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Chapter 3  Suppressive properties of TAMs and 
MDSCs in vitro 
   Macrophages are essential for the initiation and resolution of pathogen or 
tissue damage–induced inflammation (Krausgruber et al., 2011). Two distinct 
phenotypic  states  have  been  proposed  for  macrophages:  the  classically 
activated (M1) and the alternatively activated (M2) phenotypes (Biswas et al., 
2008).  Tumour-associated  macrophages  (TAMs)  typically  acquire  an 
immune-suppressive, M2 phenotype (Sica and Mantovani, 2012). Myeloid-
derived suppressor cells (MDSCs) also expand in tumour bearing mice and 
suppress  T  cells  in  vitro  in  both  antigen-specific  and  antigen-independent 
manners  (Gabrilovich  et  al.,  2001,  Kusmartsev  et  al.,  2005,  Ostrand-
Rosenberg, 2010). This chapter summarizes results on the characterisation 
of immune-suppressive properties of TAMs and MDSCs with respect to TCR-
transduced T cells. Bone marrow-derived macrophages (BMDMs) polarised 
with the Th2 cytokines IL-4 and IL-13 were used as an in vitro model for 
TAMs, whereas MDSCs were isolated from immune-competent mice bearing 
EL4 tumours.  
3.1  Generation and characterisation of BMDMs 
   BMDMs present an invaluable in vitro model to study macrophage biology 
and  function  (Manzanero,  2012)  and  can  be  polarized  to  acquire 
inflammatory  M1  or  suppressive  M2  phenotypes  in  vitro.  As  TAMs  have 
characteristics of an M2 phenotype (Galdiero et al., 2013), BMDMs polarised 
with the Th2 cytokines IL-4 and IL-13 were used as an in vitro model for 
TAMs. Firstly, we tested whether BMDMs, which were generated by culturing 
bone  marrow  cells  in  the  presence  of  M-CSF  for  7  days  (Materials  and 
Methods  section  2.11.1)  give  rise  to  typical  macrophages.  As  shown  in 
Figure 3-1, >90% of gated cells were positive for CD11b and F4/80, which is 
commonly expressed by tissue macrophages (Lin et al., 2005). Greater than 
75%  of  cells  in  BMDMs  cultures  expressed  the  monocyte/macrophage 
marker M-CSF receptor-1 (CSFR-1). Moreover, BMDMs were negative for RESULTS 
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the  monocytic  marker  Ly6C  and  approximately  half  of  the  cells  stained 
positive for the granulocytic marker Ly6G. This cell surface phenotype was 
similar to the phenotype of macrophages found in tissues (Hettinger et al., 
2013).  
 
Figure 3-1. Characterisation of BMDMs by flow cytometry. BMDMs were 
differentiated  from  total  bone  marrow  cells  cultured  for  7  days  in  the 
presence of 20ng/ml of recombinant mouse M-CSF as described in Materials 
in methods section 2.11.1. Adherent cells were analysed by flow cytometry 
for  the  surface  expression  of  the  monocyte  marker  Ly6C,  the 
monocyte/macrophage  markers  CD11b  and  CSFR-1,  the  macrophage 
marker  F4/80  and  the  granulocytic  marker  Ly6G.  Demonstrated  flow 
cytometry plots are representative of two independent experiments (n=2). 
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3.2  Phenotyping of in vitro polarised BMDMs 
   Next we used Th1 and Th2 cytokines to polarise BMDMs and assessed 
resulting  M1  and  M2  phenotypes  by  evaluating  characteristic  gene 
expression  and  cytokine  production,  as  described  in  the  Materials  and 
Methods section 2.11.2. Specifically, BMDMs were either cultured overnight 
in the presence M-CSF (M0), or were polarised with LPS + IFN-γ (M1), LPS 
only  (control)  or  were  treated  with  IL-4  +  IL-13  (M2).  Cells  were  then 
washed and cultured in the presence or absence of LPS for 6 hours prior to 
gene  expression  analysis  and  cytokine  release  assays.  Surprisingly,  the 
pro-inflammatory  genes  TNF-α,  IL-1  and  IL-12p70  were  up-regulated 
predominantly  in  M2  (IL-4  +  IL-13  polarised)  macrophages  cultured  with 
LPS, reaching statistical significance for TNF-α (p=0.0031) (Figure 3-2A). 
IL-6  was  expressed  in  similar  levels  by  M0  BMDMs,  LPS  only  treated 
MBDMs  or  M2  BMDMs  cultured  with  LPS.  The  inducible  nitric  oxide 
synthase  (iNOS),  another  pro-inflammatory  gene,  was  up-regulated  in 
BMDMs polarized with LPS + IFN-γ (M1) and cultured with LPS (p≤0.0001).  
   Regarding anti-inflammatory markers, IL-10 was expressed predominantly 
by BMDMs polarised with M-CSF (M0) and cultured with LPS (p=0.003). In 
addition,  the  arginine  catabolising  enzyme  ARG-1  was  expressed 
predominantly by M2 BMDMs cultured in the absence of LPS (p=0.0128), 
as expected. Cytokine release analysis of cell culture supernatants revealed 
that the pro-inflammatory cytokine IL-12p40 was released predominantly by 
BMDMs  polarised  with  IL-4  and  IL-13  (M2)  and  cultured  with  LPS 
(p=0.0013), mirroring the gene expression data (Figure 3-2B). IL-10 was 
released predominantly by BMDMs polarised with M-CSF (M0) and cultured 
with  LPS  (p≤0.0001)  and  also  BMDMs  polarised  with  IL-4  +  IL-13  (M2) 
cultured  without  LPS  (p=0.003),  as  shown  in  Figure  3-2B.  These  data 
indicate that treatment with M1 (IFN-γ + LPS) or M2 (IL-4 + IL-13) polarising 
cytokines did not induce typical M1 or M2 phenotypes, respectively. 
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Figure 3-2. Phenotyping of polarised BMDMs. The gene expression and 
cytokine release profile of M0, M1 and M2-polarized BMDMs was studied as 
described  in  Materials  and  Methods  section  2.11.  A.  Gene  expression  of RESULTS 
  115 
inflammatory (IL-1, IL-6, IL-12p40, iNOS and TNF-α) and anti-inflammatory 
genes (IL-10 and ARG-1) was quantified by qRT-PCR using TaqMan probes. 
2
−ΔΔCT values were calculated in relation to the housekeeping gene 18S. B. 
Levels  of  Interleukin-10  (IL-10)  and  Interleukin-12p40  (IL-12p40)  were 
measured  in  the  macrophage  culture  supernatant  by  ELISA.  Values 
represent  the  mean  ±  SEM  of  triplicate  samples.  Means  were  compared 
using  unpaired  t-test.  *  p≤0.05,  **  p≤0.005,  ***p≤0.0005.  Data  are 
representative of two independent experiments (n=2). 
3.3  Effect of polarised macrophages on in vitro T cell 
proliferation 
     In order to evaluate the functional properties of polarised BMDMs we 
tested  whether  M2-polarised  macrophages  inhibited  the  proliferation  of 
TCR-transduced T cells in vitro in response to antigen-specific or polyclonal 
stimulation, as described in Materials and Methods sections 2.16 and 2.17. 
Briefly,  polyclonal  CD8
+  T  cells  were  transduced  with  a  retroviral  vector 
encoding  the  F5-TCR,  which  recognises  the  immunodominant  H-2D
b-
restricted  epitope  derived  from  the  Influenza  A  virus  nucleoprotein  (NP) 
(Cordaro et al 2000). F5-TCR transduced CD8
+ T cells were labelled with 
the CFSE cell proliferation dye and stimulated with anti-CD3 and anti-CD28 
microbeads  or  irradiated  EL4-NP  cells  in  the  presence  or  absence  of 
polarised  macrophages.  T  cell  proliferation  was  measured  after  a  3-day 
culture  period  by  flow  cytometric  analysis  of  CFSE  dilution.  These 
experiments did not reveal a clear pattern of inhibition of T cell proliferation 
by  BMDMs  polarised  with  the  different  cytokines  (data  not  shown). 
Inconclusive results were also obtained when experiments were repeated 
several times using different T cell to BMDM ratios and total cell densities.   
3.4  Accumulation of Gr-1
+ MDSCs in EL4 tumour-bearing 
mice 
   It has been shown that myeloid cells isolated from tumour bearing mice 
may  be  “educated”  by  tumour-derived  factors  and  acquire  a  more  stable 
suppressive  phenotype  (Quail  and  Joyce  2013).  An  important  group  of 
monocytic  and  granulocytic  precursors  termed  Myeloid-derived  suppressor RESULTS 
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cells  (MDSCs)  isolated  from  tumour-bearing  mice  have  been  shown  to 
suppress T cell function in vitro via a range of mechanisms, including pro-
inflammatory mediators such as NO, reactive oxygen and nitrogen species or 
through  the  breakdown  of  the  essential  amino  acid  Arginine  by  the  anti-
inflammatory enzyme ARG-1 (Kusmartsev et al., 2005, Sica and Mantovani, 
2012).  In  the  murine  system,  MDSCs  are  routinely  isolated  by  positive 
staining with the anti-Gr-1 antibody, which recognises a common epitope in 
the  Ly6C  and  Ly6G  receptors,  expressed  by  monocytic  and  granulocytic 
cells, respectively (Gabrilovich et al., 2001). Previous published studies have 
shown  that  Gr-1
+  MDSCs  expand  in  the  spleen  and  tumour  tissue  of 
immune-competent mice bearing EL4 tumours and suppress T cells ex vivo 
in  both  antigen-dependent  and  independent  manners  (Youn  et  al.,  2008, 
Kusmartsev et al., 2005, Lesokhin et al., 2012, Qin et al., 2014).  
   Prior to isolating Gr-1
+ MDSCs from EL4 tumour bearing mice and testing 
their capacity to suppress F5-TCR transduced CD8
+ T cells activated in vitro, 
we  investigated  whether  this  myeloid  population  accumulated  in  immune-
competent mice bearing EL4 tumours, as previously observed (Youn et al., 
2008, Kusmartsev et al., 2005, Lesokhin et al., 2012, Qin et al., 2014). Flow 
cytometric analysis revealed that CD11b
+ Gr-1
+ MDSCs accumulated in the 
tumour  tissue,  spleen  and  blood  of  EL4  tumour  bearing  mice,  reaching 
statistical significance in the spleen and blood when compared to tumour-free 
mice (p=0.0170 and 0,0111, respectively), as shown in Figure 3-3. Similar 
findings were observed for absolute cell numbers in the spleen (p= 0,0015). 
The  percentages  and  absolute  numbers  of  CD11b
+  F4/80
+  macrophages 
were also higher in EL4 tumour-bearing mice compared to tumour-free mice 
albeit not as robustly as observed for Gr-1
+ MDSCs, with values not reaching 
statistical  significance  for  the  percentages  of  viable  cells  (p=0.0691  for 
spleen and 0.0964 for blood) and absolute cell numbers for the spleen (P= 
0.0914) (Figure 3-3B-C). This data suggests that Gr-1
+ MDSCs preferentially 
accumulate  in  the  EL4  model,  confirming  previous  findings  from  the 
literature.  RESULTS 
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Figure 3-3. Quantification of Gr-1
+ MDSCs and F4/80
+ macrophages in 
immune-competent  mice  bearing  EL4  tumours.    Tumour-free  and 
C57BL/6  mice  bearing  subcutaneous  EL4  tumours  were  sacrificed  at  3 
weeks after tumour challenge and numbers of CD11b
+ Gr-1
+ MDSCs and 
CD11b
+  and  F4/80
+  macrophages  were  quantified  in  the  tumour  tissue, 
spleen  and  peripheral  blood  by  flow  cytometry  A.  Flow  cytometry  plots 
showing  increased  frequency  of  CD11b
+  Gr-1
+  and  CD11b
+  F4/80
+  cells 
within  live  cell  gate  (PI  negative)  in  mice  bearing  EL4  tumours.  B. 
Percentages of CD11b
+ Gr-1
+ or CD11b
+ F4/80
+ cell populations identified in 
tumours, blood and spleen of EL4 tumour-bearing and control mice. Values RESULTS 
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were displayed as the percentage of total viable cells (PI negative), as given 
by  FACs.  C.  Absolute  numbers  of  CD11b
+  Gr-1
+  or  CD11b
+  F4/80
+ 
populations  infiltrating  tumour  tissue  or  blood,  which  were  calculated  by 
multiplying the percentages given by FACs by the total number of viable cells 
in cells suspensions with (spleen) or without (tumour tissue) red blood cell 
lysis,  which  were  counted  using  the  Trypan  blue  dye  exclusion  method. 
Values  for  (B)  and  (C)  represent  the  mean  ±  SEM  taken  from  two 
independent experiments with n=3 per group for each experiment.  Means 
were compared using unpaired t-test. * p≤0.05, ** p≤0.005, ***p≤0.0005. 
 
3.5  Isolation of myeloid populations from EL4 tumour 
bearing mice 
   Gr-1
+  MDSCs  were  isolated  from  spleens  and  tumour  tissue  of  EL4 
tumour-bearing mice using a protocol developed by Bayne and Vonderheide 
(Bayne and Vonderheide, 2013), which consists of  isolating Gr-1
+ cells by 
positive  selection  using  magnetic  beads  purification  system  (MACS). 
Similarly,  we  isolated  CD115-expressing  bone  marrow  cells  using  MACS-
purification, as described by Yona et al (Yona et al., 2010). We hypothesised 
that  bone  marrow  CD115
+  cells  might  resemble  the  monocytic  subset  of 
MDSCs,  since  CD115  is  expressed  by  monocytes  along  with  myeloid 
precursors  found  in  the  bone  marrow,  including  the  macrophage  and 
dendritic  cell  precursor  (MDP)  and  the  recently  described  monocyte-
restricted progenitor cell derived from the MDP (Hettinger et al., 2013).  In 
the  present  study,  bone  marrow  cells  isolated  on  the  basis  of  CD115 
expression were termed “CD115
+ monocytic cells” or “CD115
+ monocytes” 
for simplicity. The purity of Gr-1
+ MDSCs and CD115
+ monocytic cells was 
analysed  by  flow  cytometry  in  the  pre  and  post-purification  samples  and 
represented as the percentage of total viable cells. As shown in Figure 3-4, 
Gr-1
+ MDSCs isolated from the spleens reached average purities of 75.6% in 
EL4  tumour-bearing  mice  and  65.9%  in  tumour-free  mice,  across  four 
repeated experiments. The purity of CD11b
+ Gr-1
+ MDSCs isolated from the 
tumour  tissue  of  EL4  tumour-bearing  mice  was  more  variable,  with  94,7, 
70.3, 61.1 and 50.7% (mean=69.2%) obtained in four different experiments 
(Figure 3-4). Regarding the isolation of CD115
+ cells from the bone marrow, RESULTS 
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average percentages of CD11b
+ CD115
+ cells reached 78% for EL4 tumour-
bearing and 75.8% for tumour-free mice across four repeated experiments 
(Figure 3-4B).  
 
Figure 3-4. Purification strategy and purity assessment of Gr-1
+ MDSCs. 
Gr-1
+  MDSCs  were  isolated  from  spleens  or  tumour  tissue  by  MACS-
purification  as  described  by  Bayne  and  Vonderheide.  CD115
+  cells  were 
enriched from the bone marrow by a similar method, as developed by Yona 
et al. A. Flow cytometry analysis demonstrating tissue sample composition 
prior to (top panel) and after (lower panel) MACS-purification. FACs plots 
show staining for CD11b versus Gr-1 (Gr-1 sort) or CD11b versus CD115 
(CD115 sort). Populations were pre-gated on the viable (PI negative) gate 
(not  shown).  B.  Post-purification  purity  assessment  demonstrating  the 
percentages of CD11b
+ Gr-1
+ (Gr-1 sort) or CD11b
+ CD115
+ (CD115 sort) 
double-positive cells represented as a percentage of total viable (PI negative) 
cells.  Values  represent  the  mean  ±  SEM  obtained  in  four  independent 
purification experiments. 
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3.6  Effect of Gr-1
+ MDSCs and CD115
+ monocytic cells on T 
cell function in vitro 
   Next  we  wanted  to  study  the  ability  of  Gr-1
+  MDSCs  and  CD115
+ 
monocytic  cells  isolated  from  EL4  tumour  bearing  mice  to  suppress  the 
function  of  F5-TCR-transduced  CD8
+  T  cells.  Gr-1
+  MDSCs  and  CD115
+ 
monocytic  cells  were  co-cultured  with  F5-TCR  transduced  CD8
+  T  cells 
stimulated  with  either  irradiated  EL4-NP  cells  or  anti-CD3  and  anti-CD28 
beads in vitro as described in Materials and methods sections 2.16 and 2.17. 
Different ratios of myeloid to F5-TCR transduced CD8
+ T cells were tested 
(3:1, 1:1, 1:2, 1:4 and 1:8). F5-TCR transduced CD8
+ T cells (and EL4-NP 
tumour  cells  in  the  antigen-specific  assays)  were  maintained  at  a  fixed 
number  throughout  the  different  ratios,  whereas  the  numbers  of  Gr-1
+ 
MDSCs and CD115
+ monocytes were decreased progressively towards the 
lowest ratios in order to assess their effectiveness at suppressing F5-TCR 
transduced CD8
+ T cells.  
  After  a  3-day  culture  period,  F5-TCR  transduced  CD8
+  T  cells  were 
identified by flow cytometry after staining for CD8
+, vβ11 (the variable region 
used by the F5-TCR) and CD19 (co-expressed by the vector encoding for the 
F5-TCR) (Figure 3-5A). T cell proliferation was analysed based on the CFSE 
dilution  profile,  represented  either  as  overlay  plots  or  by  measuring  the 
Proliferation Index, which estimates the average number of times a cell in the 
population has divided. As shown in Figure 3.5B, at the 3:1 ratio, F5-TCR 
transduced  CD8
+  T  cells  cultured  with  either  Gr-1  MDSCs  or  CD115
+ 
monocytes did not proliferate significantly compared to unstimulated controls. 
However, at the lower myeloid: T cell ratios, only CD115
+ cells isolated from 
the bone marrow of either EL4 tumour bearing or tumour-free mice inhibited 
T  cell  proliferation  (Figure  3.5B-C).  The  inhibitory  effect  of  CD115
+ 
monocytic  cells  was  more  pronounced  in  the  antigen-specific  assays. 
Moreover,  the  concentration  of  IL-2  and  IFN-γ  were  measured  in  tissue 
culture supernatants after overnight culture. As shown in Figure 3-5D, the 
presence  of  either  Gr-1
+  MDSCs  or  CD115
+  monocytic  cells  did  not RESULTS 
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significantly  change  IFN-γ  and  IL-2  concentrations  compared  to  F5-TCR 
CD8
+ T cells stimulated in the absence of either myeloid population. 
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Figure  3-5.  Effect  of  Gr-1
+  MDSCs  and  CD115
+  monocytic  cells  from 
EL4-tumour bearing mice on T cell proliferation in response to antigen-
specific or polyclonal stimulation in vitro. Polyclonal CD8
+ T cells isolated 
from murine spleens were transduced with the F5-TCR, cultured for 3 days, 
labelled  with  the  cell  proliferation  dye  CFSE  and  re-stimulated  with  either 
irradiated EL4-NP cells or anti-CD3 and anti-CD28 beads in the presence of 
Gr-1
+  MDSCs  or  CD115
+  monocytic  cells  isolated  form  either  EL4-tumour 
bearing or tumour-free (T.F.) mice. T cell proliferation was analysed at day 3 RESULTS 
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of  culture  by  flow  cytometry  and  the  concentration  of  IFN-γ  and  IL-2 
measured  in  supernatants  taken  18h  after  cultures  were  established,  as 
described in materials and methods section 2.16 and 2.17. Positive control: 
F5-TCR  transduced  CD8  T  cells  stimulated  in  the  absence  of  myeloid 
populations.  Negative  control:  CD8  T  cells  cultured  with  NP-negative  EL4 
cells  or  without  anti-CD3  and  anti-CD28  stimulation,  in  the  absence  of 
myeloid populations. A. Gating strategy used to measure the proliferation of 
F5-TCR transduced CD8
+ T cells. The lymphocyte gate was based on the 
forward scatter versus side scatter profile. Viable cells, which are negative for 
the live stain marker Propidium Iodide (PI), were gated on CD8 positivity in 
order to exclude myeloid cells and EL4-NP tumour cells. Transduced F5 TCR 
CD8
+ T cells were gated based on positive staining for the Vβ11 chain and 
the CD19 marker. T cell proliferation was assessed by measuring a decrease 
in fluorescence intensity of the CFSE (FITC) channel by FACs. B. Overlay 
histograms showing CFSE dilution profile linked to T cell proliferation. The 
absence  of  CFSE  intensity  shift  indicates  suppression  of  proliferation  by 
myeloid  cells.  Overlay  plots  shown  were  taken  from  one  representative 
experiment.  C.  Graphs  demonstrating  changes  in  proliferation  index  of  T 
cells in response to co-culture with MDSCs and myeloid cells. Proliferation 
index was calculated as described in Materials and Methods section 2.8.1. D. 
Quantification of IFN-γ and IL-2 in the supernatants at 18h-culture period by 
ELISA. Positive controls: F5-TCR transduced CD8
+ T cells stimulated with 
EL4-NP  cells  (“T  cells  only”)  or  PMA  +  Ionomycin  (“PMA  +  Iono”)  in  the 
absence of myeloid populations. Negative control: F5-TCR transduced CD8
+ 
T  cells  stimulated  with  EL4  cells  (“unstimulated”).  Values  on  (C)  and  (D) 
represent the mean ± SEM taken from three (antigen-specific stimulation) 
and  two  (polyclonal  stimulation)  independent  experiments.  Means  were 
compared using unpaired t-test. * p≤0.05, ** p≤0.005, ***p≤0.0005. 
3.7  Conclusions  
  We showed that BMDMs polarised with Th1 or Th2 cytokines did not give 
rise  to  typical  M1  and  M2  macrophages,  respectively,  suggesting  that 
polarised BMDMs are not a valid model for TAMs. Moreover, the inhibition of 
F5-TCR transduced CD8
+ T cells by M1 or M2 polarised BMDMs did not 
follow a reproducible pattern.  
  We  tested  the  suppressive  potential  of  myeloid  cell  populations  isolated 
from tumour-bearing mice.  We showed that CD115
+ monocytic cells potently 
suppressed the antigen-specific and non-antigen specific proliferation of F5-
TCR CD8
+ T cells in vitro. Surprisingly, Gr-1
+ MDSCs, isolated from immune-
competent  mice  bearing  EL4  tumours  showed  a  weak  suppressive  effect. RESULTS 
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These findings raised the question of whether TAMs, MDSCs and CD115
+ 
monocytes are suppressive in vivo.  
   The next chapter describes the development of two murine tumour models 
that  were  subsequently  used  to  study  the  influence  of  myeloid  cell 
populations on the anti-tumour function of F5-TCR transduced CD8
+ T cells 
in vivo.  
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Chapter 4  Optimisation of murine tumour models  
   After exploring the effect of BMDMs, Gr-1
+ MDSCs and CD115
+ monocytes 
on the in vitro function of F5-TCR transduced CD8
+ T cells, we aimed to 
characterise  this  interaction  in  vivo,  using  murine  tumour  models.  Our 
strategy consisted in measuring the impact of myeloid cell depletion in vivo 
on  the  anti-tumour  function  of  adoptively  transferred  F5-TCR  transduced 
CD8
+ T cells. In order to achieve this objective, the tumour models required 
tumours expressing the specific antigen recognised by F5-TCR transduced 
CD8
+ T cells in order to reflect the current clinical protocols using adoptively 
transferred antigen-specific TCR-transduced T cells. Secondly, there should 
be evidence that accumulation of TAMs and MDSCs occurs in order to test 
the effect of depleting these myeloid populations on the anti-tumour function 
of F5-TCR transduced CD8
+ T cells. Thirdly, tumour clearance by F5-TCR 
transduced  CD8
+  T  cells  should  be  sub-optimal,  providing  a  window  of 
opportunity  to  test  whether  their  function  is  improved  following  myeloid 
depletion.  In  the  present  study,  the  ID8  ovarian  carcinoma  and  the  EL4 
lymphoma models were modified to acquire these characteristics.  
4.1  Development of the ID8 Ovarian tumour model  
   The  ID8  ovarian  carcinoma  tumour  cell  line  was  originally  generated 
through the spontaneous transformation of murine ovarian surface epithelial 
cells (MOSEC) after multiple passages in vitro (Roby et al., 2000). ID8 cells 
injected  intra-peritoneally  into  immune-competent,  syngeneic  mice  have 
been  shown  to  form  vascularised  solid  deposits  throughout  the  peritoneal 
cavity and the mesentery, with mice typically being euthanised approximately 
7-8 weeks after tumour challenge due to the weight increases caused by the 
accumulation  of  malignant  ascites  (Leinster  et  al.,  2012).  Established  ID8 
tumours are typically accompanied by the infiltration of immune cells, mainly 
CD3
+ T cells and macrophages (Leinster et al., 2012), in addition to pro-
angiogenic  DCs  co-expressing  DC  and  endothelial  cell  markers  (Conejo-
Garcia  et  al.,  2004).  CD11b
+  Gr-1
+  MDSCs  have  also  been  shown  to RESULTS 
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accumulate in the ascites and tumour tissue of ID8 tumour-bearing mice and 
to suppress T cell function ex vivo (Yang et al., 2006). However, there is also 
conflicting  evidence  suggesting  that  CD11b
+  Gr-1
+  cells  isolated  from  the 
ascites  of  mice  bearing  advanced  ID8  tumours  may  play  an  immune-
stimulatory, rather than a immune-suppressive role (Tomihara et al., 2010). 
Importantly, the function of tumour antigen-specific TCR transduced T cells 
and the influence of TAMs and MDSCs on the function of such T cells has 
not  previously  been  characterised  in  this  model.  In  order  to  obtain  an 
antigen-specific system, we modified luciferase-positive ID8 cells (ID8luc) to 
express NP and determined whether ID8luc-NP cells engrafted in immune-
competent syngeneic mice. Subsequently, we tested the anti-tumour effect of 
F5-TCR CD8
+ T cells in mice bearing ID8luc-NP tumours.  
4.1.1 Generation of the ID8luc-NP cell line for in vivo tumour 
protection experiments 
   ID8  cells  were  engineered  to  express  a  fragment  of  a  model  antigen 
derived from the Influenza A virus nucleoprotein (NP), which is recognised by 
the  F5-TCR  (Cordaro  et  al.,  2000).  This  was  achieved  by  amplifying  the 
sequence coding for NP from EL4-NP cells and inserting it into a pMP71-
invCRE-IRES-GFP retroviral vector, followed by the transduction of ID8luc 
cells  with  the  newly  produced  pMP71-NP-IRES-GFP  vector,  as  described 
below. 
4.1.2 Transduction of ID8luc cells with a vector encoding the 
NP peptide 
   The  sequence  encoding  NP  was  amplified  from  EL4-NP  cells  using 
sequence-specific primers engineered to contain Not1 and Sal1 restriction 
sites, as described in Materials and Methods section 2.1. As shown in Figure 
4-1A, a band of 543bp was obtained, which corresponds to the expected size 
of the NP sequence expressed by EL4-NP cells, based on the previously 
published sequence data (Cordaro et al., 2000). Subsequently, the known in-
house vector pMP71-invCRE-IRES-GFP vector was digested with Not1 and RESULTS 
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Sal1  enzymes,  which  removed  the  invCRE  sequence  and  allowed  the 
ligation of the NP sequence into the cut vector, as shown in a diagram in 
Figure 4-1B. The ligation product was then transformed into MaxEfficiency 
Bacteria, following manufacturer’s instructions. Plasmid DNA extracted from 
different  bacterial  colonies  was  digested  with  Not1  and  Sal1  restriction 
enzymes to confirm the insertion of the NP-encoding sequence. As shown in 
Figure 4-1C, colonies 2-7 (transformed with the newly produced pMP71-NP-
IRES-GFP vector) had a fragment of the predicted size for the NP sequence, 
in addition to the larger vector backbone. A bacterial colony transformed with 
the unligated pMP71-invCRE-IRES-GFP control vector (lane 1) had a smaller 
fragment of the predicted size for the InvCre sequence, in addition to the 
larger  fragment  corresponding  to  the  vector  backbone  following  digestion 
with the Not1 and Sal1 restriction enzymes (Figure 4-1C).  
   Subsequently, the pMP71-NP-IRES-GFP vector and the pMP71-invCRE-
IRES-GFP  control  vector  were  packaged  into  retroviral  particles  and 
transduced into ID8luc cells, as described in Materials and Methods section 
2.4. Figure 4-1D shows that the majority of ID8luc-NP (transduced with the 
pMP71-NP-IRES-GFP vector) and ID8luc-control vector (transduced with the 
NP-negative,  pMP71-invCRE-IRES-GFP  vector)  cells  demonstrated  high 
levels of GFP expression. Flow cytometric sorting (Aria) increased the purity 
of ID8luc-control vector and ID8luc-NP cells further to 93% (of viable cells 
expressing GFP) (Figure 4-1D). Moreover, ID8luc-control vector and ID8luc-
NP  cells  maintained  a  stable  in  vitro  luciferase  expression  following 
transduction, as shown in Figure 4-1E.   RESULTS 
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   Figure 4-1 Generation of ID8luc-NP ovarian tumour cells for in vivo 
tumour protection experiments. The sequence coding for NP was cloned 
from  EL4-NP  cells,  ligated  into  the  pMP71-invCRE-IRES-GFP  retroviral 
vector, followed by the transduction of ID8luc cells with the newly produced 
pMP71-NP-IRES-GFP vector. Transduced cells were enriched by FACs sort. 
A. The sequence encoding the NP fragment was amplified from EL4-NP cells 
by PCR. The expected fragment size was 543bp. B. Diagram of the cloning 
strategy used to create the pMP71-NP-IRES-GFP vector, as described in the 
text.  C.  Plasmid  DNA  formed  from  the  ligation  between  the  cut  pMP71-RESULTS 
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invCRE-IRES-GFP  vector  and  the  NP  insert  was  extracted  from 
MaxEfficiency Bacteria and digested with Not1 and Sal1 enzymes to confirm 
the  success  of  the  ligation  and  transformation  reactions.  Lane  1:  pMP71-
invCRE-IRES-GFP  control  vector  (NP  negative).  Lanes  2-7:  pMP71-NP-
IRES-GFP  vector  (NP  positive).  D.    GFP  expression  of  ID8luc  cells  spin-
transduced with the NP-positive pMP71-NP-IRES-GFP vector (ID8luc-NP) or 
the  NP-negative  pMP71-invCRE-IRES-GFP  vector  (ID8luc-control  vector). 
The resulting ID8luc-NP and ID8luc-control vector cells were further enriched 
for GFP expression by flow cytometric sorting (Aria). Representative FACs 
plots are shown after gating on viable cells. E. In vitro luciferase expression 
by ID8luc-NP and ID8luc-control vector cells. Positive control: untransduced 
ID8luc cells (ID8luc). Negative control: Luciferase-negative ID8 cells (ID8). 
Luciferase  expression  was  measured  with  the  Xenogen  IVIS-100 
bioluminescence imaging as described in Materials and Methods section 2.5. 
 
4.1.3 In vitro antigen-specific recognition of ID8luc-NP cells 
by F5-TCR transduced CD8
+ T cells 
   ID8luc-NP  cells  were  cultured  with  F5-TCR  transduced  CD8
+  T  cells  in 
order to test whether ID8luc-NP cells present the NP peptide and stimulate 
F5-TCR transduced CD8
+ T cells in vitro. CD8
+ T cells were purified from 
murine splenocytes by magnetic bead sorting and transduced with retroviral 
particles  encoding  the  F5-TCR.  F5-TCR  transduced  CD8
+  T  cells  were 
stained with an anti-Vβ11 antibody to determine the transduction efficiency 
(Figure 4-2A). Subsequently, F5-TCR transduced T cells were labelled with 
eFluor-670 and stimulated with irradiated ID8luc-NP or ID8luc-control vector 
(NP negative) cells at different target: effector ratios and cultured for 4 days. 
As shown in Figure 4-2B, at a 1:1 ratio, F5-TCR transduced CD8
+ T cells 
proliferated  in  response  to  ID8luc-NP  cells  (18.7%  of  cells  diluted  the 
eFluor670 dye), whereas F5-TCR transduced CD8
+ T cells stimulated with 
ID8luc-control  vector  (NP  negative)  cells  exhibited  a  similar  eFluor670 
dilution  to  unstimulated  cells.  However,  proliferative  responses  were 
significantly  greater  when  EL4-NP  cells  were  used  as  targets.  Regarding 
cytokine  production,  at  the  5:1  and  1:1  target:  effector  ratios,  F5-TCR 
transduced  CD8
+  T  cells  secreted  IFN-γ  in  response  to  ID8luc-NP  at 
significantly  higher  levels  compared  to  F5-TCR  transduced  CD8
+  T  cells 
stimulated with ID8luc-control vector, albeit at much lower levels compared to RESULTS 
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F5-TCR transduced CD8
+ T cells stimulated with EL4-NP cells or PMA + 
Ionomycin (Figure 4-2C).  This data suggests that ID8luc-NP cells were less 
well recognised by F5-TCR transduced CD8+ T cells than EL4-NP cells. That 
may be due to fact that ID8luc-NP cells express lower surface levels of MHC 
Class I compared to EL4-NP cells (Figure 4-2D).  
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Figure 4-2. Antigen specific recognition of ID8luc-NP and EL4-NP cells 
by F5-TCR transduced CD8
+ T cells. Murine CD8
+ T cells were isolated 
from spleens of C57BL/6 mice and spin-transduced with a retroviral vector 
encoding the F5-TCR, as described in Materials and Methods section 2.7. 
F5-TCR transduced CD8
+ T cells were labelled with the Cell Proliferation Dye 
eFluor670,  cultured  with  ID8luc-NP  cells  and  the  proliferation  of  F5-TCR 
transduced CD8
+ T cells was studied by measuring the dilution of eFluor670 
after 4 days. Tissue culture supernatants were removed after an overnight 
incubation  period  and  assessed  for  IFN-γ  production.  A.  Transduction 
efficiency was determined by subtracting the percentage of Vβ11 expression 
observed in mock transduced CD8
+ T cells (endogenous levels) from F5-
TCR transduced CD8
+ T cells. B. eFluor670 profile of F5-TCR transduced 
CD8
+  T  cells  cultured  with  ID8luc-NP  and  ID8luc-control  vector  at  a  1:1 
target: effector ratio. Cells were pre-gated on the lymphocyte gate followed 
by Thy1.2
+ to exclude tumour cells (not shown). Gates were set in relation to 
unstimulated  cells.  Positive  controls:  F5-TCR  transduced  CD8
+  T  cells 
stimulated with EL4-NP cells or PMA + Ionomycin. FACs plots shown were 
taken  from  one  representative  experiment  (n=2).  C.  F5-TCR  transduced 
CD8
+ T cells were stimulated for 18h with the different tumour cells lines at 
5:1, 1:1, 1:10 and 1:20 target: effector ratios. Supernatants were collected 
and tested for IFN-γ production by ELISA. Values represent the mean ± SEM 
taken  from  two  independent  experiments.  Means  were  compared  using 
unpaired t-test. * p≤0.05, ** p≤0.005, ***p≤0.0005. D. Overlay plots showing 
MHC  Class  I  expression  in  ID8luc-NP  tumours  cells  compared  to 
untransduced ID8luc cells and EL4-NP cells. Cells were pre-gated on the 
viable  (PI  negative)  gate  (not  shown).  Plots  shown  were  taken  from  one 
representative experiment (n=2). 
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4.1.4 In vivo engraftment of ID8luc-NP cells  
   After generating NP-expressing ID8luc cells and demonstrating antigen-
specific recognition of ID8luc-NP cells by F5-TCR transduced CD8
+ T cells 
in vitro, the engraftment of ID8luc-NP cells in immuno-competent syngeneic 
mice was studied. Previous work from our laboratory has shown that EL4-
NP  cells  do  not  readily  engraft  in  immuno-competent  syngeneic  mice 
without pre-conditioning (unpublished observations). It is therefore possible 
that endogenous T cell responses against NP-derived epitopes may result 
in the rejection of ID8luc-NP tumours in vivo. In order to determine whether 
ID8luc-NP tumours engraft in immune-competent C57BL/6 mice in a similar 
fashion as the parental ID8luc cells, ID8luc-NP cells were injected i.p. and 
tumour growth monitored using bioluminescence imaging. A tumour load of 
1  x  10
7  cells  was  chosen  as  a  previous  tumour  titration  experiment 
demonstrated  that  1  x  10
7  untransduced  ID8luc  cells  grew  optimally  in 
unconditioned  syngeneic  C57BL/6  mice  (data  not  shown),  confirming 
findings  from  the  published  literature  (Yang  et  al.,  2006,  Leinster  et  al., 
2012). Control groups were: untransduced ID8luc cells and the NP-negative 
but  transduced  ID8luc-control  vector  cells.  As  expected,  ID8luc  tumours 
grew progressively in immune-competent animals, which were sacrificed on 
week 8 due to weight increase following ascitic fluid accumulation (Figure 
4-3A-B,  top  panels).  ID8luc-NP  tumours,  however,  failed  to  grow  in 
immune-competent mice ID8luc-control vector tumour grew in a subset of 
mice, although the signalling intensity was lower than that observed with 
ID8luc tumours (Figure 4-3A-B, top panels). These findings suggest that 
ID8luc-NP tumours were rejected by endogenous lymphocytes. Moreover, 
an  immune  response  against  exogenous  proteins  coded  by  the  pMP71-
IRES-GFP  retroviral  vector,  such  as  GFP,  may  have  contributed  to  the 
impaired engraftment of the NP-negative ID8luc-control vector tumour cells.  
   As a result, we tested whether the ablation of endogenous lymphocyte 
populations allows ID8luc-NP and ID8luc-control vector tumours to engraft 
in wild-type C57BL/6 mice. In order to test this hypothesis, C57BL/6 mice RESULTS 
  134 
were sub-lethally irradiated with 5.5Gy prior to the injection of 1 x 10
7 ID8luc, 
ID8luc-NP or
 ID8luc-control vector cells. As shown in Figure 4-3A-B, middle 
panels, all 3 mice injected with ID8luc cells developed tumours that grew 
progressively  throughout  the  abdominal  cavity,  whereas  2  out  of  3  mice 
injected with ID8luc-control vector cells developed large tumours. ID8luc-NP 
tumours developed only in one mouse, although at much lower signalling 
intensity compared to ID8luc and ID8luc-control vector tumours. As a result, 
although  the  growth  of  ID8luc-control  vector  tumours  was  moderately 
improved in conditioned mice, ID8luc-NP tumours still did not engraft.  
   Considering  that  the  slow  growing  nature  of  this  tumour  model,  it  is 
plausible that lymphocytes re-populating after irradiation may mediate the 
clearance of ID8luc-NP and ID8luc-control vector tumours. As a result, a 
more profound depletion of endogenous lymphocytes may be required to 
allow these tumour cell lines to engraft. Consequently, 1 x 10
7 ID8luc-NP or
 
ID8luc-control  vector  cells  were  injected  into  Rag-1
-/-  mice,  which  lack 
mature B and T cells due to their inability to initiate V(D)J recombination of 
BCR and TCR genes (Shultz et al., 2000). In a preliminary experiment with 
2 mice/group, two mice and one mouse bearing ID8luc-control vector cells 
and  ID8luc-NP  tumours,  respectively,  developed  large  tumours  (Figure 
4-3A-B,  bottom  panels)  and  had  to  be  euthanized  at  week  8  due  to 
extensive weight gain. Subsequent experiments with larger numbers of mice 
confirmed that ID8luc-NP tumours engraft in Rag-1
-/- mice (Figure 4-5).  RESULTS 
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Figure  4-3.  Growth  of  ID8luc,  ID8luc-NP  and  ID8luc-control  vector 
tumours in immunocompetent, conditioned and Rag-1
-/- mice. 1 x 10
7 
untransduced ID8luc, ID8luc-NP or ID8luc-control vector cells were injected 
i.p into unconditioned C56BL/6 mice, sub-lethally irradiated (5.5Gy) C57BL/6 
mice or Rag-1
-/- mice and tumour growth tracked by serial bioluminescence 
imaging. A. Images obtained at different time points with the Xenogen IVIS-
100 imaging device. The scale denotes areas of varying signalling intensities, 
with red being the highest and dark blue the lowest. B. Bioluminescence data 
was analysed from a region of interest drawn over the abdominal region of 
the  mice  using  Living  Image  software  (Xenogen)  and  presented  as 
photons/s. In case of experiments with immune-competent and conditioned 
C57BL/6  mice,  each  black  line  represents  the  photons/s  values  obtained 
from one individual mouse and coloured lines represent the mean tumour 
growth. For the Rag-1
-/- tumour challenge experiments, the red and green 
lines indicate individual mice challenged with ID8luc-NP and ID8luc-control 
vector cells, respectively. Data was taken from two independent experiments 
with 3 mice/group each (6 mice/group in total) in the case of experiments 
with immune-competent mice and one experiment with 3 and 2 mice/group 
each in the experiments performed with conditioned C57BL/6 mice and Rag-
1
-/- mice, respectively.  RESULTS 
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4.1.5 Myeloid infiltration in Rag-1
-/- mice bearing ID8luc-NP 
tumours 
    Following  the  successful  engraftment  of  ID8luc-NP  tumours  in  Rag-1
-/- 
mice,  we  aimed  to  determine  whether  F4/80
+  TAMs  and  Gr-1
+  MDSCs 
accumulate in the tumour microenvironment in this system. As the myeloid 
compartment is preserved in Rag-1
-/- mice (DeNardo et al., 2009), we expect 
ID8luc-NP tumours to induce the accumulation of TAMs and MDSCs in Rag-
1
-/-  mice  as  has  been  observed  in  immuno-competent  mice  bearing  ID8 
tumours (Liu et al., 2008, Hagemann et al., 2008, Tomihara et al., 2010). 
Flow  cytometric  analysis  revealed  that  CD11b
+  Gr-1
+  and  CD11b
+  F4/80
+ 
cells  accumulated  in  the  ascites,  spleens  and  peripheral  blood  of  Rag-1
-/- 
mice  bearing  established  ID8luc-NP  tumours  (Figure  4-4).  Moreover,  the 
CD11b+ Gr-1+ cells were predominantly Gr-1
high, suggesting a neutrophilic 
phenotype (Pillay et al., 2010). When compared to tumour-free Rag-1
-/- mice, 
the levels of CD11b
+ Gr-1
+ and CD11b
+ F4/80
+ cells were elevated in the 
ascites, reaching statistically significant differences for CD11b
+ Gr-1
+ cells 
when  comparing  ID8luc-NP  tumour-bearing  with  tumour-free  Rag-1
-/-  mice 
(p=0.0030) (Figure 4-4B). This suggests that the development of ID8luc-NP 
in  Rag-1
-/-  mice  is  associated  with  the  accumulation  of  these  myeloid 
populations preferentially in the tumour site, rather than a broader systemic 
effect.  RESULTS 
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Figure 4-4. Infiltration of CD11b
+ Gr-1
+ MDSCs and CD11b
+ F4/80
+ TAMs 
in Rag-1
-/- mice bearing ID8luc-NP tumours. Rag-1
-/- mice bearing ID8luc-
NP tumours were euthanized at week 8 post-tumour challenge and the levels 
of CD11b
+ Gr-1
+ MDSCs and CD11b
+ F4/80
+ TAMs in the ascites, spleen 
and blood were analysed by FACs. A. FACs plots showing the percentages 
of gated viable cells expressing CD11b and Gr-1 or CD11b and F4/80 in 
tumour-free  or  ID8luc-NP  tumour  bearing  Rag-1
-/-  mice.  Populations  were 
pre-gated on the live (PI negative) gate (not shown). B. Percentages of the 
CD11b
+  Gr-1
+  or  CD11b
+  F4/80
+  double-positive  populations  given  as  a 
proportion of total viable cells (PI negative), as given by FACs. Values are 
displayed as a percentage of total viable cells (PI negative). Values represent 
the mean ± SEM taken from two independent experiments with 3 mice/group RESULTS 
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each (total of six mice/group). Means were compared using unpaired t-test. * 
p≤0.05, ** p≤0.005, ***p≤0.0005. n.s.= not statistically significant. 
4.1.6 Tumour protection by F5-TCR transduced CD8
+ T cells 
in ID8luc-NP tumour bearing Rag-1
-/- mice  
  Finally, we studied whether F5-TCR transduced CD8
+ T cells were able to 
mediate tumour protection in Rag-1
-/- mice bearing ID8luc-NP tumours. F5-
TCR transduced CD8
+ T cells were adoptively transferred at either 3 x 10
5 or 
7  x  10
5  transduced  cells/mouse  on  day  8  post-tumour  challenge. 
Bioluminescence  analysis  revealed  that  the  bulk  of  the  tumour  mass  was 
effectively cleared in mice receiving either dose of F5-TCR transduced CD8
+ 
T cells. However, a residual tumour mass persisted without progression over 
the time period investigated (8 weeks post-tumour challenge). Mice treated 
with  the  lower
  dose  of  F5-TCR  transduced  CD8
+  T  cells  may  have  lost 
tumour  control  at  weeks  6-7,  but  numbers  were  insufficient  to  draw 
conclusions (Figure 4-5). As expected, mock transduced CD8
+ T cells did not 
mediate tumour protection, as mice receiving mock-transduced CD8
+ T cells 
developed large tumours similar in size to mice challenged with tumour only 
and  not  receiving  T  cells  (Figure  4-5).  These  data  suggest  that  antigen-
specific recognition is needed for effective T cell mediated tumour clearance 
in  vivo.  In  summary,  ID8luc-NP  tumours  engrafted  in  Rag-1
-/-  mice  and 
induced the accumulation of TAMs and MDSCs. In addition, F5-TCR CD8
+ T 
cells provided an efficient albeit incomplete anti-tumour effect in this model, 
enabling  us  to  study  the  effect  of  myeloid  depletion  on  the  anti-tumour 
function of F5-TCR transduced CD8
+ T cells. 
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Figure 4-5. Tumour protection by F5-TCR transduced CD8
+ T cells in 
Rag-1
-/- mice bearing ID8luc-NP tumours. F5-TCR transduced CD8
+ T cells 
were adoptively transferred at 3 x 10
5 or 7 x 10
5 transduced cells/mouse to 
Rag-1
-/- mice bearing ID8luc-NP tumours on day 8 post-tumour challenge and RESULTS 
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tumour  growth  was  monitored  by  bioluminescence  imaging.  A.  Images 
obtained at different time points with the Xenogen IVIS-100 imaging device. 
The scale denotes areas of varying signalling intensities, with red being the 
highest  and  dark  blue  the  lowest.  Pictures  are  representative  of  two 
independent experiments. B. Data was analysed from a region of interest 
drawn over the abdominal region using Living Image software (Xenogen) and 
presented  as  photons/s.  Values  obtained  for  individual  mice  were  plotted 
(black  lines);  coloured  lines  represent  the  mean  fluorescence  intensity 
(photons/s). Data shown was taken from two independent experiments with 3 
mice/group each (total of 6 mice/group).  
 
4.2  Development of the EL4-NP tumour model 
   Previous  work  in  our  laboratory  showed  that  CD4
+  and  CD8
+  T  cells 
transduced  with  the  F5-TCR  conferred  tumour  protection  in  conditioned 
syngeneic mice bearing subcutaneous EL4 tumours expressing NP (EL4-NP) 
(Ahmadi et al., 2011, Morris et al., 2005). In this system, non-myeloablative 
irradiation is needed for the engraftment of EL4-NP tumours and the in vivo 
expansion  of  adoptively  transferred  F5-TCR  CD8
+  T  cells.  Since  non-
myeloablative  irradiation  can  deplete  endogenous  myeloid  populations  in 
vivo (Hashimoto et al., 2011a), we determined whether TAMs and MDSCs 
accumulated in this model prior to investigating the role of infiltrating myeloid 
cells on the function of TCR transduced T cells, which is unknown in this 
tumour model. 
4.2.1 Reconstitution of the myeloid compartment in 
conditioned EL4-NP tumour bearing mice 
   Preliminary experiments showed that CD11b
+ F4/80
+ mature macrophages 
and CD11b
+ Ly6C
+ monocytes were severely depleted in conditioned mice 
bearing EL4-NP tumours, with the percentages of these myeloid populations 
being  significantly  lower  compared  to  the  percentages  obtained  in 
immunocompetent mice bearing EL4 tumours (data now shown). As a result, 
further optimisation of the EL4-NP model was required in order to study the 
influence of myeloid depletion on the function of F5-TCR transduced CD8
+ T 
cells.  RESULTS 
  142 
   In the murine system, the vast majority of tumour-infiltrating TAMs derive 
from  circulating  Ly6C
high  CD115
+  monocytes  expressing  the  chemokine 
receptor CCR2 (Leuschner et al., 2011, Franklin et al., 2014). We therefore 
tested  whether  the  adoptive  transfer  of  CD115
+  monocytes  leads  to  the 
reconstitution  of  monocytes  and  macrophages  in  the  tumour  tissue  and 
spleen  of  conditioned  mice  bearing  EL4-NP  tumours.  Monocytes  were 
isolated  from  the  bone  marrow  of  immune-competent,  tumour-free, 
congenically marked (CD45.1
+) mice by positive selection based on CD115 
expression (Yona et al., 2010), as performed in section 3.5. 1 x 10
6 CD115
+ 
monocytes (CD45.1
+) were adoptively transferred i.v. into conditioned EL4-
NP  tumour-bearing  C57BL/6  mice  (CD45.2
+)  on  either  days  3  or  8  post-
tumour  challenge.  The  fate  of  the  adoptively  transferred  cells  and  the 
resulting changes in levels of CD11b
+ Ly6C
+ and CD11b
+ F4/80
+ cells in the 
tumour tissue and spleen was studied by FACs analysis. Figure 4-6A shows 
a schematic diagram of the experimental design. As shown in Figure 4-6B, 
CD45.1
+ monocytes infiltrated the tumour tissue and spleen when adoptively 
transferred on day 3. Adoptive transfer of monocytes on day 8, however, did 
not lead to significant monocyte infiltration into tumour tissue and spleen, as 
the  percentages  of  CD45.1
+  cells  were  equivalent  to  the  “no  monocytes” 
control  group,  which  consists  of  conditioned  EL4-NP  tumour-bearing  mice 
that  did  not  receive  monocytes  (Figure  4-6B).  Surface  marker  expression 
analysis  revealed  that  the  vast  majority  of  CD45.1
+  cells  infiltrating  the 
tumour tissue and spleen were double-positive for the monocyte/macrophage 
marker  CD11b  and  the  monocyte  marker  Ly6C,  with  lower  levels  of 
expression being obtained for the mature macrophage marker F4/80
+ (Figure 
4-6B). In short, adoptively transferred CD115
+ monocytes infiltrated tumours 
and spleens when adoptively transferred on day 3 post-tumour challenge and 
maintained primarily a monocytic phenotype.  
   Subsequently, we studied the effect of adoptively transferred monocytes on 
the  percentages  and  absolute  numbers  of  CD11b
+  Ly6C
+  monocytes  and 
CD11b
+ F4/80
+ macrophages in the tumour tissue and spleen. As shown in 
Figure 4-6C-D, significantly higher percentages of CD11b
+ Ly6C
+ cells were RESULTS 
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observed in the spleen of conditioned EL4-tumour bearing mice adoptively 
transferred with monocytes on day 3 compared to the “no monocytes” group 
(p=0.0491)  (Figure  4-6C-D).  The  percentages  of  CD11b
+  F4/80
+  cells, 
however,  did  not  differ  between  these  two  groups  (Figure  4-6C-D). 
Importantly,  mice  receiving  adoptively  transferred  monocytes  on  day  3 
developed  enlarged  spleens  compared  to  conditioned  mice  that  did  not 
receive CD115
+ monocytes.  
   Higher absolute cell numbers of CD11b
+ Ly6C
+ and CD11b
+ F4/80+ cell 
populations were observed in the spleen of conditioned EL4-tumour bearing 
mice adoptively transferred with monocytes on day 3 compared to the “no 
monocytes” group, with statistically significant differences being observed for 
CD11b
+ F4/80
+ cells (p=0.0034) (Figure 4-6E). In the tumour tissue, higher 
percentages of CD11b
+ Ly6C
+ and CD11b
+ F4/80
+ cells were observed in 
conditioned mice adoptively transferred with monocytes on Day 3 compared 
to the “no monocytes” group, with statistically significant differences being 
observed  for  CD11b
+  F4/80
+  (p=0.002)  and  CD11b
+  Ly6C
+  (p=0.003)  cell 
populations (Figure 4-6C-D). No significant changes in absolute cell numbers 
were observed for both myeloid cell populations in these two experimental 
groups (Figure 4-6E). 
   The  percentages  and  absolute  numbers  of  CD11b
+  Ly6C
+  and  CD11b
+ 
F4/80
+  cells  in  conditioned  mice  bearing  EL4-NP  tumours  receiving 
monocytes  were  also  compared  with  immune-competent  mice  bearing 
established EL4 tumours, where the expansion of CD11b
+ Gr-1
+ MDSCs and 
CD11b
+ F4/80
+ TAMs was previously observed (section 3.4). As shown in 
Figure 4-6C-E, the percentages and absolute numbers of CD11b
+ Ly6C
+ and 
CD11b
+  F4/80
+  cells  were  significantly  lower  in  conditioned  mice  bearing 
EL4-NP  tumours  receiving  monocytes  on  day  3  compared  to  immune-
competent mice bearing EL4 tumours. In conclusion, the adoptive transfer of 
CD115
+  monocytes  on  day  3  post-tumour  challenge  partially  restored  the 
levels  of  CD11b
+  F4/80
+  macrophages  and  CD11b
+  Ly6C
+  monocytes  in 
conditioned mice bearing EL4-NP tumours.  RESULTS 
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Figure  4-6.  Reconstitution  of  CD11b
+  Ly6C
+  monocytes  and  CD11b
+ 
F4/80
+  macrophages  in  conditioned  EL4-NP  tumour-bearing  mice 
following the adoptive transfer of CD115
+ monocytes on days 3 or 8 
post-tumour  challenge.  1 x 10
6 monocytes isolated by positive selection 
based on CD115 expression from the bone marrow of immune-competent, 
tumour-free congenically marked (CD45.1
+) C57BL/6 mice were injected i.v. 
into  sub-lethally  irradiated  C57BL/6  (CD45.2
+)  mice  bearing  subcutaneous RESULTS 
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EL4-NP  tumours  on  either  day  3  or  8  post-tumour  challenge.  The  fate  of 
adoptively  transferred  monocytes  and  the  changes  in  percentages  and 
absolute numbers of CD11b
+ Ly6C
+ and CD11b
+ F4/80
+ cells in the tumour 
tissue  and  spleen  were  studied  by  FACs.  Positive  control:  immune-
competent mice bearing EL4 tumours without monocyte adoptive transfer. 
Negative  control:  conditioned  mice  bearing  EL4-NP  tumours  without 
monocyte adoptive transfer (“no monocytes”). A. Flow diagram showing the 
overall  experimental  design.  B.  FACs  plots  showing  the  percentages  of 
CD45.1
+  cells  in  the  viable  cell  fraction  (PI  negative).  The  expression  of 
CD11b,  Ly6C  and  F4/80  was  studied  in  gated  in  CD45.1
+  cells  from 
conditioned  EL4-NP  tumour-bearing  mice  receiving  CD115
+  monocytes 
(CD45.1
+)  on  day  3.  C.  FACs  plots  showing  the  percentages  of  cells 
expressing CD11b and Ly6C or CD11b and F4/80. Populations were pre-
gated on the live (PI negative) gate (not shown). D. Percentages of CD11b
+ 
Ly6C
+  and  CD11b
+  F4/80
+  cells  in  tumours  and  spleens  measured  as  a 
proportion  of  viable  (PI  negative)  cells.  E.  Absolute  numbers  of  viable 
CD11b
+ Ly6C
+ and CD11b
+ F4/80
+ cells infiltrating tumour tissue and spleen. 
Values  were  calculated  by  multiplying  the  percentages  of  viable  CD11b
+ 
Ly6C
+ or CD11b
+ F4/80
+ double-positive populations, as given by FACs, by 
the total number of viable cells in the single cell suspensions, which were 
counted using the Trypan Blue dye exclusion method following (spleen) or in 
the absence of (tumour tissue), red blood cell lysis. Values for (D) and (E) 
represent the mean ± SEM taken from two independent experiments with 3 
and  2  mice/group  each  (total  of  five  mice/group).  Means  were  compared 
using unpaired t-test. * p≤0.05, ** p≤0.005, ***p≤0.0005. 
 
4.2.2 Effect of adoptively transferred monocytes on the anti-
tumour function of F5-TCR CD8
+ T cells. 
   Previous  published  work  from  our  laboratory  showed  that  F5-TCR 
transduced CD8
+ T cells promote tumour regression and long-term survival 
of conditioned mice bearing EL4-NP tumours when adoptively transferred on 
day 1 post-tumour challenge, at a dose of 3 x 10
5 transduced cells/mouse 
(Ahmadi et al., 2011). Subsequent experiments in our group demonstrated 
that  F5-TCR  CD8
+  T  cells  given  at  later  time  points  (eg.  day  10)  and  at 
densities as low as 5 x 10
4 transduced cells/mouse still mediate effective 
tumour clearance, leading to long-term survival of the treated mice (Pedro 
Velica, unpublished observations). Since CD115
+ monocytes suppressed F5-
TCR  transduced  CD8
+  T  cells  in  vitro  (section  3.6)  and  increased  the 
numbers of splenic and tumour-infiltrating CD11b
+ Ly6C
+ and CD11b
+ F4/80
+ RESULTS 
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cells  in  vivo  when  adoptively  transferred  to  conditioned  EL4-NP  tumour 
bearing mice, we hypothesised that CD115
+ monocytes may impair the anti-
tumour function of F5-TCR CD8
+ T cells in vivo. To test this hypothesis, 1 x 
10
6 monocytes/mouse were adoptively transferred i.v. on Day 3 post-tumour 
challenge,  since  improved  migration  of  monocytes  into  tumour  tissue  and 
spleens was observed at this time point, as shown above (Figure 4-6). 2 x 
10
5 transduced F5-TCR transduced CD8
+ T cells/mouse were transferred i.v 
on day 5 and mice monitored for tumour growth and survival. Figure 4-7A 
shows an overview of the experimental approach.  
  In the absence of monocytes (control mice), F5-TCR transduced CD8
+ T 
cells conferred tumour protection and promoted the long-term survival of 5 
out  of  10  mice  (Figure  4-7B-C),  whereas  the  remaining  5  mice  were 
euthanised  within  10  days  following  the  adoptive  transfer  of  F5-TCR 
transduced  CD8
+  T  cells  due  to  weight  loss,  likely  as  a  result  of  toxicity 
associated with adoptive immunotherapy with F5-TCR transduced CD8
+ T 
cells, as observed previously in our group. As expected, all 10 mice treated 
with mock transduced CD8
+ T cells developed large tumours and had to be 
euthanized by day 21 (Figure 4-7B-C). Importantly, the adoptive transfer of 
CD115
+  monocytes  did  not  impair  the  anti-tumour  function  of  F5-TCR 
transduced  CD8
+  T  cells  (Figure  4-7B-C),  even  when  monocytes  were 
adoptively transferred on the same time point as F5-TCR transduced CD8
+ T 
cells (Day 5) (data not shown). Interestingly, complete tumour clearance and 
long-term survival was observed in 2 out of 10 mice receiving monocytes 
only (Figure 4-7B-C). RESULTS 
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Figure 4-7. Effect of adoptively transferred CD115
+ monocytes on the 
anti-tumour function of F5-TCR transduced CD8
+ T cells in conditioned 
EL4-NP tumour-bearing mice. 1 x 10
6 monocytes/mouse were adoptively 
transferred  i.v.  on  day  3  post-tumour  challenge,  followed  by  F5-TCR RESULTS 
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transduced CD8
+ T cells i.v. at 2 x 10
5 transduced cells/mouse on day 5. 
Tumours  were  measured  with  a  calliper  every  two  days  and  animals 
monitored  for  long-term  survival.  A.  Flow  diagram  showing  the  overall 
experimental  design.  B.  Tumour  size  was  calculated  by  multiplying  the 
horizontal diameter by the vertical diameter of the tumour. Each black line 
represents the tumour size (in mm
2) for one mouse. C. Survival curves show 
the percentage of mice surviving over time. Data was taken from a total of 
two independent experiments with 5 mice/group each, giving a total of 10 
mice/group. 
 
4.2.3 Myeloid infiltration in Rag-1
-/- mice bearing EL4-NP 
tumours 
   The lack of in vivo suppressive effect by CD115
+ monocytes observed in 
conditioned EL4-NP tumour-bearing mice may be due to the fact that the 
myeloid  compartment  was  not  completely  restored  following  the  adoptive 
transfer of CD115
+ monocytes in this mouse model (section  4.2.1). As a 
result,  we  decided  to  use  Rag-1
-/-  mice  in  subsequent  tumour  protection 
experiments  as  the  myeloid  compartment  is  maintained  in  these  mice 
(DeNardo  et  al.,  2009).  Moreover,  our  previous  data  with  conditioned 
C57BL/6 suggests that EL4-NP tumours are expected to engraft, and that 
adoptively  transferred  F5-TCR  transduced  CD8
+  T  cells  will  expand  in     
Rag-1
-/- mice due to the absence of endogenous T cells.  
    Firstly, we investigated whether CD11b
+ F4/80
+ TAMs and CD11b
+ Gr-1
+ 
MDSCs accumulated in the tumour tissue, spleen and blood of Rag-1
-/- mice 
bearing  established  EL4-NP  tumours  (day  15  post-tumour  challenge).  As 
shown in Figure 4-8, flow cytometric analysis revealed that CD11b
+ Gr-1
+ 
MDSCs and CD11b
+ F4/80
+ TAMs accumulated in the tumour tissue, spleen 
and  blood  of  Rag-1
-/-  mice  bearing  EL4-NP  tumours.  When  compared  to 
tumour-free  Rag-1
-/-  mice,  the  percentages  of  CD11b
+  Gr-1
+  in  EL4-NP 
tumour-bearing  Rag-1
-/-  mice  were  higher  in  the  spleen,  and,  most 
dramatically in blood, were statistically significant differences were observed 
(p=0.0030). Small differences were seen when comparing the percentages of 
CD11b
+ F4/80
+ cells in the spleens and blood of EL4-NP tumour bearing and RESULTS 
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tumour-free Rag-1
-/- mice (Figure 4-8B). As a result, a preferential expansion 
of  CD11b
+  Gr-1
+  MDSCs  over  CD11b
+  F4/80
+  TAMs  occurred  in  Rag-1
-/- 
mice bearing EL4-NP tumours, as seen in immune-competent mice bearing 
EL4 tumours (section 3.4).  
 
Figure  4-8.  Percentages  of  Gr-1
+  MDSCs  and  F4/80
+  TAMs  in  Rag-1
-/- 
mice  bearing  subcutaneous  EL4-NP  tumours.  Rag-1
-/-  mice  bearing 
subcutaneous  EL4-NP  tumours  were  taken  down  3  weeks  after  tumour 
challenge and the percentages of CD11b
+ Gr-1
+ MDSCs and CD11b
+ and 
F4/80
+ macrophages in the tumour tissue, spleen and peripheral blood were 
analysed by FACs and compared with tumour-free Rag-1
-/- mice. A. FACs 
plots show the percentages of cells expressing CD11b versus Gr-1 or CD11b RESULTS 
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versus F4/80. Populations were pre-gated on the live (PI negative) gate (not 
shown).  Plots  are  representative  of  two  independent  experiments.  B. 
Percentages  of  the  CD11b
+  Gr-1
+  or  CD11b
+  F4/80
+  double-positive 
populations  as  given  by  FACs  analysis.  Values  are  displayed  as  a 
percentage of total viable cells (PI negative). Values represent the mean ± 
SEM taken from two independent experiments with 3 and 4 mice/group each 
(total of seven mice/group). Means were compared using unpaired t-test. * 
p≤0.05, ** p≤0.005, ***p≤0.0005. n.s.= not statistically significant. 
 
4.2.4 Tumour protection by F5-TCR transduced CD8
+ T cells 
in Rag-1
-/- mice 
   In order to test whether F5-TCR transduced CD8
+ T cells mediate tumour 
protection in the presence of an intact myeloid compartment, 2 x 10
5 F5-TCR 
transduced  CD8
+  T  cells/mouse  were  adoptively  transferred  into  Rag-1
-/- 
bearing EL4-NP tumours on days 5 or 10 post-tumour challenge and tumour 
growth and mice survival measured. Conditioned C57BL/6 mice received the 
same adoptive T cell transfer regimen (positive controls) as F5-TCR CD8
+ T 
cells  were  expected  to  mediate  tumour  protection  under  these  conditions. 
The transduction efficiency of the adoptively transferred F5-TCR transduced 
CD8
+ T cells was evaluated by the co-expression of Vβ11 chain and the B 
cell marker CD19 (a truncated version of CD19 is encoded by the F5-TCR 
vector). As a result, non-transduced T cells should be negative for CD19. As 
shown in Figure 4-9A, approximately 40% of the viable CD3
+ CD8
+ T cells 
adoptively  transferred  on  either  day  5  or  10  expressed  the  F5-TCR.  As 
expected, F5-TCR CD8
+ T cells controlled tumour growth when adoptively 
transferred into conditioned mice on either day 5 or day 10 and significantly 
improved mice survival compared to Rag-1
-/- treated with mock CD8
+ T cells 
(Figure 4-9B-C). Furthermore, the survival of conditioned mice treated with 
F5-TCR CD8
+ T cells on day 5 was significantly improved when compared to 
conditioned mice treated with F5-TCR CD8
+ T cells on Day 10 (p≤0.0001). 
Importantly, F5-TCR CD8
+ T cells adoptively transferred on Day 5 were less 
effective  in  Rag-1
-/-  compared  to  conditioned  C57BL/6  hosts  as  tumours 
recurred in a large proportion of Rag-1
-/- mice, leading to significantly lower 
survival (p≤0.0001) (Figure 4-9B-C). In addition, F5-TCR transduced CD8
+ T RESULTS 
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cells were unable to control tumour growth when adoptively transferred to 
Rag-1
-/- mice on day 10 as all 8 mice were euthanized by day 21 due to high 
tumour burden, mirroring the findings obtained with mock transduced CD8
+ T 
cells (Figure 4-9B-C). As a result, F5-TCR CD8
+ T cells were significantly 
less effective at mediating tumour protection when adoptively transferred to 
Rag-1
-/- compared to conditioned C57BL/6 mice.  
 RESULTS 
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Figure 4-9. Tumour protection by F5-TCR transduced CD8
+ T cells in 
Rag-1
-/- mice.  2  x  10
5  F5-TCR  transduced  CD8
+  T  cells  were  adoptively 
transferred to EL4-NP tumour-bearing Rag-1
-/- hosts on days 5 or 10 post-
tumour challenge. Positive control for tumour engraftment: EL4-NP tumour-
bearing Rag-1
-/- mice treated with mock-transduced CD8
+ T cells. Positive 
control  for  the  function  of  F5-TCR  transduced  CD8
+  T  cells:  conditioned 
C57BL/6  mice  bearing  EL4-NP  tumours  treated  with  F5-TCR  transduced 
CD8
+ T cells on Days 5 or 10. A. Transduction efficiency was determined by 
FACs prior to the adoptive transfer of F5-TCR CD8
+ T cells on days 5 or 10. 
Cells were pre-gated on the lymphocyte gate based on the forward versus 
side scatter characteristics, followed by gating on viable cells (PI negative). 
CD8
+ T cells were identified based on positive staining for CD8 and the pan 
T cell marker CD3. Transduced CD8
+ T cells were double-positive for the 
CD19 marker and the Vβ11 chain. B. Tumour size was measured with a 
calliper and tumour size calculated by multiplying the horizontal diameter by 
the vertical diameter of the tumour. Each black line represents the tumour 
size  for  one  mouse.  Coloured  lines  indicate  the  mean  tumour  growth.  C. 
Survival curves represent the percentage of mice surviving over time and 
were compared using the Log Rank test (****p≤0.0001). Data in (B) and (C) 
was taken from a total of two independent experiments with 4 mice/group 
each, giving a total of 8 mice/group.  
 
4.3  Conclusions  
   The newly generated ID8luc cells expressing NP (ID8luc-NP) stimulated 
F5-TCR  CD8
+  T  cells  in  vitro,  were  rejected  in  immune-competent  and 
conditioned  C57BL/6  mice  but  engrafted  in  Rag-1
-/-  mice.  In  the  EL4-NP 
model, although the adoptive transfer of CD115
+ monocytes partially restored 
the myeloid cell compartment of conditioned mice bearing EL4-NP tumours, 
it did not affect the anti-tumour function of F5-TCR transduced CD8
+ T cells RESULTS 
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at  the  T  cell  doses  examined.  Importantly,  accumulation  of  endogenous 
TAMs and MDSCs was observed in Rag-1
-/- mice bearing ID8luc-NP or EL4-
NP tumours. Moreover, T cell-mediated tumour destruction was incomplete 
in Rag-1
-/- hosts in both tumour models, especially in the EL4-NP model. As 
a result, the optimisation of the ID8luc-NP and EL4-NP models allowed us to 
meet the 3 initial objectives stated at the beginning of this chapter, allowing 
us to test the hypothesis that TAM/MDSC depletion improves the anti-tumour 
function of F5-TCR CD8
+ T cells in vivo in Rag-1
-/- mice, as presented in the 
next chapter.   
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Chapter 5  Effect of TAM and MDSC depletion on 
the anti-tumour function of F5-TCR CD8
+ T cells in 
vivo 
   After optimising the in vivo murine models, we studied the effect of TAM 
and MDSC depletion on the anti-tumour function of F5-TCR CD8
+ T cells in 
Rag-1
-/- mice bearing ID8luc-NP or EL4-NP tumours. We expected the anti-
tumour function of F5-TCR CD8
+ T cells to be improved in these models if 
these myeloid cell populations are indeed immunosuppressive.  
5.1    In vivo depletion of myeloid cell populations  
   In order to test this hypothesis, it was necessary to select a robust and 
reproducible method of in vivo myeloid cell depletion. We tested whether two 
established  methods  of  myeloid  depletion,  Clodronate  liposomes  and  the 
anti-Gr-1 antibody (clone RB6-8C5), eliminated TAMs and MDSCs in vivo.  
5.1.1 Clodronate Liposomes 
   Clodronate  liposomes  (CLs)  are  composed  of  multilamellar  liposomes 
containing  the  negatively  charged  biphosphonate  drug  Clodronate,  which 
becomes  unable  to  cross  the  hydrophobic  portion  of  the  phospholipid 
bilayers  once  encapsulated  into  the  liposomal  particle  (van  Rooijen  and 
Hendrikx,  2010).  CLs  are  taken  up  non-specifically  by  phagocytic  cells, 
including  monocytes,  macrophages  and  DCs  (Van  Rooijen  and  Sanders, 
1994). Following the fusion of the internalised phagosome with the lysosome, 
CLs are broken down by phospholipases, leading to the release of soluble 
clodronate,  which  triggers  cell  apoptosis  in  the  absence  of  a  pronounced 
release of pro-inflammatory cytokines (Van Rooijen and Sanders, 1994). The 
site of myeloid cell depletion depends on the route of administration, as CLs 
do not cross endothelial barriers in a physiological setting (van Rooijen et al., 
1997). CLs were administered via the intraperitoneal or intravenous routes 
and the level of macrophage depletion in different organs was studied one RESULTS 
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day  after  the  end  of  a  2-week  administration  regimen,  as  described  in 
Materials  and  Methods  section  2.20.1.  As  shown  in  Figure  5-1A, 
intraperitoneal (i.p) administration of CLs led to significant cell death in the 
peritoneal cavity compared to control liposomes, as cells were mostly FSC
low 
SSC
high  cells,  which  was  associated  with  the  depletion  of  CD11b
+  F4/80
+ 
resident  tissue  macrophages  (Rosas  et  al.,  2010),  in  addition  to  CD11b
+ 
Ly6C
+  cells  monocyte/macrophages  and  CD11c
+  DCs.  Depletion  was  not 
observed  in  the  spleen  and  liver  (Figure  5-1A)  or  the  bone-marrow  and 
draining  lymph  nodes  (data  not  shown).  Regarding  intravenous 
administration, CLs led to significant cell apoptosis in the spleen, whereas no 
changes were observed in the blood and liver (Figure 5-1B), ascites, bone 
marrow and draining lymph nodes (data not shown). Quantification of viable 
cell  numbers  by  the  trypan  blue  dye  exclusion  method  confirmed  that 
administration of CLs i.p and i.v led to a dramatic decrease in the number of 
viable cells in the ascites and spleen, respectively (Figure 5-1C). Based on 
these  data,  it  can  be  concluded  that  myeloid  cell  depletion  by  CLs  given 
intraperitoneally and intravenously is mainly confined to the intraperitoneal 
cavity and spleen, respectively.  RESULTS 
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Figure  5-1  In  vivo  myeloid  depletion  by  Clodronate  liposomes  (CLs) 
administered i.p. or i.v. C57BL/6 mice were treated with clodronate, control 
liposomes  or  PBS  only  as  described  in  Materials  and  Methods  section 
2.20.1. Different tissues were processed and stained with a series of myeloid 
markers one day after the last dose. A. Samples from ascitic fluid, spleen 
and liver of mice treated with CLs i.p. Shown are the forward scatter versus 
side  scatter  profile  and  staining  for  the  monocyte/macrophage  markers 
CD11b  and  Ly6C,  the  macrophage  marker  F4/80  and  the  dendritic  cell 
marker CD11c (ascitic fluid only). For myeloid staining, cells were pre-gated 
on  the  live  gate.  Samples  shown  are  representative  FACs  plots  from  two RESULTS 
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independent  experiments  with  3  mice/group/experiment  (total  of  6 
mice/group). B. Samples from spleen, blood and liver of mice treated with 
CLs  i.v.  FACs  analysis  was  performed  as  in  (A).  C.  Quantification  of  the 
percentage of live cells in the ascites (i.p. administration) and in the spleen 
(i.v. administration). Live cells were discriminated from dead cells by FACs 
according to their forward scatter and side-scatter characteristics or by the 
Trypan Blue dye exclusion method. Values represent the mean ± SEM from 
two  independent  experiments  with  3  mice/group/experiment  (total  of  6 
mice/group).  Means  were  compared  using  unpaired  t-test.  *  p≤0.05,  ** 
p≤0.005, ***p≤0.0005. n.s.= not statistically significant.  
 
5.1.2 Anti-Gr-1 antibody  
   As clodronate liposomes are taken up by a range of phagocytic cells and 
led to extensive cell apoptosis in the ascites and spleen (Figure  5-1), we 
tested the efficacy of a more specific depletion strategy targeting Myeloid-
derived  suppressor  cells  (MDSCs).  MDSCs  are  a  myeloid  population  with 
known T cell suppressive properties (Kusmartsev et al., 2005; Youn et al., 
2008; Lesokhin et al., 2012; Qin et al., 2014). The commercially available 
anti-Gr-1 depleting antibody (BioXcell) is derived from the RB6-8C5 clone 
and  recognises  a  common  epitope  in  the  Ly6C  and  Ly6G  receptors 
expressed  by  cells  of  the  monocyte  and  granulocyte  lineage,  respectively 
(Alizadeh  et  al.,  2014).  We  tested  whether  Gr-1
+  MDSCs  are  depleted  in 
immune-competent mice bearing EL4 tumours by administering the anti-Gr-1 
antibody  intraperitoneally,  starting  on  Day  10  post-tumour  challenge  and 
given on consecutive days at a concentration of 0.2mg/mouse, as previously 
published (Srivastava et al., 2012, Ma et al., 2012). Animals were euthanised 
on day 15 and the percentages and absolute numbers of Gr-1
+ cells in the 
spleen, blood, tumour tissue and ascites analysed by FACs and compared to 
mice injected with PBS only. The experimental approach is outlined in Figure 
5-2A. As shown in Figure 5-2B-C, the percentages of CD11b
+ Gr-1
+ cells 
were significantly lower in the spleen and blood of mice treated with the anti-
Gr-1  antibody  compared  to  mice  treated  with  PBS  only  (p=0.0024  and 
0.0004,  respectively).  Depletion  was  also  observed  in  tumour  tissue, 
although it did not reach statistical significance (p=0.1664) (Figure 5-2B-C). RESULTS 
  161 
In contrast, the depletion of CD11b
+ Gr-1
+ cells was negligible in the ascites 
(p= 0.8356) (Figure 5-2B-C).  
   Due to the fact that the depleting anti-Gr-1 antibody and the fluorochrome-
conjugated antibody used to measure the percentages of Gr-1
+ cells by flow 
cytometry are derived from the same clone (RB6-8C5), steric hindrance may 
have blocked the binding of the antibody used for flow cytometry, resulting in 
an under-estimation of the values of Gr-1
+ cells. To exclude this possibility, 
samples were stained with an anti-Ly6C antibody (Clone AL-21). Ly6C
+ cells 
were expected to become depleted since the anti-Gr-1 antibody binds to both 
Ly6C and Ly6G receptors. As seen in Figure 5-2C, CD11b
+ Ly6C
+ cells were 
depleted in the spleen and blood (p=0.0230 and 0.0102, respectively) and to 
a  lesser  extent  in  tumour  tissue  (p=0.1382),  whereas  no  depletion  was 
observed  in  the  ascites  (p=0.5639),  mirroring  the  staining  profile  obtained 
with  the  anti-Gr-1  antibody.  Similar  depletion  pattern  was  observed  for 
mature CD11b
+ F4/80
+ macrophages (P=0.0112, 0.0429, 0.2261 and 06784 
for spleen, blood, tumour and ascites, respectively) (Figure 5-2C).  
    Quantification  of  absolute  cell  numbers  showed  statistically  significant 
differences  in  the  spleen  (p=  0.0029,  0.0050,  0.0084  for  CD11b
+  Gr-1
+, 
CD11b
+  Ly6C
+  and  CD11b
+  F4/80
+  populations,  respectively)  whereas 
differences obtained for tumour tissue were not statistically significant (p= 
0.4941, 0.3508, 0.3249 for CD11b
+ Gr-1
+, CD11b
+ Ly6C
+ and CD11b
+ F4/80
+ 
populations, respectively) (Figure 5-2D). As a result, robust depletion was 
obtained  in  the  spleen  and  blood,  confirming  findings  from  the  literature 
(Srivastava et al., 2012, Ma et al., 2012). RESULTS 
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Figure 5-2 Myeloid depletion by the anti-Gr-1 antibody administered i.p. 
The anti-Gr-1 antibody (Clone RB6-8C5) was administered intraperitoneally 
to immune-competent C57BL/6 mice bearing subcutaneous EL4 tumours on 
days 10, 12 and 14 post-tumour challenge. Animals were euthanised on day 
15  and  the  depletion  of  CD11b
+  Gr-1
+  cells,  CD11b
+  Ly6C
+  and  CD11b
+ 
F4/80
+ cells studied by FACs analysis of tumour tissue, spleen, peripheral 
blood and ascites. Mice injected with sterile PBS only were used as controls. 
A.  Flow  diagram  showing  the  overall  experimental  design.  B.  FACs  plots 
showing  the  percentages  of  cells  expressing  CD11b  versus  Gr-1,  CD11b 
versus Ly6C or CD11b versus F4/80. Populations were pre-gated on the live 
(PI  negative)  gate  (not  shown).  C.  Percentages  of  the  CD11b
+  Gr-1
+  or 
CD11b
+ F4/80
+ double-positive populations as given by FACs. Values are 
displayed  as  a  percentage  of  total  viable  cells  (PI  negative).  D.  Absolute 
numbers of CD11b
+ Gr-1
+ or CD11b
+ F4/80
+ populations infiltrating tumour 
tissue and spleen, calculated by multiplying the percentages given by FACs RESULTS 
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by the total number of viable cells following (spleen) or in the absence of 
(tumour tissue) red blood cell lysis. Viable cells were counted with a standard 
hemocytometer under a light microscope using the trypan blue dye exclusion 
method. Values for (B) and (C) represent the mean ± SEM taken from two 
independent experiments with 3 mice/group each (total of six mice/group). 
Means  were  compared  using  unpaired  t-test.  *  p≤0.05,  **  p≤0.005, 
***p≤0.0005. n.s.= not statistically significant. 
 
5.1.2.1  Effect  of  mono-therapy  with  the  anti-Gr-1  antibody  on  the 
growth of EL4 tumours in immune-competent mice 
   If  Gr-1
+  MDSCs  suppress  the  T  cell-mediated  anti-tumour  effects  in  the 
EL4  model,  their  in  vivo  depletion  may  enhance  tumour  protection  by 
endogenous T cells, leading to tumour regression in the absence of adoptive 
T cell immunotherapy. To test this hypothesis, the anti-Gr-1 antibody was 
injected  intraperitoneally  on  days  10,  12  and  14,  as  performed  in  the 
depletion experiments described above. Tumour size was measured every 
two  days  and  mice  monitored  for  survival.  Unexpectedly,  the  anti-Gr-1 
antibody demonstrated a weak tumour-promoting effect as 8 out of 10 mice 
treated with the anti-Gr-1 antibody developed full-blown tumours and had to 
be euthanised, compared to 5 out of 10 mice injected with sterile PBS only 
across two independent experiments with 5 mice/group each (Figure 5-3). 
Spontaneous rejection of EL4 cells was observed several times throughout 
the study, suggesting that EL4 cells are indeed immunogenic in the absence 
of foreign antigen expression (Logan et al 2004). In addition, EL4 tumour-
bearing  mice  treated  with  the  anti-Gr-1  antibody  showed  a  trend  towards 
reduced survival, although differences between the two survival curves were 
not statistically significant (p=0.0886) (Figure 5-3).  RESULTS 
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Figure  5-3 Effect of mono-therapy with the anti-Gr-1 antibody on the 
growth of subcutaneous EL4 tumours in immune-competent mice. The 
anti-Gr-1  antibody  (Clone  RB6-8C5)  was  administered  intraperitoneally  to 
immune-competent  C57BL/6  mice  bearing  subcutaneous  EL4  tumours  on 
days 10, 12 and 14 post-tumour challenge and animals monitored for tumour 
growth and survival. A. Tumour size was measured every two days with a 
calliper and tumour size calculated by multiplying the horizontal diameter by 
the vertical diameter of the tumour. Each black line represents the tumour 
size (in mm
2) for one mouse; the coloured line (blue for PBS only and red for 
anti-Gr-1  antibody-treated  mice)  represents  the  mean  tumour  growth.  B. 
Survival curves represent the percentage of mice surviving over time and 
were compared using the Log rank test. n.s.= not statistically significant. Data 
was taken from a total of two independent experiments with 5 mice/group 
each, giving a total of 10 mice/group.  
 
5.2  Effect of Gr-1 depletion on the anti-tumour function of 
F5-TCR CD8
+ T cells 
   The  effect  of  MDSC  depletion  using  the  anti-Gr-1  antibody  on  the  anti-
tumour function of F5-TCR transduced CD8
+ T cells was tested in Rag-1
-/- 
mice bearing ID8luc-NP or EL4-NP tumours. RESULTS 
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5.2.1 ID8luc-NP model  
   MDSCs isolated from immune-competent mice bearing EL4 tumours are 
regarded as “bona-fide” MDSCs (Youn et al., 2008, Kusmartsev et al., 2005, 
Lesokhin  et  al.,  2012,  Qin  et  al.,  2014).  Evidence  from  the  literature, 
however, suggests that Gr-1
+ MDSCs isolated from immune-competent mice 
bearing ID8 tumours may have immune-stimulatory roles in vitro and in vivo 
(Tomihara et al., 2010). In this case, their in vivo depletion may impair T cell 
function.  However,  it  is  not  known  whether  MDSCs  acquire  immune-
stimulatory  or  immune-suppressive  roles  in  the  absence  of  endogenous 
lymphocytes since previous published studies using a genetically engineered 
model of breast cancer on a Rag-1
-/- background showed that the adaptive 
immune  system  played  a  key  role  in  driving  myeloid  populations  such  as 
TAMs towards an immune-suppressive phenotype (DeNardo et al., 2009). In 
order  to  address  this  question,  Rag-1
-/-  mice  bearing  ID8luc-NP  tumours 
were injected with 0.2mg/mouse of anti-Gr-1 antibody i.p. on days 3, 5 and 7 
post-tumour challenge, followed by the adoptive transfer of 3 x 10
5 F5-TCR 
transduced  CD8
+  T  cells/mouse  i.p.  on  day  8  post-tumour  challenge,  as 
described  in  Materials  and  Methods  section  2.21.  An  overview  of  the 
treatment regimen is shown in Figure 5-4A.  
   As shown in Figure 5-4B-C, F5-TCR transduced CD8
+ T cells cleared the 
bulk of the tumour, whilst the remaining subset of the surviving tumour did 
not grow further and develop into larger tumours. A very similar pattern was 
observed when the anti-Gr-1 antibody was administered prior to the adoptive 
transfer of F5-TCR CD8
+ T cells (Figure 5-4B-C). As expected, mice treated 
with  mock  transduced  CD8
+  T  cells  developed  large  tumours  and  were 
euthanized  after  7  weeks  due  to  weight  gain  as  a  result  of  ascitic  fluid 
accumulation. Furthermore, ID8luc-NP tumour-bearing mice treated with the 
anti-Gr-1 antibody as a single agent developed large tumours comparable to 
mice  treated  with  mock-transduced  CD8
+  T  cells  (Figure  5-4B-C).  In 
conclusion, the anti-Gr-1 antibody did not affect the anti-tumour function of RESULTS 
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F5-TCR CD8
+ T cells in Rag-1
-/- mice bearing ID8luc-NP tumours under the 
conditions tested.  
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Figure 5-4 Effect of myeloid depletion with the anti-Gr-1 antibody on the 
anti-tumour  function  of  F5-TCR  CD8
+  T  cells  in  Rag-1
-/-  mice  bearing 
ID8luc-NP tumours. Rag-1
-/- mice bearing ID8luc-NP tumours were injected 
with 0.2mg/mouse of anti-Gr-1 antibody i.p. on days 3, 5 and 7 post-tumour 
challenge, followed by the adoptive transfer of 3 x 10
5 F5-TCR transduced 
CD8
+ T cells/mouse i.p. on day 8 post-tumour challenge and tumour growth 
tracked  by  serial  bioluminescence  imaging.  A.  Overview  of  the  treatment 
regimen. B. Images obtained at different time points with the Xenogen IVIS-
100 imaging device. The scale denotes areas of varying signalling intensities, 
with  red  being  the  highest  and  dark  blue  the  lowest.  Pictures  are 
representative of two independent experiments. C. Data was analysed from a 
region of interest drawn over the abdominal region of the mice using Living 
Image software (Xenogen) and presented as photons/s. Values obtained for 
individual mice were plotted (black lines); coloured lines represent the mean 
fluorescence intensity (photons/s). Data shown in (C) was taken from two 
independent experiments with 4 mice/group each (total of 8 mice/group).  
 
5.2.2 EL4-NP model  
   We previously showed that F5-TCR CD8
+ T cells were unable to control 
the growth of established EL4-NP tumours in Rag-1
-/- mice, whereas F5-
TCR  CD8
+  T  cells  provided  tumour  protection  when  administered  at  the 
same  dose  and  time  point  to  conditioned  wild-type  (WT)  C57BL/6  mice 
(section 4.2.4). In order to investigate whether the presence of infiltrating 
MDSCs  is  responsible  for  the  impaired  tumour  protection  in  Rag-1
-/- 
animals, MDSCs were depleted by administering the anti-Gr-1 antibody i.p. 
on  days  5,  7  and  9  post-tumour  challenge.  2  x  10
5  F5-TCR  transduced 
CD8
+ T cells/mouse were adoptively transferred on day 10. An overview of 
the treatment regimen is shown in Figure 5-5A. 
    As  shown  in  Figure  5-5B,  although  F5-TCR  transduced  CD8
+  T  cells 
provided efficient tumour protection in conditioned C57BL/6 mice, they failed 
to  provide  long-term  tumour  protection  in  Rag-1
-/-  mice,  confirming  our 
previous findings (section 4.2.4). Administration of the anti-Gr-1 antibody did 
not  affect  the  anti-tumour  effect  of  F5-TCR  transduced  CD8
+  T  cells,  as 
tumour  regression  was  observed  in  10  out  of  10  mice  treated  with  the 
combination therapy (Figure 5-5B). Moreover, the anti-Gr-1 antibody given RESULTS 
  169 
as a mono-therapy did not affect tumour growth in Rag-1
-/- mice, as 10 out of 
10 mice developed large tumours and were euthanized by week 3. These 
findings were comparable to Rag-1
-/- mice that did not receive any treatment 
(EL4-NP  tumour  only)  (Figure  5-5B).  Although  F5-TCR  CD8
+  T  cells 
significantly improved survival in Rag-1
-/- mice compared with the anti-Gr-1 
antibody only and tumour only control groups, Rag-1
-/- mice treated with F5-
TCR  CD8
+  T  cells  showed  lower  survival  rates  compared  to  conditioned 
C57BL/6  mice,  as  observed  previously  (section  4.2.4).  Importantly, 
administration of the Gr-1 antibody prior to the adoptive transfer of F5-TCR 
transduced  CD8
+  T  cells  did  not  affect  mouse  survival  in  Rag-1
-/-  mice 
(Figure 5-5C). 
 
 RESULTS 
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Figure 5-5 Effect of myeloid depletion with the anti-Gr-1 antibody on the 
anti-tumour function of F5-TCR transduced CD8
+ T cells in Rag-1
-/- mice 
bearing EL4-NP tumours. MDSCs were depleted by administering the anti-
Gr-1 antibody i.p. on days 5, 7 and 9 post-tumour challenge at 0.2mg/mouse. 
F5-TCR CD8
+ T cells were adoptively transferred on day 10 at a dose of 2 x 
10
5 transduced cells/mouse. Tumours were measured every two days and 
animals monitored for survival. Positive control for tumour engraftment: Rag-
1
-/- mice challenged with EL4-NP tumours in the absence of treatment with 
either the anti-Gr-1 antibody or F5-TCR transduced CD8
+ T cells (EL4-NP 
tumour Rag-1
-/- mice). Positive control for the anti-tumour function of F5-TCR 
CD8
+ T cells: conditioned WT CD57BL/6 mice adoptively transferred with F5-
TCR CD8
+ T cells in the absence of anti-Gr-1 antibody treatment (F5-TCR T 
cells only irradiated WT). A. Overview of the treatment regimen. B. Tumour 
size was measured with a calliper and tumour size calculated by multiplying 
the  horizontal  diameter  by  the  vertical  diameter  of  the  tumour.  Values  for 
tumour size (in mm
2) obtained for individual mice were plotted (black lines); 
coloured  lines  represent  the  mean  tumour  growth.  C.  Survival  curves 
represent the percentage of mice surviving over time. Data was taken from a 
total of two independent experiments with 5 mice/group each (10 mice/group 
in total).  
 
5.3  Conclusions 
    Clodronate liposomes caused extensive cell death and depleted myeloid 
cells non-specifically in the ascites and spleen when administered i.p. and i.v, 
respectively. The anti-Gr-1 antibody, which depleted CD11b
+ Gr-1
+ MDSCs 
in the spleen, blood, tumour tissue of immune-competent mice bearing EL4 
tumours, was chosen for subsequent experiments investigating the effect of 
MDSC depletion on the anti-tumour function of F5-TCR transduced CD8
+ T RESULTS 
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cells.  Mono-therapy  with  the  anti-Gr-1  antibody  showed  a  weak  tumour-
promoting effect in immune-competent mice bearing EL4 tumours. Finally, 
administration of the anti-Gr-1 antibody did not affect the anti-tumour function 
of F5-TCR CD8
+ T cells in Rag-1
-/- mice bearing either ID8luc-NP or EL4-NP 
tumours.DISCUSSION 
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Chapter 6  Discussion  
   In  view  of  the  increasing  number  of  adoptive  immunotherapy  trials  with 
TCR-transduced  antigen-specific  T  cells  in  cancer  patients,  it  is  vital  to 
acquire  a  better  understanding  into  the  impact  of  the  tumour 
microenvironment  on  T  cell  function.  Of  particular  interest  is  the  role  of 
tumour-associated  macrophages  (TAMs)  and  myeloid-derived  suppressor 
cells  (MDSCs),  which  are  highly  plastic  myeloid  populations  that  expand 
during  tumour  development  and  have  been  suggested  to  play  a  T  cell-
suppressive role in established cancers (Nagaraj et al., 2013, Mantovani et 
al.,  2011b).  However,  most  published  studies  investigating  the  interaction 
between TAMs or MDSCs and T cells have used in vitro suppression assays. 
Moreover,  published  in  vivo  studies  have  typically  explored  the  effect  of 
myeloid cell modulation on endogenous T cell immunity or in combination 
with the adoptive transfer of TCR-transgenic T cells. A better understanding 
of whether TAMs and MDSCs impair or enhance the anti-tumour function of 
TCR-transduced T cells in vivo is vital prior to designing novel engineering 
approaches  to  manipulate  T  cells  to  perform  better  in  the  tumour 
microenvironment.  
   As a result, the present study aimed at understanding the effect of TAMs 
and MDSCs on the antigen-specific function of TCR-transduced T cells in 
vivo.  We  have  shown  that  bone  marrow-derived  CD115
+  monocytic  cells 
suppressed F5-TCR transduced CD8
+ T cells in vitro (section 3.6). However, 
CD115
+ cells did not affect the anti-tumour function of F5-TCR transduced 
CD8
+ T cells in vivo (section 4.2.2). Surprisingly, Gr-1
+ MDSCs isolated from 
tumours and spleens of EL4 tumour-bearing mice failed to suppress F5-TCR 
transduced CD8
+ T cells in vitro (section  3.6). Moreover, the anti-tumour 
function of F5-TCR transduced CD8
+ T cells was unaffected following the 
depletion  of  Gr-1
+  MDSCs  in  Rag-1
-/-  mice  bearing  ID8luc-NP  or  EL4-NP 
tumours  (section  5.2),  suggesting  that  mechanisms  other  than  MDSC-
mediated T cell suppression mediate tumour evasion in these models.  DISCUSSION 
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6.1  In vitro experiments 
6.1.1 Characterisation of in vitro polarised bone marrow-
derived macrophages  
    In  the  first  part  of  the  study,  we  characterised  the  phenotype  and 
suppressive properties of key myeloid populations in vitro, starting with the 
macrophages,  highly  plastic  cells  that  are  essential  for  the  initiation  and 
resolution of pathogen or tissue damage–induced inflammation (Krausgruber 
et al., 2011). Mirroring Th1-Th2 polarization, two distinct phenotypic states 
have been proposed for macrophages: the classically activated (M1) and the 
alternatively activated (M2) phenotypes (Biswas and Mantovani, 2010). M2 
macrophages, which promote the resolution of inflammation through the up-
regulation  of  pro-angiogenic,  tissue  remodeling  and  immune-suppressive 
mediators  and  are  also  thought  to  be  the  main  macrophage  subset  in 
established  tumours  (Sica  and  Mantovani,  2012).  Despite  the  limited 
experimental evidence, the current paradigm in the field suggests that M2 
macrophages  are  immune-suppressive,  whereas  M1  macrophages  are 
immune-stimulatory both in vitro and in vivo.  In the current study, M1 and M2 
macrophages  were  generated  by  polarising  murine  bone  marrow  derived 
macrophages  (BMDMs)  in  vitro  with  standard  concentrations  of  the 
prototypical  Th1  (IFN-γ)  or  Th2  (IL-4  +  IL-13)  cytokines,  as  previously 
published (Stout et al., 2005). We showed that BMDM polarization with IFN-γ 
or  IL-4  +  IL-13  cytokines  elicited  some,  but  not  all  of  the  typical  M1-M2 
hallmarks  (section  3.2).  Interestingly,  Stout  et  al  also  observed  that 
polarisation  with  the  Th2  cytokine  IL-4  prior  to  LPS  stimulation  strongly 
enhanced the production of the pro-inflammatory mediators TNF-α, IL-6 and 
IL-12  by  BMDMs.  IL-10  gene  up-regulation  and  cytokine  production  was 
observed  in  BMDMs  polarized  with  M-CSF  prior  to  stimulation  with  LPS 
(section  3.2).  Fleetwood  et  al  observed  that  BMDMs  differentiated  in  the 
presence of M-CSF secreted significantly more IL-10 compared to GM-CSF 
differentiated macrophages, with the inverse occurring for IL-12 (Fleetwood 
et al., 2007). In fact, it has been postulated that macrophages are poised to DISCUSSION 
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an M2- phenotype in vivo under the influence of M-CSF, switching to an M1-
like  state  only  in  states  of  type-1  inflammation,  which  would  avoid 
unnecessary  tissue  damage  (Krausgruber  et  al.,  2011).  Taken  together, 
BMDMs  polarised  with  exogenous  Th2  cytokines  in  vitro  did  not  fully  re-
capitulate the M2-like activation state frequently observed in TAMs isolated 
from murine tumours (Biswas et al., 2008). This may be due to the presence 
of additional M2-polarising factors in the tumour microenvironment, such as 
IL-10, VEGF and TGF-β (Mantovani et al., 2011b). Moreover, it is possible 
that the polarising effect of IFN-γ, IL-4 and IL-13 was lost in our study since 
these cytokines were washed before BMDMs were cultured in the presence 
or absence of LPS for 6 hours prior to gene expression analysis and cytokine 
release assays. It would be interesting to study the phenotype of BMDMs 
immediately after an overnight polarisation with cytokines and/or at shorter 
time points of LPS stimulation.  
6.1.2 Immune-suppressive effects of myeloid populations 
6.1.2.1  Polarised bone marrow derived macrophages (BMDMs) 
   The assays testing the suppressive properties of polarised BMDMs did not 
yield  reproducible  results,  even  when  BMDM:  T  cell  ratios  or  total  cell 
densities were varied. Although IL-4-polarised macrophages are regarded as 
typical M2 macrophages (Biswas et al., 2013), there is limited evidence in the 
literature  suggesting  that  BMDMs  polarised  with  IL-4  in  vitro  are  more 
suppressive compared to BMDMs polarised with the Th1 cytokines IFN-γ and 
LPS.  For  instance,  Huber  et  al  showed  that  IL-4  polarized  BMDMs 
suppressed the proliferation of CD4
+ and CD8
+ T cells following polyclonal 
stimulation  in  vitro,  whereas  control  (non-polarised)  BMDMs  had  no 
suppressive effect (Huber et al., 2010). Whyte et al obtained similar findings 
in an antigen-specific system (Whyte et al., 2011). However, both studies 
reported a modest level of inhibition compared to T cells stimulated in the 
absence of BMDMs. Moreover, findings from only one BMDM: T cell ratio 
(1:3)  were  reported,  which  raises  the  question  as  to  whether  non-specific DISCUSSION 
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inhibitory effects may occur at high BMDM: T cell ratios for instance due to 
the depletion of essential nutrients in the culture medium.  
6.1.2.2  Gr-1
+ MDSCs and CD115
+ monocytic cells 
    After obtaining inconclusive results with BMDMs, we tested the immune-
suppressive properties of myeloid populations isolated from tumour bearing 
mice (section  3.6). It was hypothesized that factors present in the tumour 
microenvironment  or  released  systemically  may  promote  a  more  stable 
suppressive  phenotype.  A  number  of  studies  have  shown  that  myeloid-
derived  suppressor  cells  (MDSCs)  isolated  from  tumour-bearing  mice 
suppress T cells in antigen-specific and non-antigen specific manners via a 
combination  of  pro-inflammatory  mediators,  such  as  iNOS  and  reactive 
oxygen and nitrogen species, and anti-inflammatory mediators such as ARG-
1 (Gabrilovich, et al, 2001, Kusmartsev et al., 2005, Ostrand-Rosenberg et 
al.,  2012).  MDSCs  isolated  from  spleens  and  tumour  tissue  of  immune-
competent  mice  bearing  subcutaneous  EL4  tumours  are  regarded  as 
prototypical MDSCs due to their well-characterised suppressive properties in 
vitro (Youn et al., 2008, Kusmartsev et al., 2005, Lesokhin et al., 2012, Qin et 
al., 2014).  
   However,  we  failed  to  observe  a  potent  inhibitory  effect  by  splenic  and 
tumour  tissue-derived  MDSCs  isolated  from  EL4  tumour-bearing  mice 
(section 3.6). Some published studies also failed to observe a suppressive 
effect by MDSCs in cancer. For instance, Kusmartsev et al showed that Gr-
1
+  cells  isolated  from  the  spleens  of  CT-26  tumour-bearing  mice  failed  to 
suppress the in vitro antigen-specific proliferation of TCR-transgenic T cells 
specific to an influenza hemagglutinin (HA)-derived peptide (Kusmartsev et 
al.,  2005).  It  is  possible  that  the  gain  of  suppressive  properties  by  Gr-1
+ 
MDSCs depends on the levels of conditioning factors such as GM-CSF, M-
CSF, VEGF and prostaglandins (Monu and Frey, 2012), which may vary in 
different tumour models, in addition to the experimental conditions, including 
the method of MDSC isolation, total cell density per well, time of co-culture 
with  T  cells  and  the  properties  of  the  culture  medium.  Although  we DISCUSSION 
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reproduced a previously validated protocol (Bayne and Vonderheide, 2013), 
in  which  Gr-1
+  MDSCs  were  positively  selected  with  MACS  columns 
following  treatment  with  a  biotinylated  anti-Gr-1  antibody  and  anti-biotin 
beads  (Nagaraj  et  al.,  2012,  Kusmartsev  et  al.,  2005),  it  is  possible  that 
MDSCs  lost  their  suppressive  potential  after  isolation  and/or  during  the 
period of co-culture with T cells. Interestingly, Hamilton et al showed that 
MDSCs  isolated  from  the  lungs  and  spleens  of  4T1  mammary  tumour-
bearing mice suppressed T cell responses under serum-free conditions, but 
failed  to  supress  T  cells  when  fetal  calf  serum  (FCS)  was  added  to  the 
culture medium (Hamilton et al., 2012). In this case, factors present in the 
serum may have polarized MDSCs towards a non-suppressive phenotype.  
   In contrast to Gr-1
+ MDSCs, CD115
+ cells isolated from the bone marrow 
of  EL4  tumour-bearing  or  tumour-free  mice  potently  suppressed  T  cell 
proliferation in vitro (section  3.6). To our knowledge, this is the first study 
showing a suppressive effect by bone marrow-derived cells isolated on the 
basis  of  CSF1R  (CD115)  expression.  In  addition  to  mature  monocytes, 
CD115 is expressed by myeloid precursors in the bone marrow, including the 
macrophage and dendritic cell precursor (MDP) and the recently described 
MDP-derived monocyte and macrophage-restricted progenitor cell (Hettinger 
et  al.,  2013).  Consequently,  bone  marrow-derived  CD115
+  cells  may 
resemble the CD11b
+ Gr-1
int LyG
- Ly6C
+ CD115
+ CCR2
+ monocytic MDSCs 
(Lesokhin et al., 2011). Evidence from the literature suggests that monocytic 
MDSCs suppress T cell function predominantly in an antigen-independent 
manner via ARG-1 and iNOS up-regulation and immunosuppressive cytokine 
production,  whereas  granulocytic  MDSCs  suppress  predominantly  in  an 
antigen-specific manner via ROS production (Nagaraj et al., 2013).  Despite 
impairing T cell proliferation, the levels of IFN-γ and IL-2 in the tissue culture 
supernatants were not affected by the presence of CD115
+ cells (section 
3.6). Since supernatants were removed after an overnight co-culture period, 
it  is  possible  that  CD115
+  cells  do  not  inhibit  cytokine  release  occurring 
earlier following T cell activation but impair T cell proliferation over a longer DISCUSSION 
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time period as a result of the accumulation of suppressive mediators in the 
culture medium and/or the establishment of more durable cell-cell contacts.  
6.1.3 Overall conclusions from in vitro suppression assays 
-   BMDMs polarised with Th1 and Th2 cytokines in vitro, reproduced some, 
but  not  all  phenotypic  characteristics  of  M1  and  M2  macrophages, 
respectively.  
- CD115
+ monocytes derived from the bone marrow of EL4-tumour bearing 
or  tumour-free  C57BL/6  mice  suppressed  the  antigen-specific  and  non-
antigen specific proliferation of F5-TCR transduced CD8
+ T cells in vitro. 
6.1.4 Limitations and further work (in vitro) 
   The  suppressive  effect  of  F4/80
+  mature  macrophages  isolated  from 
tumour-bearing mice was not tested due to time constraints. Kusmartsev et 
al showed that CD11b
+ F4/80
+ mature macrophages isolated from tumour, 
but  not  spleens  of  C3  fibrosarcoma  tumour-bearing  mice,  inhibited  the 
proliferation of OT-1 TCR transgenic T cells stimulated with specific peptide 
and  triggered  the  apoptosis  of  splenocytes  stimulated  with  CD3/CD28 
antibodies in vitro (Kusmartsev et al., 2005). F4/80
+ TAMs were isolated by 
positive  selection  with  MiniMACS  columns  following  the  incubation  of  cell 
suspensions with a PE-conjugated anti-F4/80 antibody followed by anti-PE 
micro-beads (Kusmartsev et al., 2005).  
   A comprehensive phenotypic characterisation of CD115
+ cells and Gr-1
+ 
MDSCs  isolated  from  tumour-bearing  mice  was  not  undertaken  in  the 
present study in order to test whether these cells conform to a typical M1 or 
M2 profile. It would be particularly interesting to compare the phenotype of 
Gr-1
+  MDSCs  isolated  from  Rag-1
-/-  mice  bearing  ID8luc-NP  or  EL4-NP 
tumours  with  the  phenotype  of  Gr-1
+  MDSCs  isolated  from  immune-
competent mice bearing ID8luc or EL4 tumours to determine whether the 
absence  of  endogenous  lymphocytes  has  an  impact  on  the  phenotype  of DISCUSSION 
  178 
these myeloid populations, as seen in the MMTV-PyMT model of mammary 
carcinogenesis (DeNardo, et al., 2009). 
   Finally, the immune-suppressive mechanisms deployed by bone marrow-
derived CD115
+ cells could be characterised by studying the up-regulation of 
candidate genes linked with known immune-suppressive pathways, followed 
by  in  vitro  validation  in  suppression  assays  in  the  presence  of 
pharmacological inhibitors such as L-NMMA (iNOS inhibitor), N-hydroxy-nor-
L-Arg  (NOHA)  (ARG-1  inhibitor)  and  sodium  dismutase  (Reactive  Oxygen 
Species  inhibitor);  blocking  antibodies  against  cytokines  or  co-inhibitory 
receptors, such as PD-1 or through gene knockout systems.   
6.2  In vivo experiments 
6.2.1 Optimisation of murine tumour models 
   We tested the effect of depleting TAMs and MDSCs on the anti-tumour 
function of F5-TCR transduced CD8
+ T cells. However, optimisation of the 
EL4  and  ID8  models  was  required  to  ensure  that  F5-TCR  CD8
+  T  cells 
recognised the Influenza A Nucleoprotein (NP)-derived epitope expressed by 
EL4 and ID8 tumour cells in the presence of infiltrating TAMs and MDSCs 
prior  to  testing  the  effect  of  subsequent  depletion  of  these  myeloid 
populations in T cell adoptive transfer models.  
6.2.1.1  Optimisation of the ID8luc-NP model 
   Although  ID8  ovarian  carcinoma  cell  lines  form  intraperitoneal  tumours 
when injected i.p. into immune-competent syngeneic mice (Leinster et al., 
2012),  ID8luc-NP  tumours  failed  to  engraft  in  immune-competent  mice 
despite  previous  conditioning  with  sub-lethal  irradiation  (section  4.1.4). 
Interestingly, ID8 cells expressing the model antigen Ovalbumin (OVA) have 
been  shown  to  engraft  in  immune-competent  mice  with  similar  kinetics 
compared to untransduced ID8 cells (Tomihara et al., 2010). However, the 
immune-dominant epitope derived from the Influenza A virus single-strand 
RNA-binding nucleoprotein Nucleoprotein (NP) (Cordaro et al 2000) may be DISCUSSION 
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more  immunogenic  compared  to  OVA.  Previous  work  in  our  lab 
demonstrated that EL4-NP tumours were also rejected in immune-competent 
mice (unpublished observations). Moreover, ID8luc-NP cells express other 
potentially  immunogenic  proteins  encoded  by  the  retroviral  vector  used  to 
transduce  ID8luc  cells  with  the  sequence  for  NP,  including  GFP.  For 
instance,  Skelton  et  al  observed  that  EL4  cells  expressing  GFP  injected 
subcutaneously  developed  with  a  delayed  tumour  progression  kinetics 
compared  to  EL4  cells  lacking  GFP expression  (Skelton  et  al.,  2001).  An 
immune  response  against  GFP  and/or  additional  vector-encoded  proteins 
may explain the fact that ID8luc-control vector cells, which are transduced 
with a vector lacking the NP sequence, developed at a slower rate compared 
to  untransduced  ID8luc  cells  (section  4.1.4).  The  expected  role  of  the 
adaptive  immune  system  in  preventing  the  engraftment  of  ID8luc-NP  and 
ID8luc-control vector tumours was confirmed by the fact that these tumour 
cell lines established large tumours in Rag-1
-/- animals (section 4.1.4).  
6.2.1.2  Optimisation of the EL4-NP model  
   Previous work in our laboratory has shown that CD4
+ and CD8
+ T cells 
transduced  with  the  F5-TCR  confer  tumour  protection  in  conditioned 
syngeneic  mice  bearing  subcutaneous  EL4-NP  tumours  expressing  NP 
(Ahmadi et al., 2011, Morris et al., 2005). However, the effect of infiltrating 
myeloid cells on the function of F5-TCR transduced CD8
+ T cells is unknown 
in  this  model.  We  initially  characterised  the  tumour-associated  myeloid 
compartment in conditioned C57BL/6 mice bearing EL4-NP tumours prior to 
exploring the effect of myeloid depletion on the anti-tumour function of F5-
TCR transduced CD8
+ T cells.  
6.2.1.2.1 Endogenous  myeloid  levels  in  conditioned  mice  bearing  EL4-NP 
tumours 
    Although  TAMs  and  MDSCs  accumulated  preferentially  in  the  tumour 
tissue,  spleen  and  blood  of  immune-competent  EL4  tumour-bearing  mice 
relative  to  tumour-free  mice,  these  myeloid  cell  types  were  significantly 
depleted in conditioned mice bearing EL4-NP tumours (section 4.2.1). Data DISCUSSION 
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from  the  literature  suggests  that  most  tissue  macrophage  populations  are 
sensitive to total-body irradiation, leading to their subsequent replacement by 
circulating  monocytes  (Murphy  et  al.,  2008).  Kodumudi  et  al  showed  that 
splenic CD11b
+ Gr-1
+ MDSCs completely reconstituted to levels comparable 
to  non-irradiated  controls  by  day  10  post-irradiation  in  B16  melanoma-
bearing and tumour-free mice conditioned with 6Gy of total body irradiation 
(Kodumudi  et  al.,  2012).  As  a  result,  we  would  expect  higher  levels  of 
myeloid reconstitution to have occurred at the time point studied (2 weeks 
after conditioning/tumour challenge). It is possible that B16 tumour release 
factors that stimulate the expansion of myeloid populations at higher levels 
compared to EL4 cells, although it is unlikely that this alone can explain the 
differences in the levels of CD11b
+ Gr-1
+ MDSCs obtained by Kodumudi et al 
and the present study. 
6.2.1.2.2 Reconstitution of the myeloid compartment with CD115
+ monocytes 
   Since the increase in TAM numbers in tumours and spleens during tumour 
progression  depends  on  the  influx  of  inflammatory  monocytes  from  the 
circulation (Qian et al., 2011, Leuschner et al., 2011, Franklin et al., 2014), 
we attempted to reconstitute TAM levels in conditioned mice bearing EL4-NP 
tumours  by  adoptively  transferring  CD115
+  monocytes.  We  showed  that 
adoptively  transferred  congenically  marked  CD115
+  monocytes  infiltrated 
spleens and tumours of conditioned EL4-NP tumour-bearing mice, resulting 
in  an  increase  in  the  levels  of  CD11b
+  F4/80
+  macrophages  and  CD11b
+ 
Ly6C
+ monocytes (section  4.2.1). Interestingly, a more pronounced effect 
was observed when CD115
+ monocytes were administered earlier (3 days) 
following  tumour  challenge  (section  4.2.1).  At  this  time  point,  pro-
inflammatory signalling generated as a result of host conditioning and the 
injection  of  tumour  cells  may  have  favoured  monocyte  infiltration.  For 
instance, preconditioning with total body irradiation (TBI) has been shown to 
damage the gastrointestinal tract and promote the translocation of microbes 
into  the  systemic  circulation,  leading  to  immune  activation  (Paulos  et  al., 
2007).  Moreover,  the  vast  majority  of  congenically  marked  CD115
+ 
monocytes  infiltrating  tumours  and  spleens  maintained  Ly6C  expression. DISCUSSION 
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Movahedi  et  al  showed  that  the  majority  of  adoptively  transferred  Ly6C
hi 
monocytes entering the tumour tissue of immune-competent mice bearing 
subcutaneous TS/A mammary carcinoma tumours differentiated into MHC II
hi 
Ly6C
low TAMs (Movahedi et al., 2010). It is puzzling why most adoptively 
transferred CD115
+ monocytes maintained Ly6C expression in the present 
study.  Perhaps  the  decrease  in  signalling  sent  by  other  immune  cell 
populations due to host conditioning may have reduced the rate at which 
monocytes differentiate into mature Ly6C
low F4/80
high macrophages.  
6.2.1.2.3 Effect  of  adoptively  transferred  CD115
+  monocytes  on  the  anti-
tumour function of F5-TCR CD8
+ T cells  
   Despite the fact that bone marrow-derived CD115
+ cells suppressed the 
proliferation of F5-TCR transduced CD8
+ T cells in vitro (section 3.6), their 
adoptive transfer into conditioned mice bearing EL4-NP tumours on day 3 
post-tumour  challenge  did  not  impair  the  anti-tumour  function  of  F5-TCR 
transduced CD8+ T cells adoptively transferred on Day 5 (section 4.2.2). As 
the  infiltration  of  CD115
+  monocytes  into  tumour  tissue  and  spleens  was 
measured  14  days  post-tumour  challenge  (section  4.2.1),  it  is  unknown 
whether CD115
+ monocytes accumulated in tumours and spleens by Day 5. 
However, most adoptively transferred monocytes are expected to infiltrate 
within  two  days  following  adoptive  transfer  since  circulating  monocytes 
exhibit  a  half-life  of  approximately  20  hours  in  mice  (Ginhoux  and  Jung, 
2014).  Importantly,  the  levels  of  monocytes/macrophages  accumulating  in 
the  tumour  tissue  and  spleen  following  the  adoptive  transfer  of  CD115
+ 
monocytes into conditioned mice bearing EL4-NP tumours were significantly 
lower compared to immune-competent mice bearing EL4 tumours (section 
4.2.1). As a result, the ratios of macrophages to F5-TCR transduced CD8
+ T 
cells may not have reached a threshold where T cell suppression may occur. 
Alternatively,  a  longer  time  period  may  be  required  for  newly  recruited 
monocytes  to  become  “educated”  in  the  tumour  microenvironment  and 
produce suppressive intermediates such as ARG-1 and Peroxynitrate.  As a 
result, we decided to develop the tumour model in Rag-1
-/- mice, as it allowed DISCUSSION 
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EL4-NP tumours to engraft in the presence of a more stable endogenous 
myeloid compartment.  
6.2.2 Anti-tumour function of F5-TCR transduced CD8
+ T cells 
in Rag-1
-/- mice bearing ID8luc-NP or EL4-NP tumours 
   We tested the anti-tumour effect of F5-TCR transduced CD8
+ T cells in 
Rag-1
-/- mice bearing ID8luc-NP or EL4-NP tumours. Our initial aim was to 
obtain  a  sub-optimal  anti-tumour  effect  in  order  to  test  whether  myeloid 
depletion improves the anti-tumour function of F5-TCR transduced CD8
+ T 
cells in both models. That would allow us to test the hypothesis that tumour-
infiltrating  myeloid  cells  impair  the  anti-tumour  function  of  F5-TCR 
transduced CD8
+ T cells. In Rag-1
-/- mice bearing ID8luc-NP tumours, F5-
TCR transduced CD8
+ T cells cleared the bulk of the tumour mass, with the 
surviving tumour mass not developing further into larger tumours (section 
4.1.6). In mice bearing established EL4-NP tumours (10 days post-tumour 
challenge),  F5-TCR  transduced  CD8
+  T  cells  provided  efficient  tumour 
protection in conditioned C57BL/6 mice (section  4.2.4).  However, tumour 
regression leading to animal death occurred in Rag-1
-/- hosts treated with F5-
TCR  transduced  CD8
+  T  cells  given  at  the  same  dose  and  time  point 
(section 4.2.4).  
   The more potent anti-tumour activity of F5-TCR transduced CD8
+ T cells in 
the  ID8luc-NP  model  was  observed  despite  the  fact  that  EL4-NP  cells 
expressed higher levels of MHC Class I and were more potent at stimulating 
F5-TCR  transduced  CD8
+  T  cells  in  vitro  compared  to  ID8luc-NP  cells 
(section  4.1.3).  This  discrepancy,  together  with  the  fact  that  tumour 
clearance  was  incomplete  in  both  models,  may  be  explained  by  non-
immunological and immunological mechanisms, as described below.  
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6.2.2.1  Non-immunological mechanisms 
   The different tumorigenicity of ID8luc-NP and EL4-NP tumour cells lines 
may explain why the subset of tumour cells that escaped F5-TCR transduced 
CD8
+  T  cell-mediated  killing  quickly  developed  into  larger  tumours  in  the 
EL4-NP  but  not  in  the  ID8luc-NP  model.    Importantly,  ID8luc-NP  tumours 
develop  slowly,  with  large  tumours  being  observed  about  2  months  after 
injection (section 4.1.4).  
6.2.2.2  Immunological mechanisms 
6.2.2.2.1 T cell infiltration into tumours 
   It is possible that F5-TCR transduced CD8
+ T cells may have accumulated 
at higher numbers in the ID8luc-NP model, since they were injected directly 
into the tumour site, whereas in the EL4-NP model, adoptively transferred 
F5-TCR transduced CD8
+ T cells had to migrate from the bloodstream into 
the tumour tissue. Moreover, the more compact and solid structure of EL4-
NP subcutaneous tumours may have posed a barrier for T cell entry and 
prevented access to the whole population of tumour cells. In contrast, ID8luc-
NP tumours are composed of more dispersed solid deposits in addition to 
free  tumour  cells  in  the  ascites,  which  may  have  facilitated  the  contact 
between F5-TCR transduced CD8
+ T cells and ID8luc-NP tumour cells.  
6.2.2.2.2  Antigen loss and MHC down-regulation 
   ID8luc-NP and EL4-NP tumour cells may have escaped recognition by F5-
TCR transduced CD8
+ T cells due to antigen loss and/or MHC Class I down-
regulation.  Although  ID8luc-NP  cells  consistently  expressed  high  levels  of 
GFP (over 98%, section 4.1.1), which is encoded on the same vector as NP, 
prior  to  injection,  NP  surface  expression  may  not  correlate  with  GFP 
expression.  In  the  EL4-NP  model,  NP
+  cells  were  selected  by  treating 
cultured  EL4-NP  cells  with  the  selective  antibiotic  G418,  which  inhibits 
protein synthesis in eukaryotic and prokaryotic cells. Transduced (NP
+) cells 
survive G418-mediated apoptosis due to the co-expression of a resistance 
gene  in  the  vector  coding  for  NP.  Antigen  loss  and  MHC  Class  I  down-DISCUSSION 
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regulation  may  not  play  a  major  role  in  the  EL4-NP  model  since  escape 
variants that survive F5-TCR transduced CD8
+ T cell-mediated attack were 
not  frequently  observed  since  complete  tumour  clearance  was  generally 
observed  in  conditioned  C57BL/6  mice  bearing  EL4-NP  tumours  (section 
4.2.4).  
6.2.2.2.3 Absence of endogenous lymphocytes 
    Alternatively, the lack of endogenous T cells in Rag-1
-/- mice may have 
contributed to tumour re-growth through a process termed epitope spreading, 
which  occurs  when  endogenous  T  cells  specific  to  unrelated  antigens 
become  activated  as  a  result  of  tumour  destruction  promoted  by  antigen-
specific T cells (Miller et al., 1997). In melanoma patients vaccinated with the 
MAGE-A3 antigen, TCR repertoire analysis revealed that T cells specific for 
non-MAGE-A3  antigens  expand  and  are  functional  in  vitro  (Hardwick  and 
Chain, 2011). Whilst F5-TCR transduced CD8
+ T cells can move directly into 
the tumour site to attack NP
+ tumour cells, endogenous naive T cells specific 
to endogenous tumour antigens can become activated in the lymph nodes by 
APCs presenting tumour-associated antigens released following tumour cell 
killing mediated by F5-TCR transduced CD8
+ T cells, enter the tumour site 
and control the re-growth of NP antigen-escape variants. 
6.2.2.2.4 Presence of a suppressive tumour microenvironment 
  We hypothesized that, since Gr-1
+ MDSCs and F4/80
+ TAMs accumulated 
in Rag-1
-/- mice bearing ID8luc-NP and EL4-NP tumours (sections 4.1.5 and 
4.2.3),  these  myeloid  populations  established  a  suppressive  tumour 
microenvironment that impaired the function of F5-TCR transduced CD8
+ T 
cells.  This hypothesis was addressed by depleting potentially suppressive 
myeloid  populations  prior  to  the  adoptive  transfer  of  F5-TCR  transduced 
CD8
+ T cells in both models.  DISCUSSION 
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6.2.3 Efficiency of myeloid depletion methods 
   After optimising the EL4-NP and ID8luc-NP in vivo models, we validated 
the efficacy of Clodronate liposomes (CLs) and the anti-Gr-1 antibody, two 
commercially  available  pharmacological  methods  used  to  deplete  myeloid 
populations in vivo. Administration of CLs intraperitoneally resulted in robust 
non-specific cell apoptosis in the ascites, leading to the depletion of myeloid 
cell populations, whereas no depletion was observed in the remaining organs 
analysed  (section  5.1.1).  Published  data  suggests  that  CLs  delivered 
intraperitoneally primarily affect peritoneal macrophages (van Rooijen et al., 
1997)  whereas  partial  depletion  occurs  in  the  spleen  (Zeisberger  et  al., 
2006). Overall, intraperitoneal delivery of CLs seem appropriate to study the 
influence of myeloid cells in tumours confined to the peritoneal cavity, such 
as  the  ID8  ovarian  cancer  model.  Intravenously  administered  CLs  led  to 
significant cell apoptosis in the spleen at the time point tested, whereas no 
changes were observed in the remaining organs analysed (section  5.1.1). 
CLs administered intravenously were originally described to deplete myeloid 
cells in the spleen and liver (van Rooijen et al., 1994). For instance, Leenen 
et al and Van Rooijen et al observed depletion of CD11b
+ F4/80
+ cells in the 
spleen two days after intravenous injection of 2mg of CLs/mouse (Leenen et 
al., 1998, van Rooijen et al., 1997). Re-population of blood monocytes had 
been shown to occur 24h after CL administration (Sunderkotter et al., 2004), 
which may explain the lack of depletion observed at the time point we tested. 
Overall,  we  concluded  that  CLs  are  inappropriate  for  the  subsequent 
experiments combining myeloid depletion with the adoptive transfer of F5-
TCR transduced CD8
+ T cells since CLs non-specifically eliminated myeloid 
populations  displaying  immune-stimulatory  or  immune-suppressive 
properties in vivo. As a result, this lack of specificity would prevent us from 
studying the particular role of myeloid populations previously implicated in 
mediating T cell suppression, such as MDSCs. 
    We  tested  the  efficacy  of  the  anti-Gr-1  antibody,  as  it  allows  for  the 
selective depletion of Gr-1
+ MDSCs. Intraperitoneal administration of the anti-DISCUSSION 
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Gr-1 antibody significantly depleted CD11b
+ Gr-1
+ cells in blood, spleen and 
tumour  tissue  of  immune-competent  EL4  tumour-bearing  mice  (section 
5.1.2). The depletion of Gr-1
+ cells following the administration of an anti-Gr-
1  had  previously  been  reported  in  the  tumour  tissue  of  mice  bearing 
subcutaneous  Lewis  lung  carcinomas  (Srivastava  et  al.,  2012)  and  in  the 
spleen and peripheral blood of mice bearing subcutaneous EL4 tumours (Ma 
et  al.,  2012).  These  studies  used  the  same  anti-Gr-1  antibody  (BioXcell), 
administered  via  the  same  route  (i.p.),  concentration  (0.2mg/mouse)  and 
regimen  (administration  on  alternative  days)  as  the  present  study. 
Interestingly,  we  observed  that  F4/80
+  macrophages  were  depleted  in  the 
tumour tissue, blood and spleen of EL4 tumour bearing mice, although less 
potently compared to Gr-1
+ MDSCs (section  5.1.2). A decrease in F4/80
+ 
macrophages  following  the  depletion  of  Gr-1
+  MDSCs  is  expected,  since 
published evidence suggests that monocytic MDSCs (MO-MDSCs) give rise 
CD11b
+ Gr-1
- Ly6C
- F4/80
+ macrophages in vivo (Movahedi et al., 2010). 
   However,  no  significant  depletion  was  observed  in  the  ascites  (section 
5.1.2).  To  our  knowledge,  no  previously  published  study  has  investigated 
whether the i.p administration of the anti-Gr-1 antibody leads to the depletion 
of Gr-1
+ MDSCs in the ascites. Although the mechanism of action of the anti-
Gr-1 antibody has not been systematically investigated, Abbitt et al showed 
that  it  involved  both  complement-dependent  and  independent  cytotoxicity 
(Abbitt  et  al.,  2009).  It  is  tempting  to  speculate  that  the  presence  of 
complement-regulatory proteins in the ascitic fluid (Bjorge et al., 2005) may 
have limited the clearance of Gr-1
+ cells by the anti-Gr-1 antibody. Moreover, 
highly phagocytic cells, such as dendritic cells present in the peritoneal cavity 
of mice bearing EL4 subcutaneous tumours may be not have reached the 
levels  necessary  to  ensure  the  clearance  of  Gr-1
+  cells  via  antibody 
dependent cell mediated cytotoxicity (ADCC).  DISCUSSION 
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6.2.4 Effect of Gr-1 mono-therapy on the growth of EL4 
tumours 
   Hans  Schreiber’s  group  was  the  first  to  demonstrate  that  mono-therapy 
with the anti-Gr-1 antibody inhibits tumour growth in a transplanted model of 
skin  cancer  (Pekarek  et  al.,  1995).  Similar  findings  were  observed  in 
immune-competent  mice  bearing  the  3LL  Lewis  lung  carcinoma,  where 
tumour  regression  following  treatment  with  the  anti-Gr-1  antibody  was 
associated  with  an  increase  in  the  frequencies  of  NK  and  CD8
+  T  cells 
expressing  higher  levels  of  IFN-γ,  perforin  and  granzyme  compared  to 
untreated mice (Srivastava et al., 2012). We therefore tested the hypothesis 
that  mono-therapy  with  the  anti-Gr-1  antibody  would  lead  to  tumour 
regression in immune-competent mice bearing EL4 tumours. Surprisingly, a 
non-significant  trend  towards  tumour  growth  and  decreased  survival  was 
observed (section 5.1.2.1). In a recent study, mono-therapy with the anti-Gr-
1 antibody (BioXcell) administered on 3 consecutive days prior to sacrifice 
had no effect on the growth of subcutaneous EL4 tumours (Qin et al., 2014). 
However, the concentration used was not reported (Qin et al., 2014). This 
suggests the effect of Gr-1 MDSC depletion on tumour growth may depend 
on the tumour model and treatment regimen adopted. Interestingly, published 
studies  observed  modest  anti-tumour  responses  when  the  small  molecule 
CSF1R inhibitor PLX3397 was given as a single agent (Zhu et al., 2014, Mok 
et al., 2014). In murine tumour models, higher efficacy of myeloid targeting 
agents  has  been  observed  in  combination  with  standard  anti-cancer 
therapies, such as chemotherapy (DeNardo et al., 2011), radiotherapy (Ahn 
et  al.,  2010)  or  in  combination  with  immune-therapy  strategies  such  as 
checkpoint  blockage  inhibition  and  adoptive  T  cell  transfer,  as  discussed 
below.  DISCUSSION 
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6.2.5 Effect of depleting Gr-1
+ MDSCs on the anti-tumour 
function of F5-TCR transduced CD8
+ T cells  
   Recent  interest  has  been  focussed  on  exploring  whether  standard 
immunotherapy  against  cancer  can  be  improved  by  the  inhibition  of 
immunosuppressive myeloid cells within the tumour microenvironment. For 
instance,  improved  tumour  regression  was  observed  when  the  CSF1R 
inhibitor  PLX3397  was  administered  in  combination  with  either  blocking 
antibodies against the co-inhibitory receptors CTLA-4 and PD1 (Zhu et al., 
2014) or with adoptively transferred pmel-1 (specific to the gp100 melanoma 
antigen) or OT-1 (specific to the OVA model antigen) TCR transgenic CD8
+ T 
cells  (Mok  et  al.,  2014).  Interestingly,  PLX3397  reduced  the  levels  of 
intratumoral macrophages without depleting these cells systemically (Mok et 
al., 2014). The anti-Gr-1 antibody, however, also depleted Gr-1
+ MDSCs in 
the blood and spleen (section  5.1.2). Selective depletion from the tumour 
microenvironment might be more advantageous from a clinical standpoint in 
order  to  boost  anti-tumour  immunity  whilst  preserving  the  important  role 
played  by  monocyte/macrophages  and  neutrophils  in  protection  against 
opportunistic infections.  
   The present study has explored the effect of depleting Gr-1
+ MDSCs on the 
anti-tumour  function  of  F5-TCR  transduced  CD8
+  T  cells  in  Rag-1
-/-  mice 
bearing ID8luc-NP or EL4-NP tumours. To our knowledge, this is the first 
study combining myeloid cell depletion in vivo with the adoptive transfer of 
TCR-transduced T cells. In both tumour models, administration of the anti-
Gr-1 antibody did not alter the anti-tumour function of F5-TCR transduced 
CD8+ T cells (section 5.2). The possible mechanisms underlying the lack of 
synergistic effect of the Gr-1
+ antibody with F5-TCR transduced CD8
+ T cells 
are discussed below.  
6.2.5.1  ID8luc-NP model 
   Previous studies investigating the immune-regulatory role of Gr-1
+ MDSCs 
in  the  ID8  model  obtained  mixed  results.  For  instance,  Gr-1
+  MDSCs DISCUSSION 
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accumulating in the ascites and spleens of ID8 tumour bearing mice were 
shown to inhibit antigen-specific T cell responses in vitro via PD-L1 (Liu et 
al., 2008) and CD80 expression (Yang et al., 2006). In contrast, Tomihara et 
al showed that CD11b
+ Gr-1
+ cells isolated from spleens and ascites of ID8 
tumour bearing mice enhanced the antigen-specific and non-antigen specific 
proliferation  of  CD4
+  and  CD8
+  T  cells  in  vitro  (Tomihara  et  al.,  2010).  
Moreover, adoptive transfer CD11b
+ Gr-1
+ cells purified from the ascites of 
OVA-expressing ID8 tumour-bearing mice enhanced the anti-tumour effect of 
OT-I  TCR  transgenic  CD8
+  T  cells  in  mice  bearing  OVA-expressing  EL4 
tumours  (Tomihara  et  al.,  2010).  If  Gr-1
+  MDSCs  do  play  an  immune-
stimulatory role in the Rag-1
-/- system, their depletion would be expected to 
lead to impaired anti-tumour responses by F5-TCR transduced CD8
+ T cells, 
which was not observed in the present study.  
   Since the anti-Gr-1 antibody and F5-TCR transduced CD8
+ T cells were 
administered at relatively early stages of tumour development, Gr-1
+ MDSCs 
may not have been “educated” by tumour-derived factors and therefore not 
yet  acquired  a  suppressive  phenotype.  Furthermore,  MDSCs  may  display 
reduced suppressive properties in Rag-1
-/- hosts. Studies using genetically 
engineered  cancer  models  have  shown  that  the  adaptive  immune-system 
plays a key role in driving M2 polarization of TAMs. For instance, DeNardo et 
al  showed  that  F4/80
+  TAMs  isolated  from  mammary  tumours  of  the 
PyMT/MMTV  breast  cancer  model  on  a  Rag-1
-/-  background  expressed 
significantly higher levels of M1 cytokines compared PyMT/MMTV mice on a 
wild-type, immune-competent background (DeNardo et al., 2009). Moreover, 
immune  complex  deposition  has  been  shown  to  drive  M2-polarization  in 
TAMs  in  an  Fc  receptor-dependent  manner  in  the  K14-HPV16  model  of 
multistage epithelial carcinogenesis (Andreu et al., 2010). It remains to be 
determined whether the phenotype and suppressive properties of MDSCs is 
affected by the absence of endogenous lymphocytes. 
   Moreover, the lack of effect of the anti-Gr-1 antibody on the anti-tumour 
function of F5-TCR CD8
+ T cells may be due to the lack of depletion of Gr-1
+ DISCUSSION 
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MDSCs in the ascitic fluid, the site of the intraperitoneal ID8luc-NP tumours. 
As F5-TCR transduced CD8
+ T cells acquire the capacity to traffic directly to 
the tumour site as a result of in vitro activation prior to transduction, Gr-1
+ 
MDSCs present in the ascitic fluid may be more relevant in this model.  
6.2.5.2  EL4-NP model 
    Since the depletion of Gr-1
+ MDSCs was observed in the tumour tissue of 
immune-competent EL4 tumour bearing mice, it is likely that similar intra-
tumoural depletion takes place in Rag-1
-/- hosts bearing EL4-NP tumours. 
However,  as  mentioned  above,  Gr-1
+  MDSCs  may  have  lost  their 
suppressive properties in the absence of endogenous lymphocytes.  
6.2.6 Overall conclusions (in-vivo) 
-  The  anti-Gr-1  antibody  depleted  Gr-1
+  MDSCs  and  F4/80
+  TAMs  in  the 
tumour  tissue,  spleen  and  blood  of  immune-competent  C57BL/6  mice 
bearing EL4 tumours.  
-  Mono-therapy  with  the  anti-Gr-1  antibody  showed  a  weak  tumour-
promoting effect in immune-competent C57BL/6 mice bearing EL4 tumours. 
- F5-TCR transduced CD8
+ T cells showed lower efficacy against EL4-NP 
tumours in Rag-1
-/- mice compared to conditioned C57BL/6 mice. 
- Depletion of Gr-1
+ cells did not affect the anti-tumour function of F5-TCR-
transduced CD8
+ T cells in the ID8-NP and EL4-NP models in Rag-1
-/- mice.  
6.2.7 Limitations and future work (in vivo) 
1- We should investigate whether mechanisms other than impaired T cell 
fitness in the tumour microenvironment, including the lack of endogenous T 
cells or tumour antigen loss/MHC down-regulation, were responsible for the 
incomplete  anti-tumour  responses  by  F5-TCR  transduced  CD8
+  T  cells  in 
Rag-1
-/-  mice.  The  role  of  endogenous  lymphocytes  could  be  tested  by DISCUSSION 
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reconstituting the endogenous lymphocyte compartment prior to the adoptive 
transfer  of  F5-TCR  transduced  CD8
+  T  cells.  Moreover,  the  tumour  mass 
could  be  resected,  digested  and  tested  for  the  ability  of  tumour  cells  to 
stimulate F5-TCR transduced CD8
+ T cells in vitro in order to study the role 
of  antigen  loss  and/or  MHCI  down-regulation  on  tumour  escape.  This 
procedure  would  be  more  challenging  for  ID8luc-NP  tumours  given  their 
dispersed nature within the intraperitoneal cavity and the mesentery.  
2-  F5-TCR  transduced  CD8
+  T  cells  mediated  the  clearance  of  the  vast 
majority of the tumour mass in Rag-1
-/- animals bearing ID8luc-NP tumours 
under  the  conditions  tested,  making  it  challenging  to  show  a  further 
improvement in the anti-tumour function of F5-TCR CD8
+ T cells. As a result, 
a more sub-optimal anti-tumour effect by F5-TCR transduced CD8
+ T cells in 
this  system  would  be  desirable.  For  instance,  the  dose  of  F5-TCR 
transduced CD8
+ T cells could be decreased further or F5-TCR transduced 
CD8
+ T cells administered at later time points in order to obtain a less potent 
anti-tumour  effect.  Not  only  would  this  approach  to  therapy  against 
established  tumours  be  closer  to  the  clinical  setting,  but  it  would  also  be 
anticipated  that  tumour  infiltrating  myeloid  cells  will  acquire  suppressive 
properties at later stages of tumour development. However, these planned 
experiments were not performed due to time constraints. 
3- Further work is required to determine the role played by Gr-1
+ MDSCs in 
the  ID8luc-NP  and  EL4-NP  tumour  models.  Since  the  anti-Gr-1  antibody 
depletes cells of the monocyte and granulocyte lineage, further experiments 
are needed to test the suppressive role of specific myeloid cell populations in 
vivo.  For  instance,  the  specific  role  of  monocyte/macrophages  can  be 
determined using orally available inhibitors specific to the M-CSF receptor, a 
neutralizing antibody specific to M-CSF or blocking antibodies specific to the 
CCR2 or CSF1R receptors. Alternatively, we could use CCR2 knockout mice 
or the macrophage Fas-induced apoptosis (MAFIA) mouse model, in which a 
human Fas receptor expressed under the Csf1r (CSF1R) promoter allows for 
the conditional ablation of Csf1r-positive cells following the administration of DISCUSSION 
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a dimerising drug AP20187, which cross-links with the transgene-encoded 
human  Fas  receptor,  inducing  apoptosis  of  cells  from  the 
monocyte/macrophage lineage (Chow et al., 2011). For instance, enhanced 
intra-tumour accumulation and anti-tumour function of adoptively transferred 
pmel-1  TCR  transgenic  CD8
+  T  cells  has  been  observed  in  CCR2
-/-  mice 
bearing B16 melanoma tumours compared to wild-type mice (Lesokhin et al., 
2012). The specific role of neutrophils could be studied by administering a 
monoclonal  antibody  (clone  1A8)  against  the  granulocyte-specific  Ly6G 
receptor.  The  role  of  neutrophils  in  tumourigenesis  is  still  being 
characterised, with recent reports suggesting these cells can be polarised 
towards N1 and N2 phenotypes analogous to macrophages (Mantovani et 
al.,  2011a).  However,  the  suppressive  properties  of  neutrophils  are  still 
poorly  characterised,  although  it  is  likely  that  they  overlap  with  the 
granulocytic subset of MDSCs.  
4- The present study used a high-affinity TCR against a viral epitope, which 
does  not  recapitulate  the  low  affinity  interactions  directed  against  tumour 
associated  antigens  frequently  observed  in  cancer  (Aggen  et  al.,  2012). 
Moreover,  evidence  suggests  that  T  cells  bearing  high  affinity  TCRs  are 
more prone to tolerance induction in the tumour microenvironment (Janicki et 
al.,  2008).  As  a  result,  the  depletion  of  potentially  suppressive  myeloid 
populations  is  more  likely  to  yield  improved  anti-tumour  properties  in  the 
context of adoptive therapy with T cells bearing low affinity TCRs (Janicki et 
al., 2008). 
5- In the allograft models used in the present study, especially the EL4-NP 
model, tumour growth occurred rapidly, which may have prevented the step-
wise process of “education” between tumour and stromal cells, as seen in 
some  genetically  engineered  cancer  models,  such  as  the  MMTV-PyMT 
model of breast cancer (Fantozzi and Christofori, 2006) and the KPC model 
of Pancreatic ductal adenocarcinoma (PDAC) (Holmstrom and Olive, 2014). 
Compared  with  transplantable  tumours,  genetically  engineered  mice  more 
faithfully  model  the  multistage  pathogenesis  of  cancer  and  the  intimate DISCUSSION 
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interplay  between  neoplastic  cells  and  tissue  microenvironments  (Dranoff, 
2012). As a result, macrophages and other myeloid cells may have been less 
likely  to  be  polarised  towards  an  M2  phenotype  in  allograft  models.  In 
addition,  the  injection  of  tumour  cells  can  create  a  pro-inflammatory 
environment pushing macrophages towards an M1-phenotype.  
   In summary, we have shown that although bone marrow-derived CD115
+ 
monocytic cells suppressed F5-TCR transduced CD8
+ T cells in vitro, they 
did not impair the anti-tumour function of F5-TCR transduced CD8
+ T cells in 
conditioned  C57BL/6  mice  bearing  EL4-NP  tumours  (section  4.2.2).  The 
lack  of  in  vivo  suppressive  effect  may  be  due  to  the  fact  that  CD115
+ 
monocytes did not come into contact with F5-TCR transduced CD8
+ T cells 
at the sufficient numbers needed to mediate suppression. Surprisingly, Gr-1
+ 
MDSCs  isolated  from  tumours  and  spleens  of  EL4  tumour  bearing  mice 
failed to suppress F5-TCR transduced CD8
+ T cells in vitro (section  3.6). 
Moreover,  the  depletion  of  Gr-1
+  MDSCs  did  not  affect  the  anti-tumour 
function of F5-TCR transduced CD8
+ T cells in Rag-1
-/- mice bearing ID8luc-
NP  or  EL4-NP  tumours.  However,  further  work  is  needed  to  determine 
whether immune evasion in these models is due to MDSC-mediated T cell 
suppression. In the ID8luc-NP model, further titration of F5-TCR transduced 
CD8
+ T cells are needed to produce a less optimal anti-tumour effect. That 
would  help  us  measure  an  improvement  in  the  anti-tumour  of  F5-TCR 
transduced CD8
+ T cells that may occur following the depletion of potentially 
immune-suppressive myeloid populations. Moreover, other myeloid depletion 
strategies  that  eliminate  myeloid  cell  populations  in  the  ascites  should  be 
tested. In the EL4-NP model, we should investigate whether the incomplete 
tumour clearance mediated by F5-TCR transduced CD8
+ T cells is due to 
mechanisms  such  as  antigen-loss,  MHC  Class  I  down-regulation  or  the 
absence of endogenous lymphocytes. REFERENCES 
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